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CHAPTER 1 
General introduction 

GENETIC ENGINEERING OFT CEll SPECIFICITY 
INTRODUCTION 
The development of new strategies for the treatment of cancer and infectious diseases have 
primarily been based on advances in basic biology. Technologies that evolved from our 
understanding of the immune system include monoclonal antibody production, isolation and cloning 
of immune cells, large scale tissue culture, cloning of genes encoding all kinds of functional 
molecules and the development of technologies to transfer these cloned genes to somatic cells of 
choice. To date the most effective and specific eradication of solid tumors is surgical removal, but 
this has not resulted in overall cure of patients because metastasis of tumors are not always 
accessible for the surgeons knife. Therefore T cell-based strategies that aim to selectively target and 
destroy cancer cells are being developed. 
IMMUNE RECOGNITION 
The presence of specific receptors on immune 
cells is fundamental to immunologically based 
therapeutic strategies. These receptors recognize 
foreign antigens such as viruses, bacteria, MHC-
antigens on partially or fully mismatched organ 
grafts or antigens on malignantly transformed 
cells. All these antigens are distinct from "self' 
antigens, and from so-called "self' antigens that 
are expressed in an "aberrant" way, and thus may 
serve as targets for the immune cells. Soluble 
antigens are primarily neutralized by antibodies 
(Abs), but when presented by MHC, by immune 
cells. The idea that the immune attack leaves 
normal and non-infected tissues "self' intact and 
eliminates "non-self' was postulated at the 
beginning of the 20th century by Paul Ehrlich in his 
hypothesis of "magic bullets" [1]. At the end of the 
19th century, studies were initiated that aimed to 
actively immunize cancer patients against their 
own cancerous tissue. Cancer patients were non-
specifically immune-stimulated with relatively 
crude leukocyte extracts such as transfer factor, 
immune-RNA, bacterial extracts such as bacillus 
Calmette-Guerain or Coley's toxin or levamisol. 
These studies were initiated in spite of the fact that 
little was known about the various components of 
the immune system that could react against 
cancer and even less was known about tumor 
associated antigen structures. 
In 1970, the immune-surveillance theory was 
reformulated by Burnett, emphasizing the critical 
role of cell-mediated immunity in the control of 
cancer and infectious diseases (2). The central 
focus in basic and applied immunology became 
the study of "self' versus "non-self' recognition by 
immune cells. Yes, the immune system 
continuously scans whether in the host "self' 
becomes "non-self' due to e.g. viral infections; to 
neoplastic transformation, or to aberrant "self' 
expression. The first line of defense we know in 
the body is provided by the relatively non-specific 
NK cells and macrophages (3). 
In the 80s, the second wave of immunotherapy 
started, now with emphasis on the adoptive 
transfer of "immune-specific" cells. Clinical studies 
were performed and adoptive transfer of immune 
cells then was combined with mAbs and cytokines 
(4,5). The ultimate goal of all these efforts was and 
is to generate a specific and long lasting immune 
response that not only eradicates or controls the 
growth of tumor cells, but also provides protection 
for future encounters: protection through 
immunologic memory. In this concept, the immune 
intervention is thought to in vivo trigger the second 
line of the body defense, which involves 
macrophages, antigen presenting cells, 
eosinophils and the full range of NK, B and T cells. 
The CD3Pos T and the lmmunoglobulinPos B cells 
of the acquired immune system demonstrate 
exquisite antigen specificity. T cells recognize 
MHC-presented antigens: through the T cell 
receptor (TCR) (6), but B cells recognize antigens 
in an MHC-unrestricted fashion: through the 
membrane anchored immunoglobulins (lg) (7). 
The T cell population comprises CD8Pos cytotoxic 
T lymphocytes (CTLs), that specifically kill target 
cells, and T helper (T H) cells that produce 
cytokines and regulate lg synthesis. Antigen 
presenting cells such as macrophages, dendritic 
cells and others are important initiators of the 
immune response against foreign invaders. At any 
rate, all immune cells communicate with each 
other through membrane anchored receptors 
which mediate cell-cell contact, followed by 
intracellular and intercellular transduction of 
immune regulatory signals and through cytokine 
production. 
T lymphocytes, key players in the cellular 
immune response. 
A major focus in modern cancer research has 
been to explore the possibility to use the prime 
mediators of adaptive cellular immunity, the T 
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lymphocytes, to combat cancer and viral 
infections. 
TCR on T lymphocytes specifically recognize and 
bind to antigens presented by MHC class I or class 
II molecules (6). As such T cells, like NK cells, 
scan the surface of body cells for the presence of 
peptides derived from degraded pathogens. The 
TCR is a multi-chain complex consisting of an lg-
like antigen binding portion: the polymorphic a~ (8) 
or y8 (9) TCRs that are non-covalently linked to 
non-polymorphic signal transducing elements: the 
CD3/8z, CD3/yz, c; and 11 chains (8). The a~ and y8 
chains are disulphide-linked heterodimers or 
tetramers and each chain contains an invariant 
constant (C) region and an antigen binding 
variable (V) region. The exquisite antigen 
specificity and diversity of TCRs is the hallmark of 
the T cell response and is mainly created through 
gene rearrangements. 
T lymphocyte immune functions comprise cytokine 
production by TH1 and TH2 cells, and lytic functions 
by cytotoxic T lymphocytes (CTL) to preserve the 
integrity of the interior milieu of an individual. 
When T lymphocytes recognize antigens in the 
absence of (a) co-stimulatory and danger signal(s) 
they become tolerant or anergic (10). Although the 
intrinsic binding affinities of TCRs for antigen are 
low in comparison to Abs, already low numbers of 
MHC-peptides per target cell alert T lymphocytes 
and induce TCR signaling that triggers immune 
functions such as cytolysis, cytokine production, 
cell-cell communication, cell trafficking and 
homing. This is possible because the same 
peptide/MHC complexes can serially bind to TCRs 
after their disengagement from TCR following 
signal transduction (11,12). 
Although most attention in cancer immunology has 
focused on CD8Pos CTL and their lytic response to 
tumor cells, CD4Pos T lymphocytes should 
deserve equal or even more attention because of 
their immune regulatory roles in e.g. the defense 
against cancer and viral infections. Adoptive 
transfer of tumor specific CD8Pos CTL has shown 
effective immune specific anti-tumor responses in 
mouse models as well as in humans (13-17). 
However, CD4Pos T l¥mphocytes not only provide 
critical help to CD8P° CTL, but also play a direct 
role in killing tumor cells. Furthermore CD4Pos T 
lymphocytes are essential in the initiation and 
persistence of a protective immune response in 
viral disease (18, 19). This was demonstrated in 
clinical studies using human Cytomegalovirus 
(CMV)-specific CTL clones for the treatment of 
CMV reactivation following bone marrow 
transplant~tion ( 1 ~~s After ado~tive transfer of 
CMV specific CDS CTL to pat1ents, which were 
deficient in CD4Pos CMV specific T lymphocytes, 
cellular immunity to CMV declined. Adoptive 
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transfer of CD4Pos tumor specific T lymphocytes 
therefore appears to be clinically relevant for 
effective anti-tumor responses. Indeed, in mice, 
the adoptive transfer of activated MHC class II 
restricted, tumor specific CD4Pos T lymphocytes 
has resulted in de novo generation of tumor 
specific CD8Pos T lymphocytes and effective anti-
tumor responses (20). 
TUMOR REJECTION ANTIGENS 
Identification of tumor rejection antigens 
presented by MHC class I and II molecules 
Clinical studies carried out with tumor-infiltrating 
lymphocytes (TIL) and in vitro stimulated 
peripheral blood mononuclear cells (PBMC) 
demonstrated that CD8Pos T cells can specifically 
lyse tumor cells, or histogeneticaly unrelated tumor 
cells, but not normal cells, in an MHC restricted 
fashion (6, 21,22). The MHC class I molecules are 
expressed on the surface of virtually all nucleated 
cells, where they serve as targets for CD8Pos T 
cells. An exemption are cells in testes and 
placenta trophoblasts, that do not express MHC 
molecules, and thus can not serve as tumor 
antigen presenting targets for CD8Pos T cells. 
Investigators set out to identify MHC presented 
antigens recognized by tumor reactive T cells, the 
so called tumor rejection antigens (TRA) (reviewed 
in 23). To this end, eDNA or DNA cosmid pools 
derived from tumor cells were transiently 
transfected into tissue cultured target cells 
expressing identical MHC class I molecules. 
These cultured target cells expressing the 
MHC/TRA complexes were then assayed for their 
ability to specifically stimulate cytokine release 
from tumor reactive T cell clones via their TCR 
(24). Transfection of individual cDNAs or cosmids 
from pools that specifically stimulated the T cell 
clones then allowed the identification of the single 
TRA. The first human TRA that was identified in 
this way by screening a large genomic library from 
a melanoma patient was termed MAGE-1 (24). To 
identify the peptide epitope encoded by the 
MAGE-1 gene, that was presented by HLA-A1 
molecules, synthetic peptides were synthesized. 
Peptides presented by MHC class I molecules are 
usually 8 to 10 amino-acids long, and contain two 
to three residues, so called anchoring residues, 
that fit into specific pockets of the MHC molecule 
(25). These synthetic peptides, that fit the HLA-A1 
pockets, were then analyzed for their capacity to 
specifically stimulate a relevant cytotoxic T cell 
clone (26). This "reversed immunology" technology 
has since identified a large number of TRA, that 
are divided into distinct categories, based on their 
expression patterns in tumors and "normal" tissues 
(Table 1 ). Next, MHC-class I peptide binding 
motifs, i.e., the nature and position of pockets that 
bind the anchoring residues of the TRA peptides 
have also been defined, allowing the screening of 
large numbers of potentially immunogenic TRA 
and other peptides (25). 
The MHC class II molecules present peptides that 
are mainly derived from the extracellular 
compartment, as opposed to peptides presented 
by MHC class I molecules that capture 
endogenously processed peptides (27). 
Table 2 shows MHC class II TRA peptides that 
have been identified. Sofar, the identification of 
class II binding peptides has met more 
problems then the identification of class I binding 
peptides due to (1) the variable length of class II 
bound peptides, and (i1) because less information 
is available on class II peptide anchoring residues. 
In fact, to date there exists no strategy for the 
identification of class II restricted antigens that 
matches the successes obtained in the 
identification of class I restricted antigens. 
Recently, technologies have emerged that 
allow the generation of soluble MHC class I and 
MHC class II molecules containing peptides of 
choice, provided of course that these peptides 
contain the right anchoring residues (28). In spite 
of the fact that monomeric soluble MHC Class I 
molecules are poorly bound by specific TCR on T 
lymphocytes they do so when converted into 
tetrameric peptide/MHC complexes. Importantly, 
when relevant tetrameric peptide/MHC class I 
molecules are complexed with a fluorochrome they 
can now be used to identify and select virus or 
tumor specific T lymphocytes (29, 30). Fortunately, 
these soluble peptide/MHC complexes can also be 
used to select antibodies with MHC restricted 
specificity from large phage display libraries (31-
33). 
Table 1: MHC Class I presented Tumor Rejection Antigens (TRA) 
Tumor antigens Testis antigens differentiation antigens overexpressed 
with mutations in tumors 
BCR-ABL MAGE-1-10 CEA G250 
CASP-8 gp100 HER-2/NEU 
Beta-eaten in MART-1 MUC-1 
Cdc27 PSA p53 
CDK4 TRP-1 Hdm2 
ETV6-AML1 Tyrosinase PRAME 
Hsp?0-2 NY-ES0-1 RAGE 
K-ras LAGE-1 Telomerase 
MUM-2 BAGE-1 
GAGE-1-8 
Table 2: MHC Class II presented Tumor Rejection Antigens {TRA) 
Tumor antigens Testis antigens 
with mutations 
CDC27/m 
TPI/m 
BCR-ABL 
MAGE-1-6 
NY-ES0-1 
differentiation antigens 
Tyrosinase 
ANTIBODIES AND TUMOR TARGETING: 
Antibodies produced by B cell derived plasma cells 
are the key molecules of the humoral immune 
system. Antigens such as bacteria, allergens and 
possibly tumor associated antigens (TAA) 
expressed on tumor cells, but not presented by 
MHC molecules, are eliminated by NK cells, 
macrophages, monocytes and mast cells 
expressing receptors 
overexpressed 
in tumors 
that bind to the Fe region of the antigen-coated Ab. 
The NK cells, macrophages, monocytes and mast 
cells exert antibody dependent cellular cytolysis of 
tumor target cells when they are targeted by TAA 
specific Ab (34). 
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Tumor Associated Antigens (T AA): tumor 
targets for antibodies 
TAA are not presented by MHC molecules and 
hence can not be identified by tumor reactive CTL, 
but are identified by Ab obtained after 
immunization of the host with TAAPos tumor cells. 
Many of these TAA are merely over- or aberrantly 
expressed on tumor cells when compared with 
expression on normal cells. Although the TAA are 
not "tumor specific' in the strict immunological 
sense, they can effectively be used to selectively 
target the immune system to tumors resulting in 
clinical anti-tumor effects (35). Like TRA, TAA are 
also categorized based on their expression 
patterns in tumors and normal tissues (Table 3). 
Finally, one can identify a group of antigens that 
are not related to tumors, with respect to 
expression patterns, but that are tissue specific. 
Antigens such as CD19 and CD20 are expressed 
by B cells and serve as target structures for 
immuno-therapeutic intervention (35). 
Table 3: Tumor associated Antigens (TAA) 
Antigen Tumor Expression 
Angiogenic endothelial Tumor vasculature overexpressed 
receptor: KDR 
Carcinoembryonic antigen: Colorectal, breast, lung and overexpressed 
CEA other cancers 
Her-2/Neu/ERB2 Adenocarcinomas overexpressed 
TAG72 Gastrointestinal adena- overexpressed 
carcinoma and pan-
adenocarcinoma 
Folate receptor Ovarian cancer overexpressed 
Vascular endothelial growth non-small-cell lung cancer overexpressed 
Factor: VEGF colorectal cancer 
Epidermal-growth-factor colorectal cancer overexpressed 
Receptor: EGFR 
Epithelial cellular-adhesion colorectal cancer overexpressed 
Molecule:EpCam 
CD33 acute myelogenous leukaemia tissue specific 
CD20 8-cell lymphoma tissue specific 
Prostate specific membrane 
Antigen:PSMA 
Prostate cancer tissue specific 
Phage display: a technology to produce 
libraries of immune receptors 
Phage display involves the expression of proteins 
on the surface of phages fused to proteins 
attached to normal phage coat proteins (36). It is 
the physical link between the protein on the phage 
surface and the gene encoding it within the phage 
that allows the rapid evolution of protein properties 
on the basis of binding by a series of repetitive 
cycles of phage binding, elution and re-growth to 
amplify the phage population of choice. The phage 
display technology also allows enhancement of the 
affinity of selected Abs by mutation and further 
selection (37). From libraries of randomly paired 
combinations of Variable (V) domains of heavy 
and light chains, structurally formatted as single 
chain Abs (scFv), Fab or diabody fragments, 
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phages can be specifically selected. Human mAbs 
can also be generated when the libraries are 
constructed from "naive" human B cells, or from 
cloned human gene segments (37, 38). Indeed 
large repertoires now have been made, with over 
1 0 billion different mAbs, and thus mAbs to any 
"chosen" antigen, and with affinities ranging from 
moderate to high, can easily be isolated. 
Because of the high affinity, Ab with the same 
MHC-restricted specificity as TCR i.e., recognizing 
peptides from tumor rejection antigens (TRA) and 
presented by MHC class I or II molecules, are 
valuable tools both for the identification of target 
tumor cells as well as the construction of receptors 
that allow specific targeting of primary human T 
lymphocytes. Only recently such Abs have been 
isolated from a large "non-immune" phage display 
library, with the advent of the technology to 
produce soluble MHC/antigen complexes (31-33). 
The phage-Ab G8, specific for the MAGE-A1 
antigen presented by HLA-A 1 was isolated from a 
large "non-immune" human Fab-phage library, 
using soluble peptide/MHC complexes (31). The 
use of peptide/MHC complexes for the selection of 
specific phages has now resulted in the selection 
of mAb specific for at least 12 different HLA-A2 
complexes presenting different tumor or viral 
peptides (32,33). These findings demonstrate that 
selection of anti-peptide/MHC antibodies against, 
in principle, any complex is feasible, and that this 
technology may become a reliable and routine 
source of viral or tumor antigen specific receptors. 
IMMUNOTHERAPY OF DISEASE WITH THE 
ADOPTIVE TRANSFER OF IMMUNE CEllS 
Tumor Infiltrating lymphocytes: Til 
As described earlier, immune system based 
therapies employing tumor reactive T cells have 
been developed for patients with, e.g. metastatic 
melanoma, and have resulted in significant tumor 
reduction or even complete remissions in patients 
(15-17, 39-41 ). Especially tumor infiltrating 
lymphocytes (Tils) that were grown from murine 
and human tumors were effective in pre-clinical 
and clinical studies. In mice, Tlls were shown to 
recognize unique antigens on murine 
transplantable tumors and adoptive transfer of 
Tlls mediated rejection of established lung and 
liver metastasis (42). 
Anti-tumor responses in melanoma patients were 
significant, with an objective regression of cancer 
in 34% of patients, irrespective whether they had 
earlier responded to lnterleukine-2 (IL-2) treatment 
or not (15). These Tlls were able to: 1) specifically 
traffic to tumor sites; 2) lyse the relevant tumor 
cells, and 3) produce cytokines following 
interaction with the tumor targets (40,41). In 
cancer patients, unfortunately, such Tlls can only 
be established at low frequencies, with the 
exception of melanoma where a success rate of 
50% could be reached (15). At this point in time 
the TIL approach therefore does not provide a 
clinically practical and reliable approach for 
immuno-therapy of cancer patients, with the 
exception of melanoma patients. 
Targeting of CTl with bi-specific-mAbs 
In contrast to the lack of success in reliably 
generating TRA-specific T lymphocytes in 
individual patients, a plethora of mAbs were 
already available with specificity for TAA that are 
common to a wide range of cancers (table 3). To 
combine the ability of these mAbs to selectively 
recognize and bind to tumors with the potent anti-
tumor functions ofT lymphocytes, bi-specific-(bs)-
mAbs were designed with the aim to retarget the 
immune specificity of T lymphocytes to TAA 
(43,44). The multiple bonds created by bs-mAbs 
between TAA and, e.g. the CD3 complex on T 
,cells result in crosslinking of receptors and 
activation of the T lymphocyte machineries for a) 
cytokine production; b) T cell proliferation, and c) 
cytolysis of target cells. The induction of human 
anti-mouse bs-mAb (HAMA) responses that were 
observed in the patients could be dramatically 
reduced or even avoided entirely when gene 
encoding Ab fragments of human origin were used 
for the construction of bi-mAbs (45). Such (bs)-
mAbs from human origin are now readily available 
due to the advances made in phage display 
technology. 
Bs-mAb targeted T lymphocytes for cancer 
treatment: the clinic. 
We and others have exploited the capacity of bs-
mAbs to induce lymphocyte activation and to 
trigger the lytic and cytokine producing 
machineries of T cells for in vivo preclinical and 
clinical studies (43-48). The first international 
multi-center study involved locoregional 
(intraperitoneal) treatment of ovarian cancer in 
patients with advanced disease (47). These 
patients were selected because of the high 
frequency of relapses after induction 
chemotherapy. This high relapse rate called for an 
innovative treatment approach. Patients eligible for 
this study underwent laparotomy in order to 
surgically reduce tumor load and to objectively 
locate and document remammg lesions. 
Immunotherapy consisted of two 5-day cycles of 
treatment of daily intraperitoneal injections of in 
vitro activated and expanded autologous T cells 
targeted with bs-mAbs specific for CD3 on T cells 
and the folate receptor which is over-expressed on 
ovarian carcinoma cells. Per infusion, 109 T 
lymphocytes that were targeted with bs-mAbs, 
were administered into the peritoneal cavity. 
Patients received one additional infusion of IL-2 
and bs-mAbs to maintain T cell survival, lytic 
activity and bs-mAb dictated specificity. An 
impressive overall anti-tumor intraperitoneal 
response of 27% was observed, with 3 patients 
showing even complete remissions in the 
intraperitoneal cavity. 
It is important to note that the beneficial and 
objective, significant anti-ovarian cancer effects of 
the bs-mAb-retargeted T lymphocytes were only 
loco-regional. Extraperitoneal lesions were not 
affected by this immune-therapy (47). Other 
clinical pilot studies that involved infusion of bs-
mAb targeted T cells regarded patients with 
malignant ascites or plural effusions resulting from 
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colon, mammary, ovarian, lung- and gastric 
carcinomas (48). In these patients also strong 
biological in vivo effects were observed within 
hours after infusion. These clinical studies have 
provided "proof of concept" and set the stage for 
the further development of combined humoral and 
cellular anticancer treatments. 
TARGETING NON-MHC RESTRICTED, TUMOR 
ASSOCIATED ANTIGENS. 
Grafting T cells with antibody-based receptors. 
The use of bs-Abs for cancer therapy is hampered 
for several reasons: (a) the inaccessibility of solid 
tumors to Ab penetration (49); (b) bs-Ab targeted T 
lymphocytes retain the bs-Ab on their surface for 
only a limited time, i.e. 48-96 hrs, due to dissociation 
(50); and (c) bs-Ab targeted T lymphocytes loose 
their signal transducing and lytic capacity following 
target cell recognition and lysis (51). We and others 
developed an alternative approach in which T 
lymphocytes are grafted with a permanent Ab-
dictated TAA specificity (reviewed in 52-54). To this 
end, chimeric receptors were constructed that exert 
two functions: 1) antigen binding mediated through 
an Ab domain, and 2) T cell activation mediated 
through an intracellular domain derived from a 
signaling receptor. Chimeric receptors have been 
constructed from VH and VL domains of Abs, and 
fused to the constant regions of TCR a and ~ 
chains, thereby creating chimeric VHC~ and VLCa 
chains (55,56). These chimeric VHC~ and VLCa 
receptors were functionally expressed on the 
membrane ofT cells, resulting in receptor mediated 
immune functions, such as target cell recognition 
and lysis as well as cytokine production. 
At that time the necessary gene-transfer technology 
to simultaneously introduce two genes into large 
numbers of primary human T cells was not yet fully 
developed, for which reason single chain Ab 
fragments have been constructed (scFv). These 
molecules incorporate the VH and VL domains from a 
mAb, joined by a flexible linker, into one gene (57-
59). Such scFv display similar antigen binding 
affinities and antigen specificities as the "parental" 
mAb from which they were derived (60-62). 
Chimeric scFv receptors were constructed by fusing 
the ligand-binding domain to a signal-transducing 
element that allows for the activation of specific 
immune functions (56,63). Most of the chimeric Ab-
based receptors described use either Fc(s)RI y or 
CD3-~ for signaling, and have been functionally 
expressed in mouse T cell hybridomas, CTLs, TILs, 
human NK cells and primary human T lymphocytes 
(57-60, 63-67). Stimulation of chimeric Ab 
receptot08 T cells with relevant TAAPos tumor cells 
results in specific T cell activation and specific 
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immune functions (52-60, 63-67). There exists a 
functional balance between the level of chimeric 
receptor expression on T lymphocytes on the one 
hand and TAA density on tumor cells on the other 
hand (68,69). In example, T lymphocytes having a 
high density of the chimeric receptor were able to 
lyse tumor cells that express either high or low 
levels of G250 antigen, whereas T cells that have 
a low density of the chimeric receptor only lyse 
tumor cells that express high levels of G250 
antigen (68). Importantly, the level of chimeric 
receptor expression may be controlled by the use 
of a tetracycline trans-activator responsive 
promotor, which enables fine-tuning of the T cell 
mediated responses (69). Next to receptor and its 
antigen, critical roles are played by adhesion and 
accessory molecules, such as C02, CD3, CD11 a, 
CD18 and CD28 in the activation of engineered T 
cells (70). 
Chimeric antibody based receptors and their in 
vivo efficacy 
The in vivo anti-tumor efficacy of T lymphocytes, 
equipped with chimeric Ab-based receptors, was 
evaluated in mouse tumor models (71-73). In one 
of these studies nude mice intraperitoneally 
implanted with human ovarian cancer were treated 
with murine TIL cells expressing a chimeric scFv/y 
receptor recognizing the folate binding protein 
(FBP), present on ovarian cancer cells. Mice 
treated with these gene modified TIL had 
significantly increased survival compared to mice 
treated with TIL expressing an irrelevant receptor 
(71 ). A study performed by Altensmidt et a!. 
demonstrated complete remission of established 
tumors expressing the ErbB2 antigen upon 
injection of syngeneic T cells transduced with the 
ErbB2 specific scFv/~ receptor (72). Furthermore, 
Mouse T lymphocytes expressing chimeric scFv/~ 
receptors specific for the carcinoembrionic antigen 
(CEA) were able to control and reject human colon 
carcinoma in scid mice or mouse colon 
adenocarcinoma in syngeneic C57BL/6 mice (73-
75). So far, in vivo studies show partial and 
complete remissions of cancer as a consequence 
of treatment with chimeric mAb-engrafted T cells. 
Chimeric receptor08, CD8Pos T cells produce 
perforin and IFN-y, that are critically involved in the 
anti-tumor effect (73-75). Other types of immune 
cells, such as natural killer, y8 T cells or 
macrophages may be effective as anti-tumor cells 
when grafted with Ab-based receptors. Wang eta!. 
reported that retroviral introduction of a FBP 
specific chimeric Ab-based receptor into mouse 
bone marrow cells resulted in significant anti-tumor 
responses (76). Importantly, in this study in vivo T 
cell depletion did not affect the observed anti-
tumor activity, suggesting an important role for 
other non-T cP.IIs in tumor rejection. 
Adoptive transfer of human T cells genetically 
engineered to express human immunodeficiency 
virus HIV) specific chimeric CD4-s receptors to 
patients was reported to be safe (77,78). 
Importantly, long-term survival and specific tissue 
trafficking following adoptive transfer of chimeric 
receptor positive, HIV specific T cells in HIV 
infected patients was observed. 
Optimal design of chimeric Ab-based 
receptors: introduction of co-signaling 
elements. 
To optimize expression and function of mAb-based 
chimeric receptors, spacer or hinge domains can 
be selected and introduced into the chimeric 
receptor constructs (Fig 1, refs 79-81 ). Spacers 
extend the distance between the antigen binding 
domains and the T cell membrane, adding 
flexibility to the chimeric receptor construct. In fact, 
incorporation of a hinge domain such as the CH2-
CH3 domain of the lg heavy chain, or the CD4 
transmembrane domain into chimeric Ab-based 
receptors enhances transgene expression and 
function of the T cell transductants (80,81 ). It is 
important to note that the transmembrane domain 
of CD3 components may negatively affect chimeric 
receptor-mediated responses. A study, analyzing 
the response of resting primary T cells derived 
from mice transgenic for chimeric receptors 
comprising the CD3-s transmembrane domain 
demonstrated that primary T cells might not 
respond upon cross-linking of the receptors (82). 
In contrast, others demonstrated efficient 
activation of chimeric receptot08 T cells, lacking 
the CD3-s transmembrane domain upon receptor 
triggering (83,84 ). These apparently conflicting 
results may well be the consequence of distinct 
structural formats of the chimeric receptors. Upon 
cross-linking of chimeric/s receptors, the CD3-s 
but not non-TCR molecules such as the MHC 
class II chain may promote association of the 
chimeric receptor with the endogenous TCR CD3 
complex, adversely affecting surface expression 
and responsiveness of the chimeric receptor. 
Chimeric receptor constructs that do support T cell 
activation, phosphorylation of the receptor ITAMs 
and recruitment of ZAP-70 to the s chain have 
been made (83). 
The use ofT lymphocytes equipped with antibody-
based receptors for adoptive immuno therapy has 
raised some concerns. The high affinity of the 
mAb-based receptors may not allow T 
lymphocytes to recycle their lytic capacity (51, 85). 
Furthermore, the strong ligand binding capacity of 
the mAb-based receptor on T lymphocytes may 
even induce T cell apoptosis (86,87). These issues 
have been addressed experimentally, and co-
stimulation of T cell constitutes an answer to the 
questions raised. Normally, resting primary T cells 
require two signals in order to become activated; 
a) one signal derived from the antigen specific 
TCR-peptide/MHC interaction, and b) a second co-
stimulatory signal, following e.g. T ceii-CD28/tumor 
ceii-CD80, CD86 interactions (88,89). These 
signals stimulate T cells to proliferate and 
differentiate into potent effector cells. CD28 cross-
linking on T cells prevents a) T cell apoptosis; b) 
results in increased cytokine production, and c) 
enhanced cytolytic activity (88,89). Hence, the 
combination of CD28 co-stimulatory signaling with 
chimeric receptor signaling leads to improved 
antigen-specific T cell activation (90-94). The 
synergistic action of two separate single chain 
chimeric receptors either linked to CD3s or CD28 
resulted in the secretion of maximum levels of IL-2 
(90). When introducing the CD28 domain into one 
single chain scFv/s or y receptors, T cell 
transductants expressing the scFv-CD28/s or /y 
receptors proliferated well, even without 
exo~enous IL-2 upon stimulation with the relevant 
TAA 08 tumor cells (91-94). These T cell 
transductants also exhibited enhanced cytokine 
secretion and protection against apoptosis upon 
antigen stimulation, but no enhanced cytolytic 
capacity. Importantly, in vivo data have allowed a 
direct comparison between T lymphocytes that 
express chimeric receptors with or without the 
CD28 signaling domain in their efficacy to 
eliminate tumor cells (74,75). These data clearly 
demonstrated superior anti-tumor activities of T 
lymphocytes equipped with receptors that 
incorporate CD28 co-signaling capacity. 
These pre-clinical in vitro and in vivo experiment 
calls for carefully designed clinical trails using 
patients T lymphocytes engineered to functionally 
express such tumor or virus specific receptors. 
Only a few clinical anti-cancer trails have been 
initiated, of which results are not yet available 
(Table 4). We designed a phase I clinical protocol 
with intend to treat patients with advanced 
metastatic renal cell carcinoma. Patients will be 
infused with autologous peripheral blood 
lymphocytes transduced with a renal cell 
carcinoma specific chimeric mAb-based receptor 
i.e. scFv G250-CD4/y (95). 
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Extracellular TM intracellular 
scFv/y 
scFv/1:, 
scFv/e 
scFv-CD4CD4/y 
scFvCH2CH3-~~~~~~~2222t[IJIIJ 
CD4/(, 
scFv-CDS/1:, 
U Fe (e)RI y 0 CD4 Tm ~ Ck .••• 
I :<<I CD3-~ ~ lgG1 
!IIIIIIllil CDS 105-165 
~ CD3-e 
Figure 1. Chimeric scFv constructs. Schematic 
presentation of distinct scFv constructs, 
comprising one or several of the following 
domains: the hinge domains lgG1 CH2CH3 or CDS 
(amino-acids 105 to 165), a short Ck fragment, the 
transmembrane region derived from CD4, the 
intracellular domain from the Fc(e)RI y chain or the 
complete CD3-I:, or CD3-& molecules, as described 
in Weijtens et al [80], Patel et al [81] and 
Willemsen et al [112]. 
Table 4: Clinical trails with TAA specific mAb-based 
chimeric receptor engineered T lymphocytes. 
Phase Disease Antigen chimeric rec 
Ovarian cancer folate receptor scFv-y 
HIV gp120 CD4-1; 
Adenocarcinoma TAG72 scFv-1; 
Adenocarcinoma CEA scFv-1; 
Lymphoma CD19 scFv-1; 
Renal cell carcinoma G250 scFv-CD4/y 
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TARGETING MHC-RESTRICTED TUMOR 
REJECTION ANTIGENS 
As indicated before, studies have demonstrated 
that cosPOS T cells specifically lyse tumor cells, or 
histo-genetically unrelated tumor cells, but not 
normal cells, in an MHC restricted fashion (6, 
21 ,22). Investigators therefore set out to identify 
MHC presented antigens, the so called tumor 
rejection antigens (TRA), recognized by tumor 
reactive T cells (reviewed in 23). MHC presented 
TRA are recognized by TCR, but not classical 
mAbs. Therefore, in order to target the immune 
system to TRA or viral antigens one needs to graft 
T lymphocytes with genes encoding TCR or TCR-
Iike receptors. Until 1995, one could only 
successfully introduce mouse TCR into mouse T 
cell lines or hybridomas, but not primary human T 
cells (96,97). Retroviral vectors were the obvious 
choice to introduce TCR genes into T cells at that 
time because they transmit genes to recipient cells 
as well as to their progeny in a relatively stable 
manner. However, retroviral vector technology was 
not advanced to a stage that sufficient numbers of 
primary human T lymphocytes could be efficiently 
transduced. Recently, we succeeded to adapt 
retroviral vectors in such a way that they efficiently 
and functionally facilitate expression of TCR and 
TCR-based receptors in primary human T 
lymphocytes (see below). 
Concerns associated with TCR gene transfer. 
Besides problems related to (retroviral) vector 
technology, the safe application of TCR gene 
transfer technology is associated with other 
problems (98). Transfer of complete TCR a and B 
genes to primary human T lymphocytes results in 
reciprocal pairing between introduced TCR aB with 
endogenous TCR aB chains, possibly, creating 
new and unknown immune-specificities. 
Theoretically, self-antigens may become 
recognized and cause an autoimmune response. 
In addition, pairing of introduced TCR with 
endogenous TCR chains dilutes the expression of 
functional introduced TCR aB heterodimers. This 
may reduce the overall T cell avidity, immune 
functions and recycling capacity (99,100). 
Unstable TCR a surface expression in T cells may 
impose yet another problem to the introduction of 
non-modified (full-length) TCR chains (1 01 ). 
Unfortunately, the limited number of TCR Va 
family type specific mAb available for the detection 
of the highly diverse TCR a chains present on T 
cells does not allow a detailed study of this 
phenomenon. 
Luckily, new strategies become at hand that 
prevent pairing of introduced and endogenous 
TCR aB chains and also resolve unstable TCR a 
expression. TCR a~ heterodimers compns1ng 
specific signals into the TCR a~ chains to enhance 
expression and exclusive pairing may be 
developed. Such an alternative is presented 
below. 
Retroviral TCR gene transfer to primary human 
T lymphocytes 
Essential to the success of genetic engineering of 
T cell specificity are improved retroviral gene 
transfer technologies. Retroviruses are widely 
used for the transfer of genes to proliferating 
somatic cells, including tumor cells and immune 
cells (1 02). Most retroviruses only infect 
proliferating cells and as a consequence, immune 
cells first have to be activated in vitro to become 
proliferative prior to transduction. Futhermore, In 
vitro gene transfer needs to be followed by in vitro 
expansion of the gene modified T cells to reach 
sufficient numbers of lymphocytes for clinical 
application. 
First generation viral vectors such as LXSN and 
first generation packaging cell lines were used 
successfully to introduce chimeric TCR-based 
receptors into mouse T cells (unpublished results), 
but had several drawbacks. First, transduction 
efficiencies of primary human T lymphocytes were 
low, usually lower than 1%, were obtained. This 
necessitated repeated and prolonged lymphocyte 
culture in media containing the appropriate 
selective antibiotics. Second, these vectors 
resulted in low membrane expression levels of the 
transgene, typically undetectable by flow 
cytometry (59). We and others developed novel 
retroviral vectors (80, 103-105). One of these, the 
pBullet vector, contains the extended Moloney 
Murine Leukemia Virus (MoML V) packaging 
signal, donor and acceptor RNA splice sites, and 
cloning sites that allow the introduction of a 
transgene at the optimal protein translation 
initiation position (Figure 2A)(105). To construct 
the pBullet vector, the U3 region of the 5' L TR was 
replaced by the cytomegalovirus immediate early 
(CMV IE) promoter to enhance RNA synthesis in 
cells that express the Adenoviral E1A protein. The 
SV40 origin of replication present in the retroviral 
vector and the retroviral helper constructs i.e. 
GAG/POL and ENV, are responsible for high copy 
numbers of the constructs, in cells that contain the 
SV40 large T protein. Transfection of pBullet and 
helper constructs into 293T cells resulted in 
transient but high virus production: up to 107 
infectious units/mi. Improved and safer stable 
packaging cell lines were also generated (106). 
The retroviral helper elements in these cells, 
GAG/POL and ENV, are now split and present on 
different plasmids to reduce the chance of 
homologous recombination, and thus prevent the 
generation of replication competent retroviruses 
(RCR). The use of distinct promoters for the 
expression of helper elements, as well as a 
reduction in sequence overlap between the 
individual constructs further decreased the 
possibility that RCR are generated. The efficiency 
of retroviral gene transfer to primary human T 
lymphocytes ultimately depends on the retroviral 
vector construct and type of packaging cell line 
used, as well as the gene transduction protocol 
one employs (102-107). 
A 
CMVRUS 
B 
U3 RUS 
U3 RUS 
U3 RUS 
U3 RUS 
U3 RUS 
U3 RUS 
U3 RUS 
U3 RUS 
SA 
U3 RU5 
Figure 2. (A) Schematic presentation of the pBullet 
retroviral vector used to express full-length and chimeric 
TCRa~ genes in human T lymphocytes. (B) Retroviral 
vectors used in other TCR transfer studies. CMV = 
cytomegalovirus promoter; R and US = regions of the 
murine leukemia virus L TR; SO = splice donor site; SA = 
splice acceptor site; '!' = packaging signal; P =internal 
promoter; Hygro/Neo = hygromycin or neomycin 
resistance gene; TCRaf3 = T-cell receptor a or f3 
transgenes; IRES = internal ribosome entry site. 
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Transduction of primary human T lymphocytes on 
retronectin coated culture disks in our hands 
results in high transduction efficiencies of up to 
90% (range 40-90%) ( 106,1 07). This high 
efficiency allowed us to develop a clinical 
applicable gene transduction protocol to transfer 
an Ab-based receptor into T cells, that meets GMP 
and GLP standards (108). In extension, advances 
in retroviral vector technology also enabled for the 
first time the efficient introduction and high-level 
expression of TCR-based receptors in primary 
human T lymphocytes. 
Genetic engineering of T cell specificity: 
introduction of chimeric TCR al3 receptors 
An alternative strategy to the transfer of full-
length TCR al3 genes was developed, to avoid 
the risk of introducing new and possibly 
undesirable specificities into primary human T 
lymphocytes (98, 105, this thesis). Based on 
knowledge that cross-linking of CD3~-Iinked 
proteins, expressed at the cell surface, induces T 
cell activation (1 09,11 0), chimeric two chain TCR 
VaCa~ and VI3CI3~ (tcTCR a~ I 13~), and chimeric 
single chain TCR VaVI3CI3~ (scTCR) genes 
were constructed. In scTCR, both TCR Vl3 and 
Va are present within one TCR chain, and in 
tcTCR a~ I 13~ the presence of ~ induces the 
preferential formation of a~ I 13~ heterodimers. 
TCR a and 13 genes were cloned from the HLA-
A 1-specific, MAGE-A 1-restricted CTL clone 
MZ2-82130 (111 ), were reformatted into chimeric 
CD3<;;-containing TCR genes and introduced into 
the retroviral vector pBullet (105, this thesis). It is 
of interest to note that retroviral introduction of 
one chimeric tcTCRI~ gene (either TCRa or 13) 
into primary human T lymphocytes did not result 
in its cell surface expression, proving that 
chimeric tcTCR a~ or 13~ do not associate with 
endogenous TCR a or 13 chains. On top of that, 
flow-cytometric analysis of tcTCR aV13~ 
transduced T lymphocytes, stained with 
fluorochrome labeled TCR Va and Vl3 family type 
specific mAbs demonstrated a strict correlation 
between cellular TCR a~ and 13~ expression, 
pointing to exclusive pairing between the 
introduced TCR!~ chains. In addition, the use of 
chimeric TCR receptors does not show unstable 
TCRa surface expression since the TCR 
transgenes easily allow detection with TCR Vl3 
and Va family-type specific mab (98,105). Flow-
cytometric analysis further demonstrated that 
chimeric tcTCR as well as scTCR genes remain 
stably expressed, at high levels, in activated, 
bulk cultured primary human T lymphocytes for 
several months. 
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Bulk cultured primary human T lymphocytes 
expressing HLA-A 11MAGE-A 1 specific chimeric 
TCR-based receptors are functionally retargeted 
and exert specific anti-tumor activities, i.e. 
,cytolysis of cancer cells and cytokine 
production. Importantly, the high percentage of 
chimeric receptor positive cells does not 
necessitate selection or cloning of chimeric TCR 
expressing cells , required for clinical application. 
Choice of signaling element: impact on 
chimeric TCR expression and function 
To investigate the role of different signaling 
domains, chimeric scTCR constructs were 
generated that incorporate signaling units such 
as CD3-~ or CD3-c:, derived from a human T cell 
clone, or the Fc(c:)RI y chain, derived from 
human mast cells. These chimeric scTCR 
receptor constructs, VaVI3CI3<;;, VaVI3CI3c: or 
VaV13CI3CD41y did all appear at the cell surface 
of primary human T lymphocytes with equal 
densities, but revealed differences with respect 
to the stability of membrane expression: 
VaVf3CI3y being most stable and VaVI3CI3~ being 
least stable (54). These differences in stability 
may be caused by differences in their ability to 
form homodimers, or alternatively, to associate 
with endogenous TCR chains. ScTCRI<;; 
receptors may associate with endogenous CD3-~ 
chains or form homodimers, whereas 
VaVI3CI3y receptors, that include the CD4-
transmembrane domain are not likely to 
associate with endogenous CD3 molecules or 
form homodimers. Down-regulation of TCR 
chains by for example IL-2 present in culture 
medium, may therefore more drastically affect 
scTCRI~ receptors than for instance scTCR!y 
(112). The scTCRPos T lymphocytes all 
demonstrated the same HLA-A1 restricted 
MAGE-A1-specificity, identical to the CTL clone 
from which the TCR gene fragments were 
cloned. Incubation of scTCRPos T lymphocytes 
with HLA-A11MAGE-A1Pos melanoma target cells 
resulted in immune specific functions such as 
cytolysis, cytokine production and activation of 
the transcription factor NFAT. Membrane 
topology of these chimeric TCR molecules was 
assessed via immuneprecipitation and 
Fluorescence Resonance Energy Transfer 
studies. Importantly, such studies show that 
chimeric TCR-based receptors, when expressed 
on T lymphocytes, interact with endogenous CD3 
and CDS components following a TCR stimulus, 
indicating that these receptors are able to initiate 
the formation of an immunological synapse and 
proximal signaling events (Debets et al, 
manuscript in preparation) 
In extension to chimeric Ab-based receptors that 
comprise the CD28 signaling domain, we also 
introduced the CD28 signaling domain into 
chimeric TCR-based receptor constructs. A direct 
comparison of T lymphocytes that express such 
"tripartite" TCR, i.e., ligand binding, CD28 and 
CD3c; or Fc(s)RI-y domains, with those that 
express chimeric TCR receptors without the CD28 
domain will further contribute to the development 
of an optimal receptor format 
Introduction of non-modified, full-length TCR 
aj3 genes 
Next to chimeric TCR gene transfer, the 
functional transfer of full-length human TCRaj3 
genes specific for TRA or viral antigens to 
human T cell lines and primary human T 
lymphocytes was also a focus of intense 
research (113-119). However, most of these 
TCR aj3 transduced T cells only responded to 
peptide pulsed target cells but not to the "native" 
TRAPos tumor cells or virally infected cells (113-
117). This lack of recognition of antigen 
expressing target cells may be due to the relative 
low expression levels of the introduced TCR aj3 
genes, or the absence or low expression of CDS 
molecules in the T cell transductants. 
The low expression levels of introduced TCR aj3 
genes is most likely a consequence of the type 
of retroviral vectors used in these studies (figure 
28). The elimination of the ENV start codon in 
most retroviral vectors to allow insertion of the 
native start codon of the transgene may have 
lowered expression levels. Furthermore, some of 
the retroviral vectors incorporate both TCR a and 
j3 genes, each having their own promoter. 
Promotor interference may cause lowered 
activity of one or both promotors. Even, when an 
internal ribosomal entry site (IRES) is used to 
express two TCR genes from the same 
promotor, the RNA encoding the TCR gene 
downstream the IRES may not be transcribed 
efficiently. Low transduction efficiencies and low 
levels of TCR aj3 expression due to the applied 
vector technology, described above, 
necessitated T cell cloning for the identification 
of clones specific for native TRAPos tumor cells 
(116,118). 
Nevertheless, functional transfer of full-length 
human TCR aj3 genes into primary human T 
lymphocytes, recognizin~ peptide pulsed target 
cells as well as TRAP0 tumor cells has met 
some success (116, 118). The use of the pBullet 
retroviral vector and an optimized retroviral 
transduction protocol (1 05,1 08) allowed 
successful introduction of full-length TCR a~ 
chains with specificities for gp100 and Hdm2 into 
primary human T lymphocytes (119, 120). High 
transduction efficiencies of full-length TCR genes 
allowed direct analysis of the cytolytic activity of 
bulk cultured TCRaj3 transduced human T 
lymphocytes. These non-enriched TCRaj3 
transduced T lymphocyte populations responded 
to peptide ~ulsed and more importantly to 
"native" TRA os tumor cells by tumor cell kill and 
cytokine production (119, 120). The introduction 
of two different retroviral vectors, each containing 
either the TCR a or j3 chain into individual 
packaging cells results in high-level gene 
transfer of the two TCR genes. Such packaging 
cells showed efficient transfer of two distinct TCR 
receptor genes into individual primary human T 
lymphocytes (119,120). 
Sources of TCR for genetic engineering of T 
cell specificity 
Although the number of CTL clones available for 
cloning of TRA or viral antigen specific TCR is 
expanding, the induction of new CTL against 
TRA is cumbersome. Therefore, alternative 
strategies are needed to construct TCR aj3 
chains with predefined TRA or viral specificity 
(120-122). In this respect, mice, transgenic for 
human HLA-A2 and human CD8a, were used 
successfully to induce T cell responses against a 
human peptide/MHC complex (120). Injection of 
an HLA-A2 binding peptide derived from the TRA 
Hdm2 resulted in an effective T cell response, 
which then allowed isolation and cloning of 
mouse CTL specific for the human Hdm2/HLA-
A2 complex. From these mouse CTL, full-length 
TCR aj3 genes were isolated and introduced into 
the pBullet retroviral vector. Primary human T 
lymphocytes genetically engineered to express 
these mouse or humanized full-length TCR aj3 
demonstrated TRA specific immune functions. 
The Mouse-TCRaj3Pos primary human T 
lymphocytes specifically lysed Hdm2/HLA-A2Pos 
tumor cells. Other strategies that allow the 
generation of TCR with new antigen specificities 
as well as TCR with enhanced affinities, such as 
TCR display, will also contribute to the expansion 
of TCR molecules to be used for genetic 
engineering ofT cell specificities (121 ,122). 
Novel technologies: TCR-Iike molecules 
Strategies that enable identification of TRA on 
tumor cells and isolation of TRA specific molecules 
allow the development of T cell based therapies 
that are not compromised by a limited availability 
of tumor or virus specific CTL. In this respect the 
phage display technology offers high throughput 
selection of antibodies with MHC-restricted 
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specificity (31). An alternative approach, 
immunization of mice with tumor cells and 
subsequent use of the hybridoma technology to 
isolate peptide/MHC specific mAb, did neither 
prove to be successful nor provided a high 
throughput technology for the selection of 
peptide/MHC specific molecules. The production 
of soluble peptide/MHC complexes allowed the 
isolation of Fab-phages from a large "non-immune" 
library that demonstrated exquisite HLA-
A1/MAGE-A1 specificity (31). Up to now, the 
combined use of phage display and the production 
of soluble peptide/MHC complexes resulted in the 
selection of Abs against at least 12 different HLA-
A2-based complexes, with each selection taking 
no more than 3 weeks (32,33). The genes 
encoding the Fab VH and VL domains of the HLA-
A1/MAGE-A1 specific phage were used to 
construct a chimeric two-chain-Fab receptor (123, 
this thesis). We linked the VH as well as the VL 
gene fragment to the CD4 transmembrane domain 
and the intracellular domain of Fc(c:)RI y. Primary 
human T lymphocytes transduced with chimeric 
Fab-CD4/y genes specific for HLA-A1/MAGE-A1 
functionally demonstrated the introduced 
specificity. Incubation of bulk cultured Fab-
CD4!/08 lymphocytes with HLA-A1P08, MAGE-
A 1 Po melanoma cells resulted in peptide/MHC 
restricted tumor cell lysis and cytokine production. 
Phage display derived TCR-Iike Ab have several 
advantages over full-length TCR ai3 for the genetic 
engineering of T cell specificity: 1) the relative 
ease of isolation, expansion and handling of 
phages, 2) and the option to manipulate phage 
displayed Abs with respect to ligand binding 
affinity and format i.e. Fab or scFv. In example, we 
increased the ligand binding affinity of the original 
HLA-A1/MAGE-A1 specific Fab fragment G8 18 
fold. The resulting Fab, i.e., Hyb3, was cloned and 
reformatted into a chimeric receptor. This high 
affinity chimeric FabCD4/y receptor could be 
efficiently expressed in primary human T 
lymphocytes, and resulted in increased immune 
specific activities (124, this thesis). As a 
consequence, tumors that present low levels of 
peptide/MHC complexes on their membrane may 
not escape from recognition by such high affinity 
Fab transduced T cells. Indeed, recently it was 
demonstrated that high avidity CTL provide better 
protection against viral infection because they 
require less antigen to become activated; they 
initiate cell lysis more rapidly and thus are able to 
eliminate more infected cells (125). 
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SCOPE OF THIS THESIS: GENETIC 
ENGINEERING OFT CELL SPECIFICITY 
The current thesis deals with the development of 
strategies to permanently graft primary human T 
lymphocytes with MHC-restricted, tumor-
specificity. The design and functional introduction 
of two types of chimeric TCR-based receptors in 
primary human T lymphocytes is described in 
chapter 2. These chimeric tc-TCRI~ and scTCRI~ 
receptors provide an alternative to the introduction 
of to full-length TCRaj3 genes into human T 
lymphocytes. The difference in fine-specificity of 
two scTCR, with identical TCR VaVj3, but with 
distinct transmembrane and intracellular signaling 
domains is described in chapter 3. Furthermore, 
we demonstrated that differences must exist for 
MHC class I molecules that are loaded intracellular 
with tumor peptides and MHC-class I molecules 
that are loaded extracellular with tumor peptides. 
In chapter 4 the functional transfer of chimeric tc-
TCRI~ to CD4Pos T lymphocytes is described. The 
requirement for CD8a co-expression into these 
CD4+, tc-TCRI~+ was shown to be a prerequisite 
for chimeric receptor mediated immune functions 
such as cytokine release and cytotoxicity. 
The second part of this thesis deals with a unique 
type of receptors, based on novel MHC-restricted, 
tumor specific antibody fragments isolated from a 
large phage display library. In chapter 5 the design 
and functional expression of such an antibody 
based receptor with "TCR-Iike" specificity, the two 
chain FA8G8-CD4/y receptor, is described. Chapter 
6 describes the in vitro affinity maturation of the 
MHC-restricted, tumor specific antibody fragment 
that was used in the experiments described in 
chapter 5. T lymphocytes equipped with this high 
affinity antibody-based receptor proved to be more 
responsive to tumor cells, i.e. higher levels of 
cytokine production were observed as well as 
enhanced cytolytic functions of receptor engrafted 
T lymphocytes. 
Finally, chapter 7 describes an alternative way to 
improve receptor mediated functions of T 
lymphocytes grafted with antibody-based chimeric 
receptors. Incorporation of the CD28 co-signalling 
domain into chimeric scFv receptors resulted not 
only in enhanced cytokine release, but also in 
increased cytolytic functions of the receptor 
grafted T lymphocytes. 
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Grafting primary human T lymphocytes with cancer-
specific chimeric single chain and two chain TCR 
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Primary human activated T lymphocytes were genetically 
grafted with chimeric T cell receptors (TCR). Three domain 
single chain (sc-) TCR as well as two chain (tc-) TCR gene 
constructs were derived from the melanoma-specifi ccyto-
toxic human T cell (CTL) clone 82/30, and linked to the CD3-
;; signaling element. Chimeric TCR a and f3 receptor genes 
were structurally designed to prevent pairing with endogen-
ous TCR a and f3 chains in order to prevent the generation 
of unpredictable immune specifi citiesAfter transduction of 
polyclonally activated human peripheral blood lymphocytes 
with retroviral vectors harboring the chimeric receptor genes, 
genetically engineered cells specifi cally recognized and 
responded to MAGE-A1P08/HLA-A1eos cells. Importantly, 
each type of transduced T lymphocytes that bound specifi -
cally to peptide!MHC complexes also showed specifi canti-
tumor reactivity as well as lymphokine production. Geneti-
cally engineered primary human T lymphocytes expressing 
chimeric sc- or tc-TCR therefore hold promise for disease-
specific therapies. Gene Therapy {2000) 7, 1369-1377. 
Keywords: chimeric; T cell receptor; MAGE-A 1; HLA-A 1; T lymphocytes 
Introduction 
Adoptive transfer of MHC-restricted, antigen-specific 
CTL can mediate anti-tumor effects in patients with, for 
example, metastatic melanoma.1 Unfortunately, most 
patients do not mount a strong and effective in vivo cyto-
toxic T cell response to their tumors. Moreover, isolation 
of tumor-specific T lymphocytes is only successful in a 
fraction of patients and expansion of cancer-specific, 
MHC-restricted human T lymphocytes to therapeutic 
doses presents other difficulties. Hence, the rate of suc-
cess in obtaining autologous therapeutic T lymphocytes 
is unpredictable, and this has hampered their clinical 
application in adoptive T lymphocyte transfer for the 
treatment of cancer and viral infections. In contrast, 
monoclonal antibodies (mAb) with specificity for a wide 
range of tumor types are available. Therapeutic stra-
tegies, which combine the tumor-specific recognition 
capacity of mAbs with the lytic potential of CTL, have 
been developed by ourselves and others/·3 for example, 
ovarian tumor recognition by CTL was obtained by retar-
geting CTL using bispecific mAbs4•5 (bsmAb). Also, 
human CTL have permanently been stably retargeted 
with mAb-based tumor selectivity and anti-tumor 
activity by transduction of genes coding for chimeric Ab-
type receptors."-11 . This genetic approach avoids loss of 
tumor selectivity due to dissociation of the bs-mAbs from 
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nology, Academic Hospital Rotterdam, Daniel den Hoed Cancer Center, 
PO Box 5201, 3008 AE Rotterdam, The Netherlands 
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the CTL surfaceP However, all recently identified tumor 
rejection antigens (TRA), for example, MAGE, tyrosine, 
MART, BAGE and RAGE13 are processed intracellularly 
by tumor cells and presented by MHC class I molecules 
on the membrane.14 These TRA can be recognized by 
(human) CTL in vivo and in vitro.14·15 
Retroviral transduction of transgenes encoding for TCR 
that are derived from existing MHC-restricted T cell 
clones specific for TRA in principle should confer TRA 
immune specificity to activated human T lymphocyte 
populations. This genetic programming of human lym-
phocyte specificity would bypass the requirement to iso-
late TRA-specific T lymphocytes from individual cancer 
patients and/ or their in vitro generation using autologous 
tumor stimulator cells. 
Indeed, the ability of chimeric tc-TCR ai:/13~ heterodi-
mers16 and of full-length crj3 TCR heterodimers17 to bind 
antigen/MHC complexes has previously been tested by 
exposure of either rat RBL-2H3 cells, expressing chimeric 
tc-TCRs, or human Jurkat cells expressing full-length 
crj3TCRs, respectively, to target cells pulsed with relevant 
peptides. Following antigen-specific triggering rat RBL-
2H3 cells secreted serotonin, and human Jurkat cells 
secreted IL-2. However, relevant native tumor antigen-
positive tumor cells did not trigger any immune reac-
tivity. Chung18 suggested that introduction of complete 
TCR "' and j3 chains in T lymphocytes may have resulted 
in suboptimal levels of TCR crj3 cell surface expression 
due to instability of the exogenous TCR a chain/8 which 
prohibits detection of immune functions. Lack of recog-
nition of native tumor antigen by the Jurkat transfectants 
was also ascribed to the need for additional factors in 
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order to allow selective discrimination of specific native 
peptide/MHC complexes within a more complex context 
in the tumor cell membrane. After all, tumor cells present 
native antigen amidst a multitude of irrelevant, yet 
highly homologous complexes of the same MHC mol-
ecules carrying a variety of 'self' or 'non-self' peptides. 
Activation by native antigen therefore may require simul-
taneous co-signaling by CDS or need the involvement of 
adhesion molecules in order to activate T cells during 
TCR/MHC interaction.15•17•19 Moreover, the genetically 
introduced TCR ex and i3 chains may have paired with 
endogenous TCR ex and i3 chains in the T lymphocytes 
that resulted in unpredictable, irrelevant immune speci-
ficities at the expense of the numbers of engineered rel-
evant TCR to become expressed in the T lymphocyte 
membrane. Until now, attempts to introduce functional 
human chimepc single chain- or two chain-TCR exi3 genes 
into primary human T lymphocytes have remained 
unsuccessful. 
Here we describe the first successful, reproducible and 
functional transduction of primary human T lymphocytes 
with chimeric sc- and tc-TCR genes encoding MAGE-
A1/HLA-A1-specific TCR. High percentages and high 
levels of chimeric TCR exi3 expression in primary human 
T lymphocytes were obtained as visualized using fluor-
ochrome-labeled TCR family typing antibodies. 
Our results also show that soluble MAGE-A1/HLA-A1 
complexes can be used to identify human T lymphocytes 
expressing chimeric TCR exi3 genes and these T lympho-
cytes exert MAGE-A1/HLA-A1-specific anti-tumor reac-
tivities as evidenced by tumor cell kill and lymphokine 
production. 
Results 
Chimeric sc- and tc-TCR expression on the membrane 
of gene-transduced primary human T lymphocytes 
Chimeric sc-TCR VexVi3Ci3~ genes and chimeric tc-TCR 
VexCex~ and Vi3Ci3~ genes were constructed from TCR ex 
and i3 chain DNA fragments (Figure 1), derived from the 
MAGE-A1-specific, HLA-A1-restricted human T cell 
clone MZZ-82/30, that had been isolated from a mela-
noma patient.14 Based on knowledge that antibody-
mediated cross-linking of proteins, expressed at the cell 
surface, and linked to CD3-~, induces T cell activation/·20-
22 the sc-TCR Vex Vi3Ci3, and the tc-TCR V exCex and Vi3Ci3 
genes were ligated to the ~ gene that was cloned from a 
cytotoxic T cell clone, as previously described.23 Chimeric 
tc-TCR VexCex-~ and Vi3Ci3-~ genes were formatted to 
exclude pairing with endogenous TCR exi3 chains on T 
11c-TCR VnVPC~<:; 
ILl 
tc-TCR-a.:: 
lc I Vo 
tc-TCR-flc; 
lc I VP 
lui V[l !OIJ I 
ca I~EclgMI (Cy 
Figure 1 Chimeric-T cell receptor af3 constructs. Schematic 
representation of: (1) the chimeric sc-TCR VaVf3Cf3{ gene and (2) 
chimeric tc-TCR V aCa{ and Vf3Cf3~ genes (L, leader; V, variable region; 
r joining region; D, diversity region; C, constant region; EC, extracellular 
region; Tm, transmembrane region; Cy, Cytoplasmic region; Li, linker). 
Constructs were made as described in Materials and methods. 
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lymphocytes. This was accomplished by fusion of the 
extracellular TCR exi3 domains in frame to CD3-~, which 
was shown to induce preferentially heterodimerization of 
the chimeric TCR exi3 genes.16·:" In chimeric sc-TCR 
Vex Vi3Ci3~ genes, the V regions are covalently joined by 
a short peptide linker and hence, the problems associated 
with unstable TCR ex expression and pairing with 
endogenous TCR exi3 chains were avoided.18 Chimeric tc-
TCR VexCex-~ and Vi3Ci3-~ genes were then cloned into 
the retroviral vector pStitch23 and the chimeric sc-TCR 
VuVi3Ci3~ gene was introduced into the pBullet vector, 
that was derived from the pStitch vector (Materials and 
methods). These retroviral vectors were specifically 
designed to transduce efficiently human T lymphocytes. 
To obtain 'therapeutic' numbers (approximately 109) of 
dividing T lymphocytes as well as optimal gene trans-
duction efficacy, fresh or cryopreserved/ thawed periph-
eral blood mononuclear cells (PBMC) derived from 
donors were polyclonally activated using soluble anti-
CD3 monoclonal antibody (mAb) supplemented with 
recombinant interleukin-2 (IL-2). Activation could also be 
performed on immobilized anti-CD3 and anti-CD28 
mAbs plus IL-2. Retroviral transduction of chimeric tc-
TCR VexCu~ and Vi3Ci3~ gene constructs was then per-
formed by cocultivating the anti-CD3 mAb activated 
human lymphocytes with virus-producing 293T packag-
ing cells. The chimeric sc-TCR VexVi3Ci3~ gene was intro-
duced into human T lymphocytes by: (1) cocultivation 
with virus producing 293T cells or (2) by incubation with 
supematant obtained from PG13 packaging cells that 
contained the chimeric sc-TCR VexVi3Ci3~ gene. 
Flow cytometric analysis of gene-transduced T lym-
phocytes demonstrated expression of: (1) chimeric sc-
TCR VexVi3Ci3~ and (2) chimeric tc-TCR VexCex~ and 
Vi3Ci3~ transgenes, in as high as 15 to 40% of primary 
polyclonally activated human T lymphocytes (Figure 2). 
Apparently, no pairing of chimeric TCR exi3 molecules 
with endogenous TCR exi3 chains occurred, as suggested 
by the FACS staining pattem that shows a strictly coordi-
nated expression of the chimeric TCR Vex12.1 and Vi31 
chains (Figure 2). Moreover, no expression of either the 
chimeric tc-TCR VexCex~ or Vi3Ci3~ transgene was 
observed when only one of these genes was introduced 
into activated human T lymphocytes (Figure 2c and d). 
The level of chimeric-TCR exi3 expression in the lympho-
cyte membrane varied over a 100-fold range. Chimeric-
TCR ui3P05, CD4NEG T lymphocytes were then enriched 
by flow sorting using fluorochrome-labeled Vex-12.1, Vi31 
family typing mAbs and anti-CD4-Cy5 mAb. FACS 
sorted T lymphocyte fractions where then used for func-
tional analysis, ie specific binding of soluble MAGE-AI 
peptide/MHC complexes; MAGE-A1-specific target cell 
cytolytic capacity, and lymphokine production during 
stimulation with peptide pulsed target cells or native 
melanoma cells (see below). 
Chimeric TCR af3Pos T lymphocytes specifi callybind 
soluble MAGE-A1/HLA-A1 complexes 
The MAGE-A1/HLA-A1 complexes (peptide: 
EADPTGHSY) and irrelevant Influenza/HLA-A1 com-
plexes with a peptide derived from Influenza virus A 
nucleoprotein (peptide: CTELKLSDY) were generated 
and used for the identification of MAGE-A1/HLA-A1-
specific engineered TCR in the membrane of bulk gene-
transduced human polyclonal T lymphocytes. It 
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Figure 2 Cell surface expression of chimeric-TCR a{3-transduced primary 
human T lymphocytes. Expression of: (1) chimeric sc-TCR VaVf3Cf3~ and 
(2) chimeric tc VaCa~ fVf3C/3{ constructs was determined by flow 
cytametry after gene transduction of primary human T lymphocytes. 
Events shown represent viable lymphocytes stained with anti-Va12.1mc 
and anti-Vf3JPE mAbs (>95% viable, checked by trypan blue staining!. 
(al) Human T lymphocytes simultaneously transduced with V aCa-~ and 
Vf3C{3-~ retraviral vectors. (als) Human T lymphocytes transduced with 
VaCa-~ and Vf3C{3-~ retraviral vectors and followed by enrichment by 
flow sorting using anti-V a12.1 FITC and anti-V{31 PE mAb. (bl) Human 
T lymphocytes transduced with VaVf3Cf3~ retraviral vectors. (bJS) 
Human T lymphocytes transduced with V aVf3Cf3~ retraviral vectors and 
enriched by flow sorting using anti-V al2.1 FITC and anti-V{31 PE mAbs. 
(c) Human T lymphocytes transduced with the VaCa-~retraviral vector. 
(d) Human T lymphocytes transduced with the Vf3Cf3-t retroviral vector. 
(e) HLA-Al restricted, MAGE-Al-specific parental CTL clone MZ2-
82/30 (positive control). (f! Human T lymphocytes transduced with the 
CD24 gene (negative control!. Data presented in al', bl', e and f were 
derived from one experiment; al, bl and c and d were derived from twa 
separate experiments. 
appeared that indeed only relevant MAGE-AI/HLA-A1-
streptavidinPE complexes specifically bound to: (I) dum-
eric sc-TCR VaVI3CI3!; (Figure 3c), and (2) chimeric tc-
TCR al:/136 (Figure 3d) expressed on the surface of 
human T lymphocyte transductants, ie control fluoro-
chrome-labeled peptide/HLA-AI complexes comprising 
the Influenza peptide did not bind. Moreover, human T 
lymphocytes that were transduced with the enhanced 
green fluorescence protein (EGFP) transgene did not 
bind the MAGE-A1/HLA-AI/streptavidinPE complexes 
(Figure 3a). 
MAGE-A 1 peptide pulsed HLA-A 1Pos target cells 
specifi callytrigger lysis and lymphokine production by 
genetically programmed CTL 
To provide optimal signaling conditions for the trans-
duced T lymphocytes we used MAGE-A1NE0 , HLA-AIPos 
melanoma cells (MEL 2A) and EBV-transformed B cell 
blasts (72-2 and APD) that had been pulsed with 10 
[Lg/rnl of MAGE-AI peptide or with irrelevant Influenza 
virus peptide. Polyclonal T lymphocyte populations 
expressing either: (1) chimeric sc-TCR V u VI3CI36 or (2) 
chimeric tc-TCR ul:/136 on their membrane, each became 
specifically activated by MAGE-AI peptide pulsed HLA-
AIPos MEL 2A melanoma cells or by MAGE-AI peptide 
pulsed HLA-A1POs B lymphoblastoid cell lines (72-2 and 
APD). Non-pulsed target cells, or target cells pulsed with 
irrelevant Influenza peptide were not lysed (Figure 4) . 
Moreover, each type of transduced T lymphocytes also 
specifically responded to MAGE-AI peptide pulsed 
melanoma target cells with production of TNF-u, GM-
CSF and IFN-'Y (Table I). Five of five donors that were 
transduced with the chimeric tc- and sc-TCR were shown 
to lyse MAGE-AI peptide pulsed target cells specifically 
(Table 2). 
Native MAGE-A1P05/HLA-A1Pos melanoma cells 
specifi callytrigger lysis and lymphokine production by 
chimeric TCR uf3Pos T lymphocytes 
We then investigated whether chimeric sc-TCR V u VI3CI36 
or chimeric tc-TCR ul:/136 expressing T lymphocytes each 
could also specifically recognize native MAGE-AI POs 
/HLA-AIPOs melanoma cells. To this end, several 
MAGE-AI Pos /HLA-A1 POS melanoma cell lines as well as 
HLA-AINEG control cell lines were mixed with aliquots 
of each type of transduced T lymphocytes. As shown in 
Figure 5, anti-Vui2JFITc and anti-VI3IPE mAbs sorted, 
chimeric sc- and tc-TCR ui3Pos T lymphocytes were each 
capable of specifically lysing native MAGE-AIPos, HLA-
AIPos melanoma cells (MZ2-MEL 3.0 and 5ISA2). To 
illustrate the specificity of lysis further, it was shown that 
addition of anti-MHC class I mAb resulted in significant 
reduction of specific tumor cell kill, whereas irrelevant 
mAb did not (Figure 5). Negative control HLA-AIPos, 
MAGE-AI NEG cell lines (MEL 2A, 72-2 and APD, see Fig-
ure 4) and distinct MHC-class rPOs (ie non-HLA-AIPOS) 
target cell lines used in this experiment were not lysed 
(MEL 78, BLM and SKRCI7-4, data not shown). Native 
MAGE-AIP05/HLA-AIPos melanoma cells also specifi-
cally induced TNF-u, GM-CSF and IFN-'Y production by 
the sorted chimeric TCR ui3POs T lymphocytes (Table 3). 
High effi cientsc-TCR VuVf3Cf3!; gene transfer into 
human T lymphocytes using retronectin-coated culture 
plates 
So far, the efficacy of retroviral gene transfer into primary 
human T lymphocytes for clinical application has been 
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Figure 3 Peptide-MHC complex binding of chimeric-TCR a{3 expressing primary human T lymphocytes. Specific binding of soluble MAGE-AI/HLA-
AI/streptavidinPE complexes by transduced and flow-sorted primary human T lymphocytes was determined by flow cytometry. Flow-sorted T lymphocytes 
were stained with soluble MAGE-AI/HLA-AijstreptavidinPE complexes (AI/MI, shaded area) and soluble Influenza peptidejHLA-AI/streptavidinPE 
complexes (AIJIFN, open area) as described in Materials and methods. 
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Figure 4 Peptide-pulsed target cells are lysed by chimeric-TCR af3-
transduced human T lymphocytes. MAGE-AI peptide-pulsed HLA-AI~"'' 
target cells were incubated with flow-sorted human T lymphocytes 
transduced with: (1) the EGFP gene, (2) chimeric tc-TCR a{/{3{ grnes, 
and (3) the chimeric sc-TCR VaV{3C{3{ gene, and tested in 6 h 51Cr 
release assays at four effector to target cell ratios (E:T). Shown are 
representative results obtained at E:T 27:1. 51Cr-labeled MAGE-AINEc, 
HLA-A1P05, EBV-transformed B cell lines 72-2 and APD, and 51Cr-
labeled MAGE-AI NEe; HLA-AIP05 MEL 2A melanoma cells were pulsed 
with MAGE-AI or InfluenZil virus peptides (10 !Lg/ml). Experiments 
were performed in triplicate, and the s.d. did not exceed 10%. Shown are 
data of one representative experiment out of three. 
hampered by poor transduction efficiencies of super-
natant transduction protocols. Our viral vectors23 in com-
bination with immobilized recombinant fibronectin frag-
ments24 now allow for high transduction efficiencies into 
primary human T lymphocytes. After bulk transduction 
on retronectin-coated culture plates of primary, CD4-
depleted activated human T lymphocytes, derived from 
three donors, with the chimeric sc-TCR V u V!3C!3' gene, 
40-70% of the transduced populations were chimeric sc-
TCR Vul2.1/V!31POs as determined by cytofluorometric 
analysis (Figure 6a). The scTCRPos T lymphocytes 
responded to MAGE-Al peptide pulsed MAGE-AlNEG, 
HLA-A1P05 melanoma cells (Mel2A) as well as native 
MAGE-AF05, HLA-AF0 s melanoma cells (MZ2-MEL3.0) 
(Figure 6b), but not to the MAGE-AlNEG, HLA-AlPos 
melanoma cells (Mel2A). 
Discussion 
Here, we describe the first successful and functional 
transduction in primary human T lymphocytes of chim-
eric TCR u!3 genes encoding sc- (VuV!3C!3Q or tc-
(VuCuUV!3C!3') TCR with immune specificity for 
MAGE-AlPos /HLA-AlP05, native as well as peptide 
loaded melanoma cells. Eight out of eight polyclonally 
activated human T lymphocyte populations were func-
tionally transduced, ie (1) the T cell transductants 
Table 1 TNF-a, GM-CSF and IFN-"{ production by cbimeric-TCR ai3-transduced CTL: incubation with MAGE-A1 peptide pulsed mela-
noma cells 
CTL 82/30 
sc-TCR VaVj3Cj3£P05 
T lymphocytes 
tc-TCR a£/ i3£ros 
T lymphocytes 
No pept. 
0.0 
56 
61 
TNF-a pg/ml 
+ MAGE-AI pept. 
2996 
105 
380 
"As described in Materials and methods. 
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MAGE-A1 peptide pulsed melanoma cells" 
GM-CSF pg/ml 
No pept. + MAGE-AI pept. 
0.0 
0.0 
0.0 
426 
629 
3767 
IFN-y pgjml 
No pept. + MAGE-A1 pept. 
39 
34 
97 
6678 
577 
1954 
Table 2 Chimeric sc- and tc-TCR-transduced T lymphocytes: FACS 
analysis and cytotoxicity 
Donor FACS analysis Cytotoxicity analysis' 
% Va 12JPOSfV{31Pos T % 51Cr release at E:T 
lymph 27:1 
pre-sort post sort no pept. + pept. 
% % % % 
tc-TCR VaCa~/V{3C{3~ 
D2 32 >906 IS 73d 
D3 26 65" 40 73" 
D4 24 52" 28 46" 
DS IS 48" 0 24' 
D6 29 64" 9 67' 
sc-TCR VaV{3C{3{ 
D1 23 63" 26 64" 
D2 28 >906 IS 73d 
D3 34 60" 11 40' 
D4 26 34" 34 63" 
'As described in Materials and methods. 
6 Enrichment by flow cytometric sorting using anti-Vcr12.IFITc and 
anti-VJ3IPE mAbs. 
"Enrichment by anti-VJ3I-coated magnetic beads. 
d MAGE-AI peptide loaded HLA-AIPOS, MAGE-AI NEe MEL2A 
melanoma cells. 
"MAGE-AI peptide loaded HLA-AIPOS, MAGE-AINEc MZ2-MEL 
2.2 melanoma cells. 
'MAGE-AI peptide loaded HLA-Airo5, MAGE-AINEc B-LCL 
cells (APD). 
expressed chimeric sc- and tc- al3 TCR on their mem-
brane, (2) specifically killed native MAGE-AlPos;HLA-
AlPOs melanoma cells as well as MAGE-Al peptide 
pulsed HLA-Al Pas target cells; and (3) were specifically 
triggered by these cells to produce TNF-a, GM-CSF and 
IFN--y. 
Table3 TNF cr, GM-CSF and IFN--y production by chlmeric-TCR 
crj3-transduced CTL: incubation with native MAGE-AIPos;HLA-
AIPOs melanoma cells 
CTL 82/30 
sc-TCR 
VcrVJ3CJ3£Pos 
T lymphocytes 
tc-TCR a£/J3<;P05 
T lymphocytes 
Native HLA-AlP05/MAGE-A1POs melanoma 
cellsu 
TNF-a pg/ml GM-CSF IFN-y 
pg/ml pg/ml 
428/06 54/06 1159/396 
85/566 I889/06 272/346 
I20/616 1785/06 306/976 
'As described in Materials and methods. 
6 Negative control HLA-AI Pos, MAGE-AI NEG cell line MZ2-MEL 
2.2. 
The ability to generate primary polyclonal human 
chimeric-TCR aj3Pos CTL with predefined immune speci-
ficities is of fundamental as well as clinical importance. 
Fundamental, because functional TCR gene grafting to 
(human) T lymphocytes allows the study of: (1) whether 
and how genetically introduced TCR (and other 
receptors) with distinct molecular configurations, and 
linked to distinct signaling elements, can interact with 
other T cell (co-) signaling/adhesion molecules, and (2) 
how these may integrate downstream with other intra-
cellular signaling pathways.25•26 Clinical, because such 
CTL can be used in disease-specific therapies.27- 29 This 
important notion is supported by recent reports that 
adoptive transfer of CMV -specific'0 or melanoma-spe-
cific31 CTL have been clinically effective in the prophy-
laxis of CMV reactivation and tumor growth control, 
respectively. 
HLA-A1"'. MAGE-1 00 ' MELANOMA 
TARGET CELLS 
a 
sc-TCR 
Va.V~C[)l;Pos 
T LYMPH, 
b 
tc-TCR 
w;t~POs 
T LYMPH. 
MZ2-MEL3.0 518A2 
·::b·::~ 
'· .. ~· .... 
~ : ~: ' 
~ "''"'·'"'' ,,, 0111J7·1•·• ,,, 
g·::~ ·::~ 
~~~ :~~ 
"'' "'' ''' ''' n,,,,, ''' ''' 
E:Tratio 
c 
PARENTAL 
CTL 62/30 
MZZ-MEL 3.0 516A2 
·::cs--< ·::~ 
.. '---,, 40 "'\:: 
~ ,. '•, ,, ~ 
~ ·., 3 " ,;, • .3,, ·~.1 :~~-,;, • .3t1 
i3 
:N:GcoNTRoL ~ ·.,:.~l-. ·.~.·L 
: EGFPP05 T LYMPH. ""' 
. . -""'" 
>Ttl •" )t1 111 :11;1 o;1 ~' 1 1; t 
E:Tratio 
anU·dlllllll mAb - - ~ontrol mAb 
Figure 5 Native MAGE-A1Pos, HLA-A1Pos melanoma cells are susceptible to lysis by chimeric-TCR a{3 transduced T lymphocytes. Cytolytic capacity 
of transduced and flow-sorted human T lymphocytes was determined in 6 h 51Cr release assays. Left two rows show results obtained with 51Cr-labeled 
MAGE-Al'05, HLA-AIPos melanoma cells (MZ2-MEL 3.0 and 518A2) incubated with sc-TCR VaV{3C{3~Pos and tc-TCR VaCa~/Vf3CNPus T 
lymphocytes. The right two rows shows results obtained with 51Cr-labeled MAGE-AlPos, HLA-A1POs melanoma cells (MZ2-MEL 3.0 and 518A2) 
incubated with the positive control CTL 82/30 and negative control EGFP gene-transduced T lymphocytes. Anti-HLA-ABC (10 p.gjml) or mouse Ig 
(10 p.gjml) was added to the melanoma target cells (MZ2-MEL 3.0 and 518A2) 15-30 min before incubation with the effector T lymphocytes. Data 
obtained with negative control MAGE-AlNEc, HLA-A1Pos target cells in this experiment are shown in Figure 4. Shown are mean percentages of 
triplicates of per cent-specific 51Cr release. Data of one representative experiment out of three are shown. 
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Figure 6 Human T lymphocytes transduced with the chimeric TCR 
VaV{3C{g on retronectin-coated culture plates show HLA-Al-restricted, 
MAGE-Al specificity. (a) Expression of chimeric single chain TCR 
VaV{3C{3~ on human T lymphocytes was determined by flow cytometry. 
Events shown represent viable lymphocytes stained with anti-V a12.1 me 
and anti-V{31PE mAbs. (b) Negative control MAGE-A1NE0 , HLA-A1POs, 
melanoma cells, MAGE-A1 peptide-pulsed HLA-Al Pas melanoma cells 
and native MAGE-AJP0s/HLA-A1P05 target cells were incubated with 
the indicated human T lymphocytes and tested in 6 h 51 Cr release assays. 
The data show the per cent-specific 51Cr release from: (1) negative control 
HLA-A1Pos MellA melanoma cells, (2) HLA-AlPos Mel2A melanoma 
cells pulsed with 10 Jl.g/ml MAGE-A1 peptide and, (3) MAGE-
Al"05/HLA-A1P05 MZ2-MEL 3.0 melanoma cells. Cytolytic activity of 
'YO T lymphocytes present in the transduced polyclonal human T 
lymphocyte populations was blocked by addition of anti-'Yi5 mAb (1:1000 
11F2 ascites) to the effector cells. Experiments were performed in 
triplicate, and the s.d. did not exceed 10%. Shown are the results obtained 
with one representative donor transduced with the chimeric scTCR 
VaVf3Cf3~ and CD24 gene from one representative experiment (one out 
of three). 
The 'pStitch' and pBullet viral vectors we developed23 
and used in this study were critical to transduce 
efficiently and functionally chimeric sc-and tc-TCR gene 
constructs into primary human T lymphocytes activated 
with anti-CD3 mAb. Each type of transduced TCR exl3 
gene was stably expressed in the transduced human T 
lymphocytes, and yielded high membrane expression 
levels of the chimeric receptors, as visualized using fluo-
rochrome-labeled TCR Vexl2.1 and Vl3l family typing 
monoclonal antibodies or specific MAGE-Al/HLA-Al 
complexes. Chimeric two chain-TCR ex{/13{ gene con-
structs were formatted to facilitate preferential efficient 
heterodimerisation and membrane expression of these 
gene products.16 We therefore expected that the chimeric 
ex{ and 13{ chains would not pair with endogenous full-
length TCR 13 and ex chains, respectively. Indeed, the 
strictly coordinated expression of chimeric TCR ex[3 
chains illustrates that no such pairing of chimeric tc-TCR 
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ex{/13{ chains as well as chimeric sc-TCR VexVI3CI3{ with 
endogenous TCR exl3 chains occurred, avoiding the cre-
ation of unknown immune specificities. Indeed, follow-
ing transfer of either chimeric TCR ex{ or 13{ genes alone, 
no chimeric ex{ or chimeric 13{ chains were detected on 
the membrane of T cell transductants that were either 
PCR Vexl2.1 or Vl3l positive, respectively (Figure 2). 
We then used in-house synthesized MAGE-Al/HLA-
Al complexes to identify relevant chimeric sc- and tc-
TCR because Altman et aP2 recently showed that fluor-
ochrome-labeled peptide/MHC class I tetramers provide 
an extremely sensitive and practical tool to identify and 
isolate T lymphocytes with MHC-restricted TRA binding 
capacity. Moreover, Y ee et aF7 recently demonstrated that 
peptide/MHC tetramers not only identify but also select 
high avidity melanoma reactive CTL from heterogeneous 
T lymphocyte populations that were generated in mixed 
T lymphocyte/peptide pulsed dendritic cell cultures. 
Importantly, the CTL with high GP100/HLA-A2 tetramer 
binding capacity recognized not only peptide pulsed tar-
gets but also native TRAPos melanoma, in contrast they 
showed that CTL with low tetramer binding capacity did 
not recognize native melanoma. Because they found no 
differences in the densities of adhesion molecules or CDS 
on the membrane of these T cells it was concluded that 
the level of tetramer binding directly reflected the level 
of TCR affinity of individual T lymphocytes in hetero-
geneous T lymphocyte populations. 
Here, we also show that primary polyclonal human T 
lymphocytes that are genetically engineered to express 
chimeric sc- or tc-TCR and bind soluble HLA-Al/MAGE-
Al complexes lyse native MAGE-AlPOs melanoma cells 
and peptide pulsed target cells. However, in our system, 
individual T lymphocytes express the same, clonal chim-
eric Vexl2.1/V13 TCR, and bind MAGE-Al/HLA-Al com-
plexes. Thus, based on published data27 the chimeric TCR 
is of high affinity. Because of the clonal nature of the 
chimeric TCR, differences in MAGE-Al/HLA-Al com-
plex binding levels (avidity) in our experiments must 
reflect differences in the absolute numbers of chimeric 
TCR expressed in individual T lymphocytes, not differ-
ences in affinities between receptors. The relatively 'low 
TRA/MHC complex binding' chimeric TCRPos T lym-
phocyte fraction lacks melanoma reactivity, and this 
could be attributed to a combination of relatively low 
TRA expression on melanoma cells on the one hand and 
the observed low chimeric TCR Vexl2.1/V131 expression 
on the CTL on the other. Indeed, we recently demon-
strated that such functional relationship between antigen 
receptor density on human T lymphocytes and tumor 
antigen density on tumor cells, respectively exists.41 
Following gene transfer on retronectin-coated culture 
plates, 40-75% of the bulk cultured, CD4-depleted poly-
clonal human T lymphocytes were chimeric sc-TCRPOs, 
and specifically killed native HLA-AlPOS/MAGE-AlPos 
melanoma cells. This makes this T cell transduction tech-
nology a promising candidate for therapeutic appli-
cations. The already large fraction of chimeric TCR ex[3Pos 
transductants in bulk-transduced human T lymphocytes 
can be directly and readily expanded in vitro to thera-
peutic numbers and used for immuno-gene therapy, ie 
without the need to clone melanoma reactive T cells 
before expansion. Moreover, the clinical use of trans-
duced polyclonal immune lymphocytes, each subtype 
having its particular lymphokine production repertoire, 
proliferative and/ or trafficking capacities, may prove 
optimal to control tumor cell growth. We have success-
fully transduced distinct lymphocyte populations, for 
example, NK cells, TCR uj3 (this article) and 'YO T lym-
phocytes, with chimeric sc- and tc-TCR uj3, that have dis-
tinct immune reactivities (manuscript in preparation). 
Moreover, we can now also confer multiple peptide or 
TRA-specific TCRs to individual T lymphocytes. The 
therapeutic use of multiple effector cell types, each 
expressing one or multiple receptor specificities may 
enhance anti-tumor activity by reducing the chance of 
tumor cells to escape from immune attack, and result in 
a prolonged anti-tumor response. To this end, large 
libraries can be composed of cDNAs encoding for any 
antigen/MHC specificity for which human CTL clones 
are or become available, they can be generated from in 
vivo isolated T lymphocytes, generated in vitro by specific 
stimulation, or created from TCR uj3 or 'YO display 
libraries. 33,34 
In conclusion, genetic engineering of T lymphocyte 
specificity with chimeric TCR uj3 provides an efficient 
and reliable tool to produce MHC-restricted, antigen-
specific human T lymphocytes that may prove of signifi-
cant use for disease-specific immune gene therapy of, for 
example, cancer and viral infections. 
Materials and methods 
Cells and antibodies 
T lymphocytes derived from healthy donors were iso-
lated and expanded as described elsewhere.23 Target cell 
lines used in this study are: (1) the MAGE-A1P05, HLA-
A1POs melanoma cell line MZ2-MEL.3.0; (2) the MAGE-
AI NEe, HLA-Alros melanoma cell line MZ2-MEL 2.2 
(kindly provided by T Boon and P Coulie, Ludwig Insti-
tute for Cancer Research, Brussels, Belgium);14 (3) the 
MAGE-A1POs, HLA-AV05 melanoma cell line 518A2 
(kindly provided by P Schrier, Leiden University Medical 
Center, Leiden, The Netherlands); (4) the MAGE-A1NEc, 
HLA-A1P05 melanoma cell line Mel 2A; (5) the HLA-
A1NEc melanoma cell line MEL 78; (6) the HLA-A1NEc 
melanoma cell line ELM (kindly provided by G Adema, 
University Hospital Nijmegen St Radboud, Nijmegen, 
The Netherlands); (7) the HLA-A1NEG renal carcinoma 
cell line SKR17-4 (kindly provided byE Oosterwijk, Uni-
versity Hospital Nijmegen St Radboud, Nijmegen, The 
Netherlands); and (8) the HLA-A1Pos EBV-transformed B 
cell blasts APD and 72-2 (kindly provided by P Traver-
sari, Instituto Scientifico HS Raffaelle, Milan, Italy). The 
human embryonic kidney cell line 293T35 (kindly pro-
vided by Y Soneoka, University of Oxford, Oxford, UK) 
was used as a packaging cell line for the pStitch 
VuCu1:fVJ3CJ3s and pBullet VuVJ3CJ3s retroviral vec-
tors.23 The mouse packaging cell line PG13 (ATCC CRL-
10686) was used to obtain stable sc-TCR VaVj3CJ3s retro-
virus producing cells. The CTL clone MZ2-82/3014 was 
used for isolation of RNA coding for the HLA-A1-restric-
ted, MAGE-A1-specific TCR uj3 (kindly provided by T 
Boon and P Coulie). The mAbs used in this study were: 
anti-HLA-ABC (clone Wf>/32, Sera-Lab, Crawley Down, 
UK); anti-CD4CY·5; anti-CD8FITC/PE (Becton Dickinson 
Biosciences, San Jose, CA, USA); the TCR Vex and Vj3 fam-
ily-specific mAbs anti-Va12.1 (T Cell Diagnostics, 
Woburn, MA, USA); and anti-Vj31 (Coulter-Immunotech, 
Marseille, France) and the anti-TCR 'Yo mAb 11F2.36 
Construction of soluble MAGE-A 1 peptide/HLA-A 1 and 
lnff uenzavirus A nucleoprotein peptide!HLA-A1 
complexes 
Cloning of HLA-A 1 heavy chain: The gene coding for the 
HLA-A101 gene was amplified by PCR from eDNA clone 
Vi105 (kindly provided by T Boon) using the primers 
GCGGCGGCGGCCATGGGCTCCCACTCCATGAGG and 
TTTCTGTGCATCCAGAATATGATGCAGGG ATCCGA 
GCTCCCATCTCAGGGT, and the product of this first 
PCR was used as template in a second PCR using the 
primers GCGGCGGCGGCCATGGGC TCCCACTCCAT-
GAGG and CGGCAGGAGAGCGGCCGCTTAACG 
ATGATTCCACACCATTTTCTGTGCATCCAGAAT. The 
restriction sites Ncoi and Not! used for cloning are under-
lined. The forward primers encode the peptide HHIL-
DAQKMVWNHR recognized by the BirA enzyme used 
for in vivo biotinylation. The PCR products were ethanol-
precipitated, digested with Ncoi and Not! enzymes, gel-
purified and ligated into the plasmid pET21d (Novagen, 
Madison, WI, USA) and transformed into DH5u, and 
clones containing an insert were sequenced. Clones with 
the correct sequence were transformed into BL21DE3 for 
protein production, together with a compatible plasmid 
containing the Bir A gene under the control of the tac 
promoter (pBirCm; Avidity, Denver, CO, USA). The plas-
mid pHNj32m was used to produce the j32m. 
Inclusion body purification of HLA-A1 proteins and 
reconstitution of peptide /HLA-A1 complexes were 
adapted from Garboczi et aP7 and Altman et aU2 Soluble 
peptide/HLA-A1/ streptavidinPE complexes were made 
by mixing equal volumes of streptavidin PE (5 fLg/rnl, 
Becton Dickinson Biosciences) and soluble peptide/HLA-
Al (120 fLg/ rnl), followed by 30 min incubation on ice. 
Construction of chimeric sc-TCR VaVf3Cf3{ genes and 
chimeric tc-TCR VaCa-{Nf3Cf3-{ genes 
For construction of chimeric sc-TCRVaVj3CJ3s genes a 
cloning vector was designed that allows construction of 
these single chain molecules. The vector was made by 
replacement of the multiple cloning site in pBluescript 
(Stratagene, La Jolla, CA, USA) by insertion of the poly l-
inker: GTACGAATTCGCAGATCTGGCTCTACTTCCG 
GTAGCGGCAAATCCTCTGAAGGCAAAGGTACTAGT 
GCGG ATCCGGCTCGAGCAGCT into the Kpni and Saci 
site. TCR Va and TCR Vj3 fragments, amplified from CTL 
82/30 with primers Va-ATG and Va-3' and Vj3-ATG and 
Vj3-3', respectively, were cloned into this vector. The 
extra-cellular domain of the TCR constant j3 chain was 
amplified separately (primers Cj3-5' and Cj3-3') and 
inserted next to the single chain TCR Va-linker-Vj3. The 
TCR Va-linker-Vj3-Cj3 fragment was then amplified with 
primers that introduced restriction sites (V a-Sfii and Cj3-
cys) allowing cloning into a retroviral expression cassette 
containing the signal sequence derived from the mouse 
immunoglobulin G250 variable heavy chain. This retrovi-
ral expression cassette pBullet-Cass was made in three 
steps: first, two Nco! sites (positions 317 and 2902) and 
an Xhoi site (position 2785) were deleted in the pStitch 
retroviral vector, followed by insertion of the linker 
CCATGGGTCGACGGATCCGCGGCCGCTCGCGACTC 
GAG into the Ncoi and BamHI sites.23 Next, the signal 
sequence of the G250 variable heavy chain (CCATG 
GACTTCGGGCTCAGATTGATTTTCCTTGTCCTGGTTT 
AAAAGGTGTCCTGTGTGCGGCCCAGCCGGCC)ands 
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chain were inserted into this vector resulting in the pBul-
let-Cass retroviral vector. Finally, the Vcr-linker-VI3-Ci3 
fragment was inserted into this vector next to the human 
~ chain. The ~ chain was isolated from the CTL clone 
Dl1.'8 For construction of the chimeric two chain TCR 
V crCcr~ and Vi3Ci3~ genes, extracellular domains from the 
TCR cr and 13 chain were amplified from the CTL clone 
MZ2-82/30, using Vcr-ATG and Ccr-cys or Vi3-ATG and 
Cl3-cys-specific primers including the appropriate restric-
tion sites. The V crCcr and Vi3Ci3 gene fragments were 
each ligated 5' to the s gene in pBluescript. Chimeric 
V crCcr-~ and Vi3Ci3-~ receptor genes were then cloned into 
the pStitch retroviral vector. Correct sequences of the 
chimeric sc-TCR VcrVI3Ci3~ and chimeric tc-TCR VcrCcr-
VV13CI3-s were verified using the T7 sequencino- kit 
(Pharmacia, Uppsala, Sweden). The sequences of the 
above mentioned primers were: 
Vcr-ATG: 5'-GCG-AAT-TCT-ACG-TAC-CAT-GGA-CAT-
GCT-GAC-TGC-CAG-C-3', Vcr-3': 5'-GCG-GAT-CCG-
GGT-TTG-ACC-ATT-ACC-CTT-G-3' Vcr-Sft~ 5'-TTA-CTC-GCG-GCC-CAG-CCG-GCC-ATG-
GCC-CAG-AAG-GTA-ACT-CAA-GCG-CAG-3', Ccr-cys: 
5'-GCG-GAT-CCA-GAT-CCC-CAC-AGG-AAC-TTT-
CTG-GGC-TGG-GGA-AGA-AGG-TGT -CTT-CTG-G-3' 
Vi3-ATG: 5'-GCG-CCA-TGG-GCT-TCA-GGC-TGC-TCT-
GC-3', 
Vi3: 5'-GCG-AAT-TCT-ACG-TAC-CAT-GGG-CTT-CAG-
GCT-GCT-CTG-CTG-TGT-GGC-3', Vi3 3': 5'-GCG-GAT-
CCG-AGC-ACT-GTC-AGC-CGG-GTG-CC-3', 
Ci3: 5'-TAC-CTC-GAG-GCA-TCG-ATG-AGC-AGG-TAC-
AGG-AGA-A-3', 
Ci3-cys: 5'-GCG-GAT-CCA-GAT-CCC-CAC-AGT-CTG-
CTC-TAC-CCC-AGG-CCT-CGG-CGC-TGA-CGA-TCT-
GC-3'. 
Retroviral chimeric-TCR af3 gene transduction into 
primary human T lymphocytes: in vitro expansion of 
transduced T lymphocytes 
Activated human peripheral blood lymphocytes (PBL) 
(5 x 106) were transduced using the pStitch or pBullet 
retroviral vector with the chimeric two chain TCR V crCcrs 
and Vi3Ci3~ receptor genes or chimeric sc-TCR VcrVI3CI3s, 
respectively, as described earlierP Briefly, anti-CD3 acti-
vated lymphocytes were incubated for 72 h with an 
irradiated (25 Gy) monolayer of recombinant retrovirus-
producing 293T cells, using culture medium (RPMI 1640 
with 25 mM Hepes, 10% human serum, 2 mM glutamine, 
penicillin 100 U/rnl and streptomycin 100 fLg/rnl) sup-
plemented with 4 fLg/rnl polybrene (Sigma, StLouis, 
MO, USA), and 360 IU/rnl human riL-2 (Proleukin; Chi-
ron, Amsterdam, The Netherlands). Retroviral transduc-
tion of the chimeric sc-TCR VcrVI3Ci3s was also per-
formed with supernatant produced by PG13 packaging 
cells containing the pBullet TCR V cr Vi3Ci3s vector essen-
tially as described.24 Expansion of transduced primary 
human T lymphocytes was performed in the presence of 
feeder cells as we have described elsewhere. 39.40 
Cytofl uorometricanalysis and sorting of retroviral/y 
transduced human T lymphocytes 
Human T lymphocytes (5 x 105) were stained with TCR 
Vcr and Vi3 family-type-specific anti-Vcr-12.1FITc (2 
fLg/rnl) and anti-VI31PE (2 fLg/rnl) mAb in a volume of 
50 fLl. For staining with soluble HLA-
Al/peptide/streptavidinPE complexes, cells (5 x 105) 
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were incubated for 30 min on ice, with a 1:10 dilution of 
freshly prepared complexes in a volume of 20 fLL Before 
staining T lymphocyte viability was assessed by trypan 
blue staining: only T lymphocyte populations >95% 
viable were used. The dot plots show viable T lymphob-
lasts selected by gating on forward (FSC) and sideward 
(SSC) light scatter signals. Analysis was performed on a 
FACSCAN instrument (Becton Dickinson Biosciences). 
Flow sorting was performed on a FACS-Vantage instru-
ment (Becton Dickinson Biosciences) using saturating 
concentrations of anti-Vcr-12.1FITc, anti-Vi3-1PE and anti-
CD4cy-s_ Flow-sorted T lymphocytes were expanded 
before use in functional assays as described elsewere.39•40 
Cytotoxicity assays 
Cytolytic activity of transduced human T lymphocytes 
was measured in 6 h 51Cr-release assays as described.O In 
experiments aimed at blocking specific cytolytic activity, 
mAbs were added to the T lymphocytes 15-30 min before 
addition of the target cells (yl/6/32: 10 flog/rnl, or irrel-
evant mig: 10 flog/rnl). Peptide loading of target cells was 
performed by addition of MAGE-A1 nonapeptide 
(EADPTGHSY) or irrelevant Influenza peptide derived 
from Influenza virus A nucleoprotein (CTELKLSDY) 
(both 10 flog/rnl) to the target cells before incubation with 
effector T lymphocytes. Percentage-specific 51Cr release 
was calculated as follows: ((test counts - spontaneous 
counts)/(maximum counts - spontaneous counts)) x 
100%. 
TNF-a, GM-CSF and IFN-y production 
To quantify TNF-cr, GM-CSF and IFN-'Y production by 
the transduced flow-sorted human T lymphocytes after 
antigen-specific stimulation, 6 x 104 transduced T lym-
phocytes were cultured for 24 h either in the presence or 
absence of 2 x 104 adherent tumor cells in RPMI-1640 
medium supplemented with 360 IU/rnl riL-2. At the end 
of culture, supernatant was harvested and levels of TNF-
cr, GM-CSF (Medgenix, Fleurus, Belgium) and IFN-'Y 
(CLB, Amsterdam, The Netherlands) were measured by 
standard ELISA according to the manufacturer's instruc-
tions. 
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CHAPTER3 
Identical scTCRaJ3 with distinct non-variable signalling elements 
have distinct specificities 
Submitted 

IDENTICAL scTCRa/3 WITH DISTINCT NON-VARIABLE SIGNALLING ELEMENTS HAVE 
DISTINCT SPECIFICITIES 
Ralph Willemsen, Cees Ronteltap, Reno Debets, and Reinder Bolhuis. 
Summary: 
We investigated the antigen specific triggerability of human CTL populations genetically 
programmed to functionally express single chain T ceil receptors (scTCRs) with: identical 
Variable alpha (Va12.1) and Variable beta (V/31) chains, but distinct non-variable 
transmembrane/intracellular signalling domains, i.e., y versus 1;. As targets we used cells 
expressing membrane bound Class 1-HLA-A1/MAGE-A1 complexes produced via the 
intracellular versus the extracellular route. The intracellular route involved: (i) native MAGE-A1 
antigen; or (ii) gene reconstituted MAGE-A1 peptide synthesis, or (iii) Intracellular MAGE-A1 
peptide transfection. The extracellular route involved: (i) addition of free synthetic MAGE-A1 
peptides produced in vitro to MAGE-A1NEG/HLA-A1Pos target cells, or (ii) immobilization of 
soluble MAGE-A1/HLA-A1 complexes to plastic, or generation of Class 1-HLA-A1/MAGE-A1 
tetramers. Both ~;-scTCRVa,2.1V~, Pas and y-scTCRVa12.1V/3/05 CTL's specifically recognized 
and lysed HLA-A1P05/MAGE-A1P 5 : (i) native melanoma cells; (ii) MAGE-A1 peptide transfected 
B-LCL, and (iii) MAGE-1 gene reconstituted antigen lost mutant Melanoma cells. Surprisingly, 
only i;-scTCRVa12.1V/31 Pas, but not y-scTCRVa12.1V/3/05, T lymphocytes responded to Mel and B-
LCL's, that expressed Class 1-HLA-A1/MAGE-A1 complexes generated via the extracellular 
route. Noteworthy, the free MAGE-A1 peptide added extracellularly was identical to the MAGE-
A1 peptide introduced intracellularly by electroporation. 
We conclude that scTCR VaV/3 specificity is not exclusively dictated by the variable VaV/3 
chains, but can be co-determined by non-variable TCR (signaling) components. Moreover, 
MAGE-A1/HLA-A1 complexes generated by the exogenous route are antigenically distinct from 
those generated via the intracellular route. 
Introduction 
Self- or foreign antigenic proteins are 
intracellularly processed into peptides that are 
transported into the endoplasmic reticulum and 
enable the formation of stable trimeric MHC 
class I heavy chain- microglobulin-peptide 
complexes (1 ,2). Class I MHC antigenic 
peptide complexes are then transported to the 
outer cell membrane where they are presented 
to CDSPos CTL. T cell receptors (TCR) on 
CDSpos cytotoxic T lymphocytes (CTL) can 
specifically recognize and respond to the 
peptides presented by Class I molecules (3,4 ). 
We and others have developed strategies to 
genetically program the specificity of human T 
lymphocytes by retroviral transfer of genes 
encoding non-MHC restricted, mAb-based (5-
13) or MHC restricted, TCRaf3-based (14-19) 
chimeric receptors. Such CTL transductants 
subsequent!:f specifically respond to the 
relevant Ag 05 tumor cells by tumor cell kill and 
Ag-triggered cytokine production (5-19). We 
and others showed that the invariant domains, 
i.e. extracellular spacers (e.g. CDS hinge, lg 
CH2CH3), transmembrane (e.g. CD4, CDS, 
Fc(s) Rl-y, CD3-l;) and intracellular domains 
(e.g. Fc(s) Rl-y, CD3-l; or s) significantly affect 
receptor stability, lymphocyte membrane 
density, and T lymphocyte triggerability, 
resulting in qualitatively and quantitatively 
different immune responses (9, 10, 13). 
In the present paper we describe two types of 
gene-transduced CTL's that each were grafted 
with identical scTCR Va12.Nf3,, linked to 
distinct non-variable y versus c; signaling 
domains. Both c;- and y-scTCRVa12.1Vf3t05 T 
lymphocytes specifically and equally well 
responded to native MAGE-A1P05/HLA-A1Pos 
melanoma cells. It has been reported that a) 
differences exist in tumor antigen reactivities 
between human CTL (clones) generated in vivo 
or in vitro by stimulation with MHC Class-IPos 
cells that present native- (intracellular route) 
versus synthetic peptide tumor antigens by 
peptide loading (extracellular route) (20,21 ). 
Moreover, complexes generated by the binding 
of free peptides to Class II MHC molecules can 
be antigenically diverse compared with those 
generated by intracellular processing (22,23). 
Hence, the c;-scTCRVa12.1Vf31 Pos and y-
scTCRVa12.1Vf3t05 T lymphocytes were then 
used to study whether differences in antigen 
responses could be detected at the scTCR 
level, i.e., triggerability, and antigen specificity 
by membrane expressed Class 1-HLA-
A1/MAGE-A1 complexes, that were generated 
via the intracellular- versus the extracellular-
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route. The intracellular route involved: 
intracellular Class I-HLA-A1 complexed with (i) 
intracellular "natural" MAGE-A 1 peptides, (ii) 
intracellular MAGE-A1 peptide generated by 
genetic reconstitution of MAGE-A 1 NEG antigen 
lost mutant melanoma cells, (iii) synthetic 
MAGE-A1 peptides introduced intracellularly by 
electroporation of B-LCL cells. These 
complexes then become expressed in the outer 
membrane of the cells. The extracellular route 
involved: a) already membrane expressed 
Class-1 HLA-A1 complexed with exogenous, 
free MAGE-A 1 peptides by peptide exchange, 
b) in vitro generated Class I-HLA-A1/MAGE-A1 
complexes immobilized to plastic, and c) in vitro 
generated Class-1 HLA-A1/MAGE-A1 
tetramers. 
At the effector cell level we clearly 
demonstrate that identical scTCRVa12.Nj3,, 
linked to either the y or c;; signaling domain each 
recognized a distinct antigenic determinant on 
Class 1-HLA-A 1/MAGE-A 1. Apparently, the 
scTCR specificity is not exclusively dictated by 
the VaVj3 chains, but critically co-determined 
by the y or c;; non-variable signalling chains. At 
the tumor target cell level, our results show that 
antigenic differences can arise between 
membrane expressed Class 1/antigen (native or 
synthetic peptides) complexes generated via 
the intracellular route versus those generated 
via the extracellular route. 
Results 
ScTCRs with identical TCR Va.12.,Vj31 chains 
but distinct ./;;versus y signaling chains differ 
in their capacity to respond to membrane 
expressed HLA-A1/MAGE-A1 complexes 
generated via the extraceiuliar route. 
We investigated the capacity of scTCR 
with identical Va12.1Nj31, but distinct signaling 
elements, c;; versus y, derived from CD3 or 
Fc(E)RI-y respectively, (Fig 1) to recognize a 
set of distinct HLA-A1/MAGE-A1 complexes on 
the membrane of target cells, generated via the 
intracellular- versus the extracellular route. 
Human c;;-scTCRVa12.Ni31 and y-
scTCRVa12.1 Vj31 gene transduced CTL's 
equally well express the c;;-scTCRVa12.Ni31 and 
y-scTCRVa12.1Vj31 in the membrane, as was 
demonstrated with TCR Va and Vj3 family type 
specific mAb's (Fig 2A), albeit at lower levels 
than the parental TCR clone MZ2-82/30 (Fig 
2A). They also specifically bound HLA-
A1/MAGE-A1 tetramers (Fig 2B); specifically 
responded to monomeric HLA-A1/MAGE-A1 
complexes immobilized to plastic with IFN-y 
production (Fig 2C), and specifically lysed 
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melanoma cells expressing native peptide: 
HLA-A1/MAGE-A1 complexes, (Fig 20). 
EXTRACELLULAR TM IC 
y-scTCR VaVJ3Cj3 
l Va. l VJ3 I CJ3 I CD4 rJ 
l;-scTCR VaVJ3Cf3 
l Va. l VJ3 I CJ3 I c; J 
Figure 1: Chimeric single chain T cell 
receptor constructs: y-scTCR Va12.1Vi31 and 
c;-scTCR Va.12.1VJ31. Schematic representation 
of chimeric y-scTCR Va12.Ni31 and 1;;-scTCR 
Va12.1Vj31. (ss, signal sequence; V, variable 
region; C, constant region; CK constant lg 
kappa chain fragment; CD4, CD4 
transmembrane region; L, linker, y, Fe(£) Rl-y 
chain; c;;, CD3-i;; 
Surprisingly, only c;; comprising 
scTCRVa12.1Vj31, but not y-scTCRVa12.1Vj3t05 
human CTL's specifically lysed melanoma 
target cells that express HLA-A1/MAGE-A1 
complexes generated via the extracellular route 
by binding of exogenous synthetic peptide to 
membrane bound Class 1-HLA-A 1 by peptide 
exchange (Fig 2E). To exclude MAGE-A1 
antigen density to be the limiting factor for the 
lack of y-scTCRVa12.Nj31 response, MAGE-A1 
peptide pulsing of melanoma target cells was 
performed with increasing MAGE-A1 peptide 
concentrations (up to 100 1-lg/ml), but no 
triggering of lysis was observed (data not 
shown). Because the y- and c;;-scTCRPos CTL's 
share the same Va12.1Vj3 1 sheets they must 
recognize distinct antigenic determinants on 
HLA-A1/MAGE-A1 complexes in the membrane 
depending on the route of complex formation. 
For the same reason this difference in antigen 
recognition pattern by the scTCRVa12.1Vj3t05 T 
lymphocytes must have been generated by 
linkage of the distinct y versus c;; non-variable 
signaling structures to the scTCRVa12.Ni31 
chains. 
These distinct antigen recognition patterns 
were also observed using IFN-y, TNFa and 
GM-CSF production as readout systems of the 
T lymphocyte response (Table I and II). 
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Figure 2A: Ceil surface expression of y-
scTCR Va.12.NJ31 and 1;-scTCR Va.12.1VI31 on 
gene-transduced primary human T 
lymphocytes. Expression of the y-scTCR 
Va.12.1VI31 and c;;-scTCR Va.12.1VJ:11 genes was 
determined by flow-cytometric analysis of 
retrovirally transduced primary human T 
lymphocytes. The T lymphocytes were stained 
with anti-Va.12.1FITC and anti-VJ31PE mAbs. The 
dot plots show viable T lymphocytes selected 
by gating on forward (FSC) and sideward 
(SSC) light scatter signals. Results of a 
representative experiment are shown. Figure 
28: y-scTCR Va.12.NJ3/05 and 1;-scTCR 
Va.12.NJ3/05 T lymphocytes specifically bind 
HLA-A1/MAGE-A1 tertramers. Transduced T 
lymphocytes were stained with MAGE-A1/HLA-
A 1 tetramers and analyzed by flow-cytometry 
as described in the Materials and Methods 
section. Figure 2C: y-scTCR Va.12.1VJ3/05 and 
1;-scTCR Va.12.NJ3/05 T lymphocytes 
specifically produce IFN-y upon incubation 
with immobilized peptide/MHC complexes. 
The production of IFNy by y-scTCRVa.12.Nt\1 
and c;;-scTCRVa.12.1VJ31 transduced T 
lymphocytes upon incubation with immobilized 
M1/A1 complexes (shaded area), and INF/A1 
complexes (white area), was determined by 
flow-cytometry as described in the Materials 
and Methods section. Figure 20: y-scTCR 
Va.12.1VJ3/05 and 1;-scTCR Va.12.1VJ3/05 T 
lymphocytes specifically lyse native MAGE-
A1/HLA-A1Pos melanoma cells. The 
cytotolytic capacity of human CD8P05, y-scTCR 
Va.12.1VJ3/05 and l;-scTCR Va.12.1VJ3/05 T 
lymphocytes towards various cell lines was 
determined in 6 h-51 Cr release assays. The 
following cell types were 51 Cr-labeled and used 
as target cells: the MAGE-A1P05/HLA-A1Pos 
melanoma cell line MZ2-MEL 3.0, the MAGE-
A1NEG melanoma cell lines MEL 2A and MEL 
78, the MAGE-A1NEG/HLA-A1NEG renal 
carcinoma cell line SCRC17 cl4, the Burkit 
lymphoma cell line Daudi and the EBV 
transformed B-LCL APD. Mean percentages of 
specific 51 Cr release of triplicate measurements 
are shown, with SDs not exceeding 1 0% of 
mean values . Data of one representative 
experiment out of three are shown. Figure 2E: 
1;-scTCR Va.12.NJ3/05 CTL but not y-scTCR 
Va.12.1VJ3/05 CTL lyse M1 peptide pulsed 
target cells. The cytolytic capacity of 
transduced human CTL's towards MAGE-A1 
peptide pulsed MAGE-A 1 NEG/HLA-A 1 Pos 
melanoma cells (MZ2-MEL2.2) was determined 
in 6h-51 Cr-release assays. The MZ2-MEL2.2 
melanoma cells were pulsed with MAGE-A1 
peptide (at 10 f.lg/ml final) 30 min prior to 
incubation with effector cells. Results in 
represented data obtained at an E:T ratio of 
27:1. Experiments were performed in triplicate, 
and the SD did not exceed 10%. Data of one 
representative experiment out of three are 
shown. 
To demonstrate that the lack of 
response of y-scTCRVa.12.1VJ3/05 T 
lymphocytes was indeed due to lack of 
interaction with stimulator cells presenting 
Class I bound to exogenous free MAGE-A1 
peptide (extracellular route), we performed cold 
target cell inhibition cytotoxicity assays. Native 
MAGE-A 1 Pos melanoma cells and MAGE-A 1 NEG 
(antigen lost mutant) melanoma cells pulsed 
with relevant or irrelevant peptide, MAGE-A 1 
and Influenza, respectively, were used as 
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"cold" targets. Expectedly, natural MAGE-A1Pos 
melanoma cells specifically inhibited lysis of 
natural 51 Cr-labeled MAGE-A1Pos melanoma 
cells by both the c:;-scTCRVa12.Nj3/0 s and y-
scTCRVa12.NI31 Pos CTL's. In contrast, the 
MAGE-A1 peptide loaded "cold" melanoma 
target cells did not inhibit lysis of the native 
MAGE-A1Pos melanoma cells by y-
scTCRVa12.Nj31 Pos CTL, but significantly 
inhibited lysis by 1:;-scTCRPos CTL (Figure 3) 
Our results thereby also demonstrate that a 
structural difference must exist between Class 
1-HLA-A1/MAGE-A1 complexes formed with 
natural (or synthetic, see below) peptide 
produced via the intracellular route versus such 
complexes produced via the extracellular route, 
i.e. by binding of exogenous free peptide to 
already membrane expressed class I-HLA-
A1/MAGE-A1, by endogenous peptide 
exchange. 
The conformational structures of Class 1-
HLA-A1/MAGE-A1 complexes formed via the 
intracellular- versus the extracellular route 
are distinct, resulting in antigenic 
differences. 
The observed differences in the 
conformational structure between membrane 
expressed Class I-HLA-A1/MAGE-A1 
complexes formed via the intracellular route 
versus the extracellular route could be due to 
differences in composition of natural versus 
synthetic peptides, e.g. differences in (a) 
amino-acid sequence (A.A.), or (b) introduction 
of side-chains. Because the peptide A.A. 
sequence of natural MAGE-A1 peptide could 
not be determined for technical reasons, we 
introduced: (i) eDNA encoding the MAGE-A1 
gene into MAGE-A 1 NEG melanoma cells (MZ2-
MEL2.2) [ref], and (ii) synthetic MAGE-A1 (non-
glycosilated) peptide into the cytosol of HLA-
A 1 Pos EBV transformed B-LCL by 
electroporation. Both procedures allow for 
intracellular Class I-HLA-A1/MAGE-A1 complex 
formation, followed by their transportation to 
and expression in the cell membrane as 
determined by the relevant scTCRVa12_1Vj3/0 s 
immune responses (Fig 4 ). 
The same synthetic peptide that was used for 
peptide loading of Class I HLA-A1 by peptide 
exchan~e was also used for electroporation of 
HLA-A1 os target cells. 
Expectedly, y-scTCRVa12.1Vj3/0 s as well as c:;-
scTCRVa12.1Vj3/0s CTL's were specifically 
triggered by MAGE-A1 eDNA transfected 
melanoma cells synthesising "natural" peptide 
(figure 4A). Interestingly, synthetic MAGE-A1 
peptide that was electroporated into the cytosol 
of HLA-A 1 Pos B-LCL, complexed with 
intracellular HLA-A 1, and then became 
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expressed in the membrane also specifically 
triggered cytokine production by both y- and c:;-
scTCRPos T cell transductants (Fig 4B and C). 
These data, together with the observed lack of 
triggering of y-scTCRVa1z.NI31 Pos CTL's by 
synthetic peptide pulsed target stimulator cells 
reveal that MAGE-A1/HLA-A1 complexes 
generated intracellular versus extracellular 
assume distinct conformational structures with 
a distinct antigenic makeup. 
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Figure 3. MAGE-A1 peptide pulsed Mel do 
not block the y-scTCR Va1z.NI31 mediated 
lysis of Mel presenting endogenously 
processed MAGE-A1 peptide. 51 Cr release of 
MZ2-MEL3.0 target cells without cold target 
cells (closed bar) and MEL3.0 cells in the 
presence of a 15 fold excess of (i) unlabeled 
MZ2-MEL3.0 cells (open bar); (ii) MZ2-MEL2.2 
cells (finely hatched bar); (iii) MZ2-MEL2.2 cells 
pulsed with INF peptide (coarsely hatched bar); 
or (iv) MZ2-MEL2.2 cells pulsed with MAGE-A1 
peptide (dotted bar), respectively, were 
measured after 6h incubations with y-scTCR 
Va12.1Vj3/0 s, i:;-scTCRVa12.1Vj3/05 T 
lymphocytes and the parental CTL clone MZ2-
82/30. Peptide loading of MZ2-MEL2.2 cells 
was performed as described in the legend of 
figure 2E. Data of one representative 
experiment out of two are shown. 
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Figure 4A: Introduction of the MAGE-1 gene 
in melanoma cells fully restores the 
triggering capacity of y-scTCR Va.12_1Vf3/05 
primary human T lymphocytes. 
The melanoma cell line MZ2-MEL2.2 was 
transfected with MAGE-A1 eDNA and used as 
a target cell for CD8P05, y-scTCR Va12_1VJ3/05 
and 1:;-scTCR Va12_1Vf3/05 T lymphocytes in 
6h-51 Cr-release assays. Shown are mean 
percentages of specific 51 Cr-release of triplicate 
measurements, with SDs not exceeding 10% of 
mean values. Data of one representative 
experiment out of two are shown. Figure 48: 
synthetic MAGE-A1 peptide complexed to 
intracellular HLA-A1 molecules are 
presented by HLA-A1 on the cell membrane. 
Flow-cytometric analysis of MAGE-A 1 peptide 
electroporated B-LCL APD, (i) immediately 
after MAGE-A 1 peptide transfection and two 
washes with PBS (control), (ii,) after MAGE-A1 
peptide transfection and 18 hours incubation at 
37°C, 5% C02 (M1 1NT), and (iii) after MAGE-A1 
peptide loading and 18 hour incubation (M1 EXT). 
Data of one representative experiment out of 
two are shown. Figure 4C: HLA-A1/MAGE-A1 
complexes generated by electroporation of 
free synthetic MAGE-A1 peptide into B-lCl 
specifically trigger y- and 1;;-scTCRPos T 
lymphocytes to produce IFN"')'. 
y-scTCR Va12.NJ3/05 and c:;-scTCR 
Va12.NJ3/05 T lymphocytes (6x1 04) were 
incubated for 18 hour with MAGE-A 1 peptide 
transfected cells, (i) immediately after MAGE-
A 1 peptide transfection and two washes with 
PBS (gray bars), (ii,) after MAGE-A1 peptide 
transfection and 18 hours incubation at 37°C, 
5% C02 (black bars) and after MAGE-A1 
peptide loading and 18 hour incubation (white 
bars) Supernatants were harvested and IFN-D 
production was quantified by standard ELISA 
(CLB, Amsterdam, The Netherlands). 
Table 1: production of TNFa:, GM-CSF and 
IFN"')' by y-scTCR Va.12.Nf3/05 and 1;;-scTCR 
Va.12.Nf3/05 T lymphocytes in response to 
native MAGE-A1/HlA-A1Pos MZ2-MEl 3.0 
melanoma cells. 
Cytoklne response to native HLA-A1P00/MAGE-1P'l" melanoma cells"' 
iNFapg/ml GM-CSFpg/ml IFNypg/ml 
CTL MZ2-82/30 428 54 1159 
scTCRft;Pos CTL 183 1889 272 
scTCR/'{05 CTL 392 2444 526 
Moci<CTL 54 12 33 
* As described In materials and methods 
Table II: No production of TNFa., GM-CSF 
and IFN"')' by y-scTCR Va:12.Nf3/05 T 
lymphoctses in response to peptide pulsed 
HlA-A1P s MZ2-MEl2.2 melanoma cells. 
Cytoklne response to rv1A.GE-A1 peptide pulsed melanoma cells 
TNFupg/ml GM-CSFpglml JFNypg/ml 
Nopept/+M1 PEPT No popl/ + M1 PEPT No pept I + M1 PEPT 
CTL MZ2-82/30 0-2996 0-426 39-6678 
scTCRI<;'"' Tlymph. 56-105 505-1351 64-577 
scTCR!i"' T lymph. 49-46 301-319 94-93 
Mock 56 -54 254-255 64-63 
·As desaibOO In materials and methods 
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Discussion 
We clearly demonstrate at the scTCR 
level that genes encoding non-variable 
signalling elements, y or I;;, that were 
individually linked to identical 
C(:lV(:lVa encoding genes results in y-or c;;-
scTCRVa1z.1Vl:l1, respectively, that recognize 
distinct antigenic determinants. y- and c;;-
scTCRVa1z.1V(:l/05T lymphocytes have distinct 
antigen specificities. This was demonstrated by 
retroviral transfer of genes encoding y- or c;;-
scTCRVa1z.Nl:l1 into aliquots of the same T 
lymphocyte populations. 
We conclude that the antigen specificity of c;;-
scTCRVa1z.Nl:l1 (15) can be chanced by 
exchanging the I;; domain with the CD4/y 
transmembrane/signaling element. These 
conclusions are based on the following 
experimental evidence. Both y- and c;;-
scTCRVa1z.1V(:l/05 T cell transductants 
recognize Class-1 HLA-A1/MAGE-A1 
complexes in the outer membrane of 
melanoma cells when these complexes were 
generated via the intracellular routes: 
intracellular synthesized Class I-HLA-A1 
complexed to 1) intracellular synthesized native 
MAGE-A 1 peptide, 2) intracellular "native" 
MAGE-A1 peptide resulting from genetic 
reconstitution of MAGE-A 1 antigen lost mutant 
melanoma cells, 3) intracellular synthetic 
peptide that was introduced by electroporation 
into the cytosol. 
In contrast y-scTCRVu1z.1Vl:l/05 T cells could 
not respond to "already" membrane expressed 
Class 1-HLA-A1 complexed to free synthetic 
MAGE-A1 peptide by peptide exchange, 
whereas i;;-scTCRVa12.1 V(:l/05 T cells did 
respond. The lack of response of y-scTCRPos T 
lymphocytes was due to lack of interaction with 
MAGE-A1 peptide loaded target cells as shown 
by cold-target cell inhibition studies. 
At the target cell level our experimental 
design and results also allow the important 
conclusion that differences in expression of 
antigenic determinants must exist between the 
various HLA-A1/MAGE-A1 complexes in the 
membrane of stimulator target cells tested. We 
show that these antigenic differences depend 
on the route of HLA-A1/MAGE-A1 complex 
formation, i.e., intracellular versus extracellular 
and was not due to differences in amino acid~ 
or side-chains between natural and/or synthetic 
MAGE-A 1 peptide. The difference in antigenic 
profiles must therefore reflect differences in 
conformational structure following a single 
peptide/MHC interaction. This has been 
described for Class II by Unanue and 
coworkers (22,23). They propose that the 
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distinct conformational structure and hence 
generation of diverse antigenic determinants is 
depended on whether or not the catalytic H2-
DM molecule was involved in the complex 
formation between Class II and IAklpeptide and 
hence, the site of complex formation (23,24 ). 
In our case Class 1-HLA-A1/ MAGE-A1 
tetramers produced in vitro, specifically bound 
to both y-scTCRVa12.Nl:l/05 and c;;-scTCR 
Va1z.Nl:l/05 CTL's, and both y-scTCR 
Va12.1Vl:l/05 as well as c;;-scTCRVa12.1V(:l/05 
CTL's specifically responded with cytokine 
production to Class 1-HLA-A1/MAGE-A1 
complexes immobilized to plastic, and no 
catalytic molecules were involved. Mixing of 
soluble synthetic MAGE-A 1 peptides with 
soluble Class 1-HLA-A 1, and 1:32-M may allow 
direct complex formation involving all contact 
residues of the MHC molecule, as in the case 
of complex formation in the ER, whereas fewer 
MHC contact residues may be involved in outer 
membrane expressed MHC when its bound 
endogenous peptide is exchanged with free 
synthetic MAGE-A1 peptide. 
As discussed, y-scTCRVa1 2.1V(:l/05 CTL's 
specifically interact with natural MAGE-A 1 Pos 
melanoma cells but not melanoma cells 
expressing Class 1-HLA-A 1 presenting MAGE-
A 1 by peptide exchange with exogenous free 
MAGE-A1 peptide. Apparently, the antigenic 
determinant that is recognized by y-
scTCRVa1z.1V(:l/05 CTL's on MHC class I 
complexes generated via the intracellular 
routes is lost on the MHC Class I-HLA-
A1/MAGE-A1 complexes generated by the 
extracellular route. In fact, 5 out of 10 point-
mu~~~ed MAG~0~ 1 peptides loaded on MAGE-A1 /HLA-A1 melanoma cells were 
recognized by i;;-scTCRVa12.Nl:l/05 CTL's, but 
never by y-scTCRVa12.N(:l/05 CTL's. 
Consequently, these results allow the 
conclusion that y- and c;;-scTCRVa12.N(:l/05 T 
lymphocytes recognize distinct antigenic 
determinants and hence that the 
conformational structure of Class I HLA-A1/ 
MAGE-A1 complexes generated extracellular 
versus intracellular are distinct. 
In conclusion, we demonstrate that the 
scTCR specificity can be critically changed by 
linking distinct non-variable signalling elements 
to the scTCR. Moreover, Class I-Hia-
A1/MAGE-A1 complexes generated via the 
extracellular route can be antigenically distinct 
from those generated via the intracellular route. 
MATERIALS AND METHODS 
Cells and antibodies. 
T lymphocytes derived from healthy do~ors 
were isolated and expanded as descnbed 
previously (25). Cell lines used as targets in 
cytotoxicity and in this study are: (i) the MAGE-
A1Pos HLA-A1Pos melanoma cell line MZ2-
' NEG A1POS MEL.3.0; (ii) the MAGE-A1 , HLA-
antigen lost mutant melanoma cell line MZ2-
MEL 2.2 (kindly provided by drs. T. Boon and 
P. Coulie, Ludwig Institute for Cancer 
Research, Brussels, Belgium (26)); (iii) the 
MAGE-A1NEG/HLA-A1Pos melanoma cell line 
Mel 2A; (iv) the HLA-A1NEG melanoma cell line 
MEL 78; (v) the HLA-A1NEG renal carcinoma 
cell line SKRC17-4 (kindly provided by dr. E. 
Oosterwijk, Academic Hos~ital Nijmeg~£s 
Nijmegen, the Netherlands); (vi) the HLA-A1 
EBV transformed B cell blast APD, and (vii) the 
MAGE A1NEG/HLA-A1 NEG Burkit lymphoma cell 
line Daudi. The human embryonic epithelial 
kidney cell line 293T (27) (kindly provided by 
dr. Y. Soneoka, Oxford University, Oxford, UK) 
was used as a packaging cell line for the 
pBullet y-scTCR and pBullet s-scTCR retroviral 
vectors (15). The CTL clone MZ2-82/30 (kindly 
provided by T. Boon and P. Coulie (25)) was 
used for isolation of RNA encoding the HLA-A1 
restricted, MAGE-A1 specific TCR a and. 13 
chains. The mAbs used in this study comprise 
the TCR family specific anti-Va12.1 mAb (T 
Cell Diagnostics, Woburn, MA, USA); and anti-
Vf31 mAb (Coulter-lmmunotech, Marseille, 
France) mAbs, anti-Class I mAb W6/32 
(Seranlab, Crawley Dawn , UK) and control 
mouse lg (Nordic, Tilburg, The Netherlands). 
The MAGE-A1 eDNA used to restore MAGE-A1 
expression in the MAGE-A1NEG' HLA-A1Pos 
melanoma cell line MZ2-MEL 2.2 was kindly 
provided by P. Coulie, Ludwig Institute for 
Cancer Research, Brussels, Belgium. 
Construction of the chimeric single chain 
TCRgenes. 
The pBullet scTCR Va.Vf3Cf3s vector was 
constructed as described (15). To construct the 
scTCR-CD4/y receptor, a Va.Vf3Cf3 fragment, re-
amplified to introduced Sfi/ and Not/ sites, was 
inserted into the pBullet retroviral vector, 
comprising an expression cassette (27).A 
schematic presentation of the chimeric scTCR 
constructs is shown in figure 1. 
Retroviral gene introduction of y-
scTCRVa12.,Vf31Cj3 and s-scTCR V~z.Nf31Cj3 
into primary human T lymphocytes. 
Human Peripheral Blood Lymphocytes (PBL) (5 
x 1 Q6 ) were activated for 2 days with anti-CD3 
mAb OKT3 and transduced using the retroviral 
vectors pBullet y-scTCRVa12.,Vf31 and pBullet s-
scTCRVa12.1Vf31 as described (see ref. 15 for 
details). In vitro expansion of transduced 
primary human T lymphocytes was performed 
in the presence of feeder cells as we described 
elsewhere (28). 
Flow-cytometric analysis and enrichment of 
retrovirally transduced human T 
lymphocytes. 
Human T lymphocytes (5x1 05 ) were stained 
with TCR Va and Vf3 family-type specific anti-
Va12.1FITC (4 f.tg/ml) and anti-Vf31PE (10 f.tg/ml) 
mAb (50 f.tl total volume). Tetramer staining of 
transduced T lymphocytes (5x1 05 ) was 
performed for 30 min on ice, with (20 ~I total 
volume) (15). Depletion of CD4 °5 . T 
lymphocyte populations was performed w1th 
anti-CD4 mAb coated magnetic beads 
according to the manufacturer's instructions 
(Dynal, Oslo, Norway). Enrichment of Vf31 P~s T 
lymphocytes was performed in two steps. F1rst, 
transduced T lymphocytes (1 07 cells) were 
labeled with anti-Vf31 mAb (5 f.tg/ml, 50 f.tl total 
volume). Next, Vf31-labeled T lymphocytes 
were incubated with goat anti-mouse mAb-
coated magnetic beads (Dynal) after which 
Vf31Pos T lymphocytes were obtained by 
magnetic selection. The dot plots show viable T 
lymphoblasts selected by gating on forward 
(FSC) and sideward (SSC) light scatter sign'Z:~N 
Analysis was performed on a FAGS 
instrument (Becton Dickinson Biosciences, San 
Jose, CA, USA). 
MAGE-A1 peptide transfection of EBV 
transformed B-cell Blasts and staining with 
HLA-A1/MAGE-A1 specific phages 
HLA-A1Pos EBV-transformed B-cell blasts 
(APD) were transfected with synthetic MAGE-
A 1 peptide using a BTX 600 electroporator. 
Cells were harvested, washed once with 
medium and resuspended in 250 f.tl ice-cold 
medium supplemented with MAGE-A1 peptide 
(50f.tg/ml final concentration). APD cells were 
then electroporated (settings, 1900 f.tF, 128 0, 
200V) and immediately transfered to ice cold 
conditions were 1 ml fresh, ice cold, medium 
was added. Transfected cells were cultured 
overnight at 37°C, 5% C02 before further 
analysis or washed and used immediately for 
staining with HLA-A1/MAGE-A1 specific 
phages as described (29). The hist~grams 
represent viable cells selected by gat1ng on 
forward (FSC) and sideward (SSC) light sea~;~ 
signals. Analysis was performed on a FAGS 
instrument (Becton Dickinson Biosciences, San 
Jose, CA, USA). 
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IFN-y capture assay. 
Induction of IFN-y production of transduced 
human T lymphocytes by immobilized 
peptide/MHC complexes was analyzed by flow 
cytometry as we described elsewhere (27). 
Cytotoxicity assays. 
Cytolytic activity of transduced human T 
lymphocytes was measured in 6 hr 51 Cr-release 
assays as described previously (15). For 
blocking purposes, mAbs were added to the T 
lymphocytes, 15-30 min before addition of the 
target cells (W6/32: 10 1-lg/ml, or irrelevant mig: 
10 J-Lg/ml final). Peptide loading of target cells 
was performed by adding MAGE-A1 
nonapeptide (EADPTGHSY, Leiden University 
Medical Center, the Netherlands) or irrelevant 
HLA-A1-binding Influenza peptide derived from 
Influenza virus A nucleoprotein (CTELKLSDY, 
Leiden University Medical Center, the 
Netherlands) at indicated concentrations to the 
target cells 5-15 min prior to incubation with 
effector T lymphocytes essentially as described 
(15).). Cold target cell inhibition experiments 
were performed by addition of unlabeled target 
cells to 51 Cr-labeled target cells (30:1 ratio) 
prior to incubation with effector cells. 
Percentage specific 51 Cr release was 
calculated as follows: ((test counts 
spontaneous counts)/(maximum counts 
spontaneous counts)) x 100%. 
TN Fa, GM-CSF and IFNy ELISA 
To quantify TNFa, GM-CSF and IFNy secreted 
by the transduced human T lymphocytes after 
antigen-specific stimulation, 6x1 04 transduced 
T lymphocytes were cultured for 24 h either in 
the presence or absence of 2x1 04 target cells in 
RPMI-1640 medium supplemented with 360 
IU/ml riL-2. At the end of culture, supernatant 
was harvested and were measured by standard 
ELISA for TNF-a. , GM-CSF (both from 
Medgenix, Fleurus, Belgium) and IFN~y (CLB, 
Amsterdam, The Netherlands) according to the 
manufacturer's instructions. 
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CHAPTER4 
Redirecting human CD4+ T lymphocytes to MHC Class I 
restricted melanoma antigen expressing tumor cells by 
TCRaf3 gene transfer: requirement for CD8a 
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REDIRECTING HUMAN CD4+ T LYMPHOCYTES TO MHC CLASS I RESTRICTED MELANOMA 
ANTIGEN EXPRESSING TUMOR CELLS BY TCRa.j3 GENE TRANSFER: requirement for CD8a. 
Ralph Willemsen, Gees Ronteltap, Mirjam Heuveling, Reno Debets and Reinder Bolhuis 
Adoptive immunotherapy involving the transfer of autologous tumor or virus reactive T 
lymphocytes has demonstrated its effectiveness in the eradication of cancer and virally 
infected cells. Clinical trails and in vitro studies have focused on CD8+ cytotoxic TCR a.j3 
lymphocytes since these are the cells that specifically kill virally infected- and tumor cells 
directly via their antigen specific T cell receptor (TCR) a.j3. However, increasing evidence 
suggests that induction of sustained immunity against cancer and viral infections depends on 
the presence of tumor- or virus specific CD4+ T lymphocytes, which are restricted by MHC 
class II. Here we show that these MHC class II restricted CD4+ T lymphocytes can efficiently be 
redirected to MHC class I restricted tumor cells by retroviral introduction of an HLA-A1/MAGE-
A1 specific chimeric two chain TCR Va.Ca.1;fVj3Cj3t;; (tcTCR/t;;). However, CD4+ and tcTCR/t;;Pos T 
lymphocytes were only able to specifically bind to HLA-A1/MAGE-A1 complexes and respond 
to HLA-A1+/MAGE-A1+ melanoma cells when the CD8a. gene was co-introduced. These CD4+, 
CD8+/tcTCR/t;;Pos T lymphocytes produce cytokines typical for CD4 T helper I cells (Th1) when 
specifically stimulated via the introduced tc-TCR/t;; with immobilized HLA-A1/MAGE-A1 
complexes or HLA-A1+/MAGE-A1+ melanoma cells. Furthermore, introduction of the CD8a. gene 
into tcTCR/t;;Pos T lymphocytes rendered these T lymphocytes cytotoxic for HLA-A1+/MAGE-A1+ 
melanoma cells. These results demonstrate that human CD4+ T lymphocytes when genetically 
grafted with an HLA-A1/MAGE-A1 specific tcTCR/t;; and CD8a. are induced to kill and produce 
cytokines upon specific interaction with the relevant melanoma cells. Hence, CD4+ T 
lymphocytes, in addition to CD8+ T lymphocytes may be critical effector cells for adoptive 
immuno-gene therapy to generate a sustained tumor specific immune response in cancer 
patients. 
Introduction 
Although both CD4+ and CD8+ T lymphocytes 
are involved in the immune response against 
cancer and viral infections, there has been a 
preferential attention to anti-tumor responses 
mediated by MHC class I restricted, CD8+ T 
lymphocytes. This focus on CD8+ T 
lymphocytes stems from experimental data 
showing that (i) many tumors express MHC 
class I but not MHC class II [1] and (ii) CD8+ T 
lymphocytes are capable to directly kill tumor or 
virally infected cells upon recognition of MHC-
presented antigenic peptides (2]. Moreover, 
(clinical) adoptive immunotherapy studies 
demonstrated that the transfer of viral or tumor 
reactive CD8+ T lymphocytes can result in 
effective anti-viral and anti-tumor responses, 
respectively [3-7]. Finally, vaccination studies 
using MHC class I immuno-dominant peptides 
have shown that protective anti-tumor immunity 
can be generated [8,9]. On the other hand, the 
important role of CD4+ T lymphocytes in the 
induction and persistence of effective immunity 
was demonstrated in studies using CMV 
specific CTL clones as well as CD4 knockout 
mice [10-15]. After adoptive transfer of CMV 
specific CD8+ CTL to patients, which lacked 
CD4+ CMV specific T lymphocytes, the CD8+ T 
cell response to CMV declined, suggesting an 
essential role for CD4+ T helper lymphocytes in 
the persistence of the transferred CD8+ CTLs 
[1 0, 11]. The efficacy of the infused CD8+ CTL 
was improved by the co-administration of the 
Th1 cytokine IL-2, supporting the notion of 
collaborations between CD4 and CD8 T cells 
[11]. Indeed, mice deficient for CD4 were 
shown to be unable to maintain Lymphocytic 
Choriomeningitis Virus (LCMV) specific CD8+ 
CTL or clear virus following a challenge with 
low dose LCMV (12]. Additionally, the induction 
of tumor specific CTL against autologous M HC 
class II negative effusion-associated 
mononuclear cell tumors was shown to be 
severely impaired indicating that CD4+ T 
lymphocytes are essential for the induction of 
protective anti-tumor CD8+ CTL [16]. Adoptive 
transfer of CD4+ tumor specific T lymphocytes 
may therefore be clinically relevant for effective 
anti-tumor responses. Indeed, in mice, the 
adoptive transfer of activated MHC class II 
restricted, tumor specific CD4+ T lymphocytes 
has resulted in de novo generation of tumor 
specific CD8+ T lymphocytes and effective anti-
tumor responses [17]. In addition, adoptive 
transfer of vesicular stomatitis virus specific 
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(VSV) CD4+ T lymphocytes into mice was able 
to confer protection against infection with a 
vaccinia virus expressing the VSV-G protein 
[18]. 
The generation of tumor specific MHC class II 
restricted CD4+ T lymphocytes is hampered by 
the lack of well defined MHC class II binding 
peptides. Powerful techniques, such as 
reversed immunology, used to identify MHC 
class I restricted peptide epitopes [19] are not 
yet available for the identification of MHC class 
II binding peptides. Moreover, the isolation of 
tumor specific MHC class II restricted CD4+ T 
lymphocytes from individual patients is 
troublesome and unpredictable, and hence 
limits its clinical application. 
We have recently demonstrated the 
reproducible and efficient transfer of HLA-A1-
restricted, MAGE-A1-specific chimeric T cell 
receptor (TCR) genes to bulk cultured primary 
human T lymphocytes [20]. These chimeric 
single chain- and two chain-TCR were 
functionally expressed on CD8+ T lymphocytes 
and have the advantage that they do not 
associate with endogenous TCR af3 chains, 
when compared with full-length TCRaf3 [20,21]. 
Upon incubation with HLA-A1+, MAGE-A1+ 
melanoma cells these transduced T 
lymphocytes were specifically activated to lyse 
the relevant tumor cells and to produce 
cytokines. In this study we addressed the 
question whether MHC class II restricted CD4+ 
T lymphocytes can be grafted with MHC class I 
restricted tumor specificity so that triggering via 
the tcTCR/1; induces CD4 helper functions. 
We demonstrate that also primary activated 
CD4+ T lymphocytes can be efficiently re-
targeted to HLA-A1 restricted, MAGE-A1+ 
melanoma cells by retroviral introduction of an 
HLA-A1/MAGE-A1 specific chimeric tcTCR/1;. 
Moreover, we demonstrate that only upon 
introduction of both the CD8a gene and the 
tcTCR/1; genes CD4+ T lymphocytes acquire 
the capacity to specifically bind to HLA-
A 1/MAGE-A 1 complexes. 
CD4+/ CD8/tcTCR!i;Pos T lymphocytes, bulk 
cultured as well as cloned T lymphocytes, 
specifically respond to immobilized HLA-
A1/MAGE-A1 complexes and HLA-A1+/MAGE-
A1+ melanoma cells, i.e. they produce Th1 
cytokines such as IFN--y, TNFa and IL-2. 
Moreover, CD4+, CD8+, tcTCR!i;Pos 
T l~mphocytes also specifically killed HLA-
A1P 8 , MAGE-A1Pos melanoma cells. Our 
results demonstrate that class II restricted 
human CD4+ T lymphocytes grafted with a 
class I specific tcTCR/1; plus CD8a exert CD4 
Th1-like immune functions that are likely to be 
important to provide sustained anti-tumor 
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responses in patients following their adoptive 
transfer. 
Results 
Retroviral transduction of activated primary 
human T lymphocytes 
Bulk populations of OKT3 mAb activated 
primary human T lymphocytes, derived from 
healthy donors, were retrovirally transduced 
with the pSTITCH tcTCR VaGal; and VJ3CJ31; 
retroviral vectors and the pBullet CD8a vector, 
essentially as described [20]. Following 
retroviral transduction, bulk cultures of T 
lymphocytes were expanded in media 
containing recombinant IL-2. To obtain 
CD4+/tcTCR!i;+, CDSa+/tcTCR/1;+ and 
CD4+/CD8a+/tcTCR/1;+ T lymphocytes 
transduced T lymphocytes were enriched by 
flow-cytometric sorting after staining with mAbs 
anti-VJ31PE , anti-Va12.1FITC and anti-CD8aAPC_ 
Enriched T lymphocyte fractions were then 
analyzed for CD4 and CD8a and chimeric 
tcTCR/1; expression. As shown in figure 1A, 
homogeneous populations of CDS+, CD4+CD8+ 
or CD4+ T lymphocytes were obtained. 
Furthermore these enriched T lymphocyte 
fractions all express the chimeric tcTCR/1; 
(Fig1B). 
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Figure 1. Expression of (A) CD4 and CD8a 
and (B) TCR Va12.1 and Vf31 on primary 
human T lymphocytes transduced with the 
chimeric tc-TCR aVJ3s genes and the CD8a 
gene and sorted by flow cytometry using mAbs 
binding to VJ31, Va12.1 and CD8a. 
T lymphocytes were stained and sorted as 
described in Materials and Methods. 
Expression of CD8a. on CD4+/tcTCRII;;+ T 
lymphocytes is required for staining with 
MAGE-A1/HLA-A1 tetramers 
Specific binding to MAGE-A1/HLA-A1 
tetramers by flow-sorted CD4+/tcTCRII;;+, 
CD8+/tcTCRII;;+ and CD4+/CD8a+/tcTCR/1;+ T 
lymphocytes was determined by flow-cytometry 
analysis as described [20]. Only CD4+ T 
lymphocytes that were transduced with both 
CDBa and tcTCR!t:; retroviral constructs 
specifically bound MAGE-A1/HLA-A1 tetramers 
(M1/A1). CD4+ T lymphocytes that lacked 
CD8a did not bind tetramers (Fig. 2) CD8+/ 
tcTCRit:;+ T lymphocytes and the CTL clone 
(MZ2-82/30, data not shown) from which the 
TCR a and J3 genes were cloned [19] served as 
positive controls and specifically bound the 
M1/A 1 tetramers. The simultaneous addition of 
anti-CD8a mAb and M1/A1 tetramers to the 
tcTCRIL;+ T lymphocytes resulted in a 
significant reduction of binding to the M1/A1 
tetramer demonstrating that CD8a is required 
for the TCRIMHC interaction (data not shown). 
Specificity of binding was demonstrated by 
incubating the CD8a+, tcTCR!c;+ T lymphocytes 
with with tetramers that contained an irrelevant 
Influenza virus peptide derived from Influenza 
virus A nucleoprotein (Flu/A 1 )(data not shown). 
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Figure 2. CD4+ T lymphocytes expressing tc-
TCR!t:; require co-expression of CD8a to bind 
HLA-A 1/MAGE-A 1 tetramers. 
T lymphocytes were stained and sorted as 
described in Materials and Methods. 
MAGE-A1 peptide loaded melanoma cells 
specifically activate CD4+1CD8+/tcTCRII;+ T 
lymphocytes to pr-oduce TN Fa 
Next, we determined whether the CD4+/ 
tcTCR/1;+ and CD4+/CD8a+/tcTCRII;+ T 
lymphocytes could be specifically activated by 
MAGE-A 1 peptide loaded melanoma cells to 
produce TNFa. Therefore, tcTCR/1;+ T 
lymphocytes were incubated for 17 hr with the 
HLA-A1+ melanoma cell line MZ2-MEL2.2 that 
had been loaded with MAGE-A 1 peptide prior 
to incubation with the transduced T 
lymphocytes. TN Fa secretion in the culture 
medium was then analyzed by ELISA. As show 
in Figure 3, TNFa was only produced by 
CD4+CD8a+/tcTCR!c;+ T lymphocytes, when 
these were incubated with MAGE-A 1 peptide 
pulsed melanoma cells and not with melanoma 
cells that lacked this peptide. CD4+/tcTCR!c;+ T 
lymphocytes were not stimulated to produce 
TNFa when incubated with the MAGE-A1 
peptide pulsed melanoma cells. 
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Figure 3. CD4+, tc-TCR/1;+ T lymphocytes 
require CD8a co-expression to produce TNF-a 
upon specific stimulation with MAGE-A1 (M-1) 
peptide loaded target cells. TNF-a production 
by transduced and sorted T lymphocytes was 
tested after stimulation for 17 hour with MAGE-
A 1 peptide pulsed melanoma cells. As 
described in Materials and Methods. 
CD4+/CD8+/tcTCRII;+ T lymphocytes 
specific~lly respond to native MAGE-A1+, 
HLA-A1 melanoma cells by TN Fa, IFN-y and 
IL-2 production. 
We then determined whether native MAGE-
A1+, HLA-A1+ melanoma cells could specifically 
activate the CD4~/CD8+/tcTCR!t:;+ T 
lymphocytes to produce TN Fa, IFN-y and IL-2. 
Therefore, CD4+/CD8+/tcTCRJc;+ T lymphocytes 
were incubated with: (1) the MAGE-A1+, HLA-
A1+ melanoma cell line MZ2-Mel3.0, (iJ) the 
MAGE-A 1, HLA-A 1 renal cell carcinoma cell 
line SKRC17 cl4, (iii) the HLA-A1 melanoma 
cell lines Mel 78 and BLM, (iv) the HLA-A1+, 
MAGE-A1 melanoma cell line MEL2A and EBV 
transformed B cell line APD. As shown in 
Figure 4, only MAGE-A1+/HLA-A1+ melanoma 
cells specifically activated the 
CD4+/CD8+/tcTCR!c;+ T lymphocytes to produce 
produced TN Fa, IFN-y and IL-2. None of these 
cytokines were produced when 
CD4+/CD8+/tcTCRII;+T lymJilhocytes were 
incubated with MAGE-A1N G or HLA-A1NEG 
target cell lines. Furthermore, no TN Fa, IFN-y 
and IL-2 was produced when CD4+/tcTCR!t:;+ T 
lymphocytes were incubated with the MAGE-
A1+/HLA-A1+ melanoma cells (data not shown). 
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Figure 4. HLA-A1-restricted, MAGE-A1 specific 
cytokine production by CD4+/CD8+/tcTCRii;;+T 
lymphocytes. To test HLA-A1/MAGE-A1 
specific production of cytokines, 
CD4+/CD8+/tcTCR/i;;+ T lymphocytes were 
incubated for 17 hour with a panel of cell lines 
positive or negative for HLA-A 1 and MAGE-A 1. 
IFN-y, TNF-a and IL-2 production were 
analyzed as described in Materials and 
Methods. 
Lysis of "native" MAGE-A1+/HLA-A1+ 
melanoma cells as well as MAGE-A1 peptide 
pulsed melanoma cells by CD4+ T 
lymphocytes expressing chimeric tcTCR/1; 
is depending on CD8a. 
To determine whether CD4+ T lymphocytes 
engrafted with chimeric tcTCR/1;; are capable to 
kill MAGE-A1+/HLA-A1+ target cells, we 
incubated CD4+/tcTCRii;;+ and 
CD4+/CD8+/tcTCR!i;;+ T lymphocytes with 51 Cr-
labeled MAGE-A1+/HLA-A1+ melanoma cells as 
well as MAGE-A1 peptide pulsed HLA-A1+ 
melanoma cells. MAGE-A1 peptide pulsed 
melanoma cells and more importantly, "native" 
MAGE-A1+/HLA-A1+ melanoma cells were 
efficiently lysed by CD4+/CD8+/tcTCRii;;+ T 
lymphocytes (Fig 5). Melanoma cells that lack 
the MAGE-A1 peptide were not lysed by 
CD4+/CD8+/tcTCRfi;;+ T lymphocytes. 
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Furthermore, lysis of MAGE-A1 peptide pulsed 
melanoma cells as well as "native" MAGE-
A1+/HLA-A1+ melanoma cells depends on the 
co-expression of CD8a. CD4+/tcTCR/i;;+ T 
lymphocytes were unable to kill these target 
cells. In addition, lysis of "native" MAGE-
A1+/HLA-A1+ melanoma cells by 
CD4+/CD8+/tcTCR/i;;+ T lymphocytes as well as 
the CTL clone MZ2-82/30 is completely 
blocked after addition of anti-COS mAb (data 
not shown). 
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Figure 5. Lysis of native HLA-A1+, MA'"'c-A1+ 
and MAGE-A1 peptide pulsed melanoma cells 
by CD4+, tc-TCR/1;;+ T lymphocytes depends on 
co-expression of CD8a. The HLA-A 1, MAGE-
A1 specific cytolytic capacity of CD4+/tcTCR/i;;+ 
and CD4+/CD8+/tcTCR/i;;+ T lymphocytes was 
analyzed in 4 hr 51 Cr-release assays, using 
HLA-A1+/MAGE-A1+ melanoma cells and 
MAGE-A1 peptide pulsed melanoma cells, as 
described in Materials and Methods. 
Discussion 
In this study, we explored the possibility to graft 
MHC class II restricted CD4+ T lymphocytes 
with an MHC class I restricted tumor specificity 
by retroviral transfer of chimeric tcTCR 
VaCai;;NJ3CJ31;;. Indeed, here we showed that 
CD4+ T lymphocytes can be functionally 
endowed with chimeric TCRaJ3 specific for 
MAGE-A 1 presented by HLA-A 1 molecules on 
melanoma cells. 
These CD4+/tcTCR/i;;+ T lymphocytes were 
induced to produce cytokines such as TNF-a, 
IFN-y and IL-2. The CD4+/tcTCR!i;;+ T 
lymphocytes also exert immune specific lysis of 
MAGE-A1+/HLA-A1+ melanoma cells. 
Moreover, we also demonstrate that co-
expression of CD8a molecules with tcTCR/1;; on 
the CD4+ T lymphocytes is a prerequisite for 
triggering of these immune response. Attempts 
to generate tumor reactive human CD4+ T 
lymphocytes have been hampered by the 
difficulty to identify MHC class II restricted 
tumor epitopes that can be used for their in 
vitro stimulation. Reproducible technologies for 
the identification of MHC class I presented 
tumor antigens have been developed [19], but 
these are Jacking for class II presented tumor 
antigens [22]. Because of fundamental 
differences in peptide processing and loading 
of the MHC class II molecules, when compared 
to MHC class I molecules, identification of class 
II presented tumor peptides awaits a technical 
breakthrough [22,23]. The availability of C04T T 
lymphocytes may be of importance because 
C04+ T lymphocytes play critical roles in the 
generation of antigen specific T cell responses 
and in the induction of memory, providing 
sustained immunity [13-1S]. 
Recently, we and others successfully grafted 
primary human T lymphocytes with MHC class I 
restricted specificity through introduction of full-
length TCRaj3, chimeric single chain and two 
chain TCR genes. Introduction of these 
(chimeric) TCR conferred the T lymphocytes 
with a new MHC restricted tumor specificity [20, 
24-26]. 
The physiological interaction between TCRaj3 
on T lymphocytes and MHC class I molecules 
on target cells has been shown to involve the 
simultaneous interaction of COSa and/or COSj3 
on T lymphocytes with the MHC class I 
molecules on target cells [27-29]. Indeed, 
addition of anti-COS mAbs generally inhibits T 
cell mediated immune functions [2S,30] or 
specific binding of soluble MHC class I 
tetramers [31]. We addressed the question 
whether C04+, tcTCR/1;+ T lymphocytes also 
require COSa to bind tetramers and become 
activated by relevant target cells. Therefore we 
introduced either the tcTCR!i; alone or COSa 
and the tcTCR!i; simultaneously into C04+ 
human T lymphocytes. Only the 
C04+/COS+/tcTCR!i;+ T lymphocytes, but not 
COSa-, C04+/tcTCR!i;+ T lymphocytes were 
able to bind tetramers and exerted tcTCR!i; 
mediated immune functions, i.e. cytokine 
production and lysis of tumor cells. The 
cytokines produced were of the Th1 type, i.e. 
IL-2, IFN-y and TN Fa, and were produced only 
after specific stimulation with the relevant 
MAGE-A1/HLA-A1 expressing target cells. We 
conclude that triggering of the Class I restricted 
Th1-type immune response, normally triggered 
by class II restricted tumor antigens, requires 
the interaction between COSa and the tcTCR/1;. 
In mice, adoptive transfer models of viral 
infections such as influenza and VSV have 
demonstrated that the transfer of C04 T cell 
clones effectively protected mice from influenza 
or VSV induced infections [1S] The 
C04+/COS+/tcTCR/i;+ T lymphocytes that exert 
Th1 immune functions may also exert help to 
generate COS+ CTL in vivo as well as memory 
responses [32]. In a clinical study it was 
demonstrated that long term persistence of 
adoptive transferred cytomegalovirus or human 
immunodeficiency virus specific CDS+ CTL 
probably requires adequate CD4 T helper 
functions [11]. Taken these clinical data and 
data obtained from adoptive transfer studies in 
CD4 knockout mice together; the adoptive 
transfer of both CDS+/tcTCR/1;+ T lymphocytes 
and CD4+/CDS+/tcTCR!i;+ T lymphocytes may 
prolong in vivo survival of the transferred cos+ 
CTL as well as help the de novo generation of 
patients CDS+ CTL with tumor specificity. 
Materials and methods 
Cells and antibodies. 
T lymphocytes derived from healthy donors 
were isolated and expanded as described 
elsewhere [33]. Target cell lines used in this 
study are: (i) the MAGE-A1+/HLA-A1+ 
melanoma cell line MZ2-MEL.3.0; (if) the 
MAGE-AnHLA-A1+ melanoma cell line MZ2-
MEL 2.2 (kindly provided by T. Boon and P. 
Coulie, Brussels, Belgium [19]; (iii) the MAGE-
AnHLA-A1+ melanoma cell line Mel 2A; (v) 
the HLA-A1" melanoma cell line MEL 7S; (vt) 
the HLA-A1- melanoma cell line BLM (kindly 
provided by G. Adema, Nijmegen, the 
Netherlands); (vit) the HLA-A1- renal carcinoma 
cell line SKR17-4 (kindly provided by E 
Oosterwijk, Nijmegen, the Netherlands); and 
(viii) the HLA-A 1 + EBV transformed B cell line 
APD. The human embryonic kidney cell line 
293T [34] and phoenix-amp [35] were used for 
production of pStitch VaCai;Nj3Cj3i; and 
pBullet CDSa retroviral vectors. The mAbs 
used in this study were: anti-CD4FtTC/PE; anti-
CDSFtTC/PEIAPc (Becton Dickinson Biosciences, 
San Jose, CA, USA); the TCR Va and Vj3 
family specific mAbs anti-Va12.1FtTc (T Cell 
Diagnostics, USA); and anti-Vj31PE (Coulter-
lmmunotech, Marseille, France). HLA-
A1/MAGE-A1 tetramers were kindly provided 
by P. van der Bruggen (Brussels, Belgium). 
Construction of retroviral vectors and 
transduction of primary human T 
lymphocytes. 
The chimeric TCR VaCai; and Vj3Cj31; genes 
were derived from the CTL clone MZ2-S2/30 as 
described previously [20]. The CDSa gene was 
amplified with primers that allowed introduction 
into the retroviral vector pBullet, from the 
pLCDSaSH vector (a kind gift from Jos 
Molenhorst, Leiden, the Netherlands). 
The chimeric TCR genes and the CDSa gene 
were introduced into anti-CD3 mAb activated 
primary human T lymphocytes essentially as 
described [25]. After two rounds of supernatant 
transduction the transduced T lymphocytes 
were expanded in culture medium, 
supplemented with r-IL2 (360 JU!ml). 
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Flow-cytometry analysis and sorting of 
retrovirally transduced human T 
lymphocytes. 
Viable human T lymphocytes (5x1 0 5) were 
stained with TCR Va and VJ3 family-type 
specific anti-Va-12.1 FITC (2 1-lg/ml) and anti-
VJ31PE (2 1-lg/ml) mAb in a final volume of 50 iJ.I. 
Transduced T lymphocytes (5x105) were 
stained with MAGE-A1/HLA-A1 tetramers (10 
nM final, 30 min on ice). T lymphocyte viability 
was assessed by trypan blue staining: only T 
lymphocyte populations > 95 % viable were 
used for flow cytometry analysis. The dot plots 
represent viable T lymphoblasts selected by 
gating on forward (FSC) and sideward (SSG) 
light scatter signals. Analysis was performed on 
a FACSCAN instrument (Becton Dickinson 
Biosciences, San Jose, USA). FAGS sorting 
was performed on a FAGS-Vantage instrument 
(Becton Dickinson Biosciences) using 
saturating concentrations of Va12.1mc, VJ31PE 
and CD8aAPc FAGS-sorted lymphocytes were 
expanded before use in functional assays as 
described [20]. 
TN F-a, IFN"'Y and IL-2 production 
To quantify TNF-a, IFN-y and IL-2 production 
by the transduced flow-sorted human T 
lymphocytes, 6x1 04 transduced T lymphocytes 
were cultured for 24 hr either in the presence or 
absence of 2x1 04 adherent tumor cells in 
RPMI-1640 medium supplemented with 360 
IU/ml rll-2 ,and where indicated, with 10 1-lg/ml 
MAGE-A1 peptide. At the end of culture, 
supernatant was harvested and levels of TNF-
a, IFN-y and IL-2 (CLB, Amsterdam, The 
Netherlands) were measured by standard 
ELISA according to the manufacturer's 
instructions. 
Cytotoxicity assays 
Cytolytic activity of transduced human T 
lymphocytes was measured in 51 Cr-release 
assays as described previously [20]. Peptide 
loading of target cells was performed by adding 
MAGE-A1 nonapeptide (EADPTGHSY, Leiden 
University Medical Center, the Netherlands) or 
irrelevant HLA-A1 binding Influenza peptide 
derived from Influenza virus A nucleoprotein 
(CTELKLSDY, Leiden University Medical 
Center, the Netherlands) at indicated 
concentrations to the target cells 5-15 min prior 
to incubation with effector T lymphocytes, at 
indicated effector to target cell ratios. The 
incubation period of effector and target cells is 
indicated in the figures. Percentage specific 
51 Cr release was calculated as follows: ((test 
counts spontaneous counts)/(maximum 
counts- spontaneous counts)) x 100%. 
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A phage display selected Fab fragment with MHC 
class /-restricted specificity for MAGE-A 1 allows for 
retargeting of primary human T lymphocytes 
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The clinical benefit of adoptive transfer of MHC-restricted 
cytotoxic T lymphocytes(CTL) for the treatment of cancer is 
hampered by the low success rate to generate antitumor 
CTLs. To bypass the need for tumor-specific CTL, we 
developed a strategy that allows for grafting of human T lym-
phocytes with MHC-restricted antigen specificity using in 
vitro selected human Fab fragments fused to the Fc(E)RI""{ 
signaling molecule. Retroviral introduction of a Fab-based 
chimeric receptor specific for MAGE-A 1/HLA-A 1 into primary 
human T lymphocytes resulted in binding of relevant 
peptide!MHC complexes. Transduced T lymphocytes 
responded to native MAGE-A 1/HLA-A 1Pos target cells by 
specific cytokine production and cytolysis. Therefore, 
peptide!MHC-specific Fab fragments represent new alterna-
tives to TCR to confer human T lymphocytes with tumor 
specificity, which provides a promising rationale for 
developing immunogene therapies. Gene Therapy (2001) 8, 
1601-1608. 
Keywords: tumor rejection antigen; Fab; MHC; cytotoxic T lymphocyte; T cell receptor; chimeric receptor 
Introduction 
T cells are equipped with unique antigen recognition 
units, the T cell receptors (TCR) that are composed of 
polymorphic TCR a~1or yo2 chains and the non-polymor-
phic CD3-y, o, E and s signaling molecules.3 A The CDS+ 
cytotoxic T lymphocytes (CTL) play an essential role in 
the eradication of virally infected cells and tumor cells, 
and specifically recognize and kill cells that present anti-
genic peptides in the context of MHC class I molecules.S·6 
Isolation and expansion of such CTL has allowed for the 
identification of genes that code for tumor rejection anti-
gens (TRA), such as the melanoma-associated MAGE 
genes.7•8 Peptides presented by MHC class I molecules 
are usually between eight and 10 amino acids long and 
are buried in a peptide binding groove, which consists 
of two antiparallel a-helices overlaying a platform of 
antiparallel ~-strands.9 Two or three positions in the pep-
tide, the anchoring residues, fit into hydrophobic pockets 
formed by the variable residues in the peptide binding 
groove.10•11 Exposed peptide residues and non-buried 
elements of the two a-helices are critical for the recog-
nition of the peptide/MHCcomplex by TCR.12 
MHC -restricted CTL with specificities for a wide range 
of TRA, such as tyrosinase, MART-1, gp100, p15, TRP-1, 
~-catenin, MAGE, BAGE and GAGE, have been identified 
and isolated from cancer patients or have been generated 
in vitro.13 The identification of these peptides has trig-
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gered the development of new immune treatment stra-
tegies, aimed either at the induction of specific T cell 
responses by vaccination/4•15 or the adoptive transfer of 
in vitro generated MHC-restricted CTL.6 TRA-specific T 
lymphocytes, however, oc= only at low frequencies in 
a small proportion of patients, probably because many of 
these TRAs represent normal differentiation antigens and 
are of a tolerogenic nature. This low CTL frequency 
together with the difficulties associated with in vitro gen-
eration of CTL-specific for cancers other than melanoma 
makes CTL-based immunotherapy impractical. In 
addition, it is important to note that peptide specific CTL 
generated in vitro by incubation of PBMC with peptide 
pulsed APC were reported to respond to peptide-pulsed 
target cells, but not to native antigen presenting tumor 
cells.16 Moreover, CTL generated in vivo by vaccination 
with peptide-loaded antigen presenting cells (APC) do 
not necessarily respond to native tumor antigen-
presenting tumor cells.17•18 
Gene-based strategies were developed which aimed at 
transferring specificities to primary human T lympho-
cytes via chimeric Igor TCR molecules.19.2° Chimeric Ig-
based receptors with specificities for tumor-associated, 
MHC non-restricted antigens (TAA) can be functionally 
expressed on human T lymphocytes.21- 24 These geneti-
cally introduced chimeric receptors do not affect the 
requirement of co-activation and adhesion receptors to 
activate T lymphocytes.25 However, in contrast to TAA, 
TRA are processed intracellularly and presented as pep-
tides in MHC molecules, and hence are not recognized 
by 'classical' mAbs per se. In addition, we recently 
showed that chimeric TCR a~ receptors can confer 
human T lymphocytes with MAGE-A1/HLA-A1 speci-
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ficity.26 However, the applicability ofT cell grafting with 
antitumor specificity is still limited by the availability of 
peptide/MHC-specific T cell clones. Methods that allow 
for in vitro selection of TRA-specific molecules from large 
repertoires would potentially provide a pool of tumor-
reactive molecules. Thus far, several approaches have 
been explored to obtain molecules that bind MHC-restric-
ted antigens on tumor cells. First, TCR libraries specific 
for peptide/MHC complexes were generated,27- 29 but 
engineering of TCR proved difficult and the TCR were of 
low binding affinity.30•31 Second, monoclonal antibodies 
(mAbs), with MHC-restricted specificity were generated 
by immunizing mice with soluble peptide-MHC com-
plexes or antigen-presenting cells. Unfortunately, these 
immunization protocols were rarely successfuP2- 35 In 
this paper, we exploited the selection power of phage dis-
play that allows for the testing of tens of millions of indi-
vidual clones with a high-throughput selection of Fabs 
with peptide/MHC complex binding capacity. Following 
this strategy, we recently selected a fully human Fab frag-
ment, termed Fab-G8, specific for HLA-AI/MAGE-AI 
complexes from a large non-immune phage-antibody 
repertoire.'6 The isolated phage specifically binds to 
MAGE-AI peptide pulsed HLA-A1Pos B-LCL, as well as 
to MAGE-AI peptide presented by HLA-Al molecules 
on antigen-expressing tumor cells. 
Here we report on the construction and retroviral 
transfer of a chimeric receptor based on this phage dis-
play selected Fab fragment, and its use to genetically pro-
gram primary human T lymphocytes with an immune 
specificity. The Fab-G8 gene fragment was ligated via the 
CD4 transmembrane domain to the intracellular Fc(E)Rly 
chain signaling molecule, resulting in the Fab-G8-CD4/ y 
receptor, which was retrovirally introduced into human 
T lymphocytes. Fab-G8-CD4/y05 T lymphocytes specifi-
cally bound MAGE-AI/HLA-AI complexes. Human T 
lymphocytes expressing this MHC restricted Fab-based 
chimeric receptor on their membrane specifically 
responded to both MAGE-AI peptide pulsed HLA-Alros 
B cell blasts and native MAGE-A1P05/HLA-AIP05 mela-
noma cells by specific tumor cell lysis, as well as cytokine 
production. Thus, peptide/MHC-specific chimeric Fab 
fragments can be used to retarget human T lymphocytes 
to TRA epitopes, which may provide a novel rationale for 
developing clinical immune-gene therapeutic modalities 
independent of CTL-derived TCR. 
Results 
Retroviral transduction of human T lymphocytes with the 
Fab-GB-CD4/y receptor 
The heavy and lambda light chains from the human Fab 
fragment G-8 specific for MAGE-AI/HLA-AI were 
obtained from a non-immune human Fab library.36 
Amplification by PCR introduced Sfii and Notl restriction 
sites, which enabled insertion into a retroviral expression 
cassette. The retroviral expression cassette used, com-
prises a signal sequence derived from the G250 mono-
clonal antibody (m.Ab) heavy chain, cloning sites, a short 
Ig constant kappa spacer (CK) linked to the CD4 trans-
membrane domain and the intracellular domain of the 
Fc(E)Rly chain. Inclusion of the CD4 transmembrane 
domain and the intracellular domain of the Fc(e)Rly chain 
in chimeric mAb-based receptor constructs resulted in 
60 
increased membrane expression.23 The cassette was 
inserted into the retroviral vector pBullet.26 The amplified 
heavy and lambda chain fragments were cloned indi-
vidually into this retroviral expression cassette resulting 
in Fab-G8-CD4/ y heavy and light chain retroviral vectors 
(Figure I). The Fab-G8-CD4/y retroviral vectors were 
then introduced into CD4-depleted, OKT3 mAb-activated 
primary human T lymphocytes by cocultivation with 
293T cells, that had been transfected with both the heavy 
and lambda retroviral vectors and retroviral packaging 
constructs.23 As a control, activated human T lympho-
cytes were cocultivated with 293T packaging cells that 
were transfected with an empty pBullet vector. 
Fab-GB-CD41(05 human T lymphocytes specifically 
bind MAGE-A 1/HLA-A 1 complexes 
Membrane expression of Fab-G8-CD4/y receptors on 
transduced human T lymphocytes was analyzed by incu-
bating the cells with soluble MAGE-AI/HLA-
AI/streptavidinPE complexes, that had also been used to 
isolate the original Fab G-8 phage. As shown in Figure 
2a, about 3% of the transduced human T lymphocytes 
specifically bound soluble MAGE-AI/HLA-Al com-
plexes. MAGE-AI/HLA-A1/streptavidinPE complex 
binding T lymphocytes were enriched using anti-PE mAb 
coated magnetic beads as described in Materials and 
methods. This resulted in more than 90% Fab-G8-CD4/y 
receptor05 T lymphocytes (Figure 2b). Enriched Fab-G8-
CD4/y05 T lymphocytes were in vitro expanded and 
used in all subsequent experiments. Nonspecific binding 
was not observed, neither for mock-transduced T lym-
phocytes using soluble MAGE-A1/HLA-A1 complexes 
(Figure 2d), nor for Fab-G8-CD4/y receptorP05 human 
T lymphocytes using soluble influenza/HLA-
AI/streptavidinPE complexes (Flu/HLA-AI). The CTL 
clone MZ2-82/30 expressing an MAGE-A1/HLA-A1-spe-
cific TCR was used as a positive control (Figure 2c). FACS 
analysis of the Fab-G8-CD4/y transduced T lymphocytes 
(ie CD4, CD8,CD56, CD16 and TCR yi5) showed that the 
effector populations almost exclusively consist of CDSP05 
cells (data not shown). 
Fab-GB-CD41(05 primary human T lymphocytes 
specifically produce IFN""f upon stimulation with 
immobilized MAGE-A 1/HLA-A 1 complexes 
We also determined whether Fab-G8-CD4/y05 primary 
human T lymphocytes could be activated by immobilized 
MAGE-A1/HLA-A1 complexes to produce IFN-y. To this 
end, we incubated transduced human T lymphocytes for 
IS-20 h either on immobilized MAGE-A1/HLA-A1 com-
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Figure 1 Fab-G8-CD4y receptor constructs. Schematic representation of 
the Fab-G8-CD4jy gene constructs: L, leader; VhCh, human heavy chain; 
VlCl, human lambda light chain; Ck constant Ig kappa chain fragment; 
CD4Tm, CD4 transmembrane region; Icy, intracellular Fc(c)Riy chain 
region. Constructs were made as described in Materials and methods. 
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Figure 2 Cell surface expression of the Fab-GS-CD4jy receptor on trans-
duced primary human T lymphocytes. Cell surface expression of the Fab-
GS-CD4jy receptor was analyzed by incubation of T lymphocytes with 
relroant MAGE-Al/HLA-Aljstreptavidin"c complexes (Ml/Al, bold 
line) and irrelevant influenzajHLA-AljstreptavidinPE complexes (Flu/Al, 
normal line). The following cell samples were used: primary human T 
lymphocytes transduced with Fab-GS-CD4/y retroviral vectors (a); human 
T lymphocytes transduced with Fab-GS-CD4jy retroviral vectors, followed 
by selection with MAGE-Al/HLA-AljstreptavidinPE complexes and anti-
PE mAb-coated magnetic beads (b); the HLA-Al restricted, MAGE-AI 
specific parental CTL clone MZ2-82/30 (positive control) and mock-trans-
duced human T lymphocytes (negative control) (c and d, respectively). 
plexes or control Flu/HLA-Al complexes and analyzed 
cells by IFN-y capture assay (see Materials and methods). 
Only MAGE-Al/HLA-Al complexes, but not control 
Flu/HLA-Al complexes, triggered Fab-G8-CD4/y05 pri-
mary human T lymphocytes to produce IFN-y (Figure 3). 
Moreover, no IFN-y was produced when mock-
transduced T lymphocytes were incubated with 
peptide/MHC complexes. A clear IFN-y production was 
observed when CTL clone MZ2-82/30 was stimulated 
with MAGE-Al/HLA-Al complexes, but not control 
complexes. 
Fab-G8-C04f(05 primary human T lymphocytes 
specifically respond to MAGE-A 1 peptide pulsed HLA-
A vos target cells by cytolysis and cytokine production 
To analyze Fab-G8-CD4/y05 primary human T lympho-
cytes for their responsiveness to cellular targets express-
ing MAGE-Al/HLA-Al, we incubated transduced T 
lymphocytes, in a first set of experiments, with HLA-
AlPos EBV-transformed B cell blasts (B-LCL APD) which 
were externally loaded with MAGE-Al peptide (at 10 
f.Lg/rnl final). B cell blasts were incubated with an irrel-
evant influenza virus peptide to monitor nonspecific 
responses. Only B-LCL pulsed with MAGE-Al peptide, 
but not influenza virus peptide were able to trigger target 
cell lysis by Fab-G8-CD4/y05 T lymphocytes (Figure 4). 
In addition, triggering of TNF-a. and TFN-y production 
was observed when Fab-G8-CD4/y05 T lymphocytes 
were incubated with MAGE-Al peptide pulsed target 
cells, but not with irrelevant influenza peptide pulsed tar-
get cells (Figure 5). Neither target cell lysis nor cytokine 
production was observed when mock transduced T lym-
fo' 
IFNy-PE 
Figure 3 IFNy production by Fab-GS-CD4j'{05 human T lymphocytes 
upon incubation with immobilized MAGE-Al/HLA-Al complexes. IFNy 
production by the Fab-GS-CD4/y transduced T lymphocytes upon incu-
bation with immobilized MAGE-Al/HLA-Al complexes (shaded area) or 
control influenza peptide/HLA-Al complexes (white area) was determined 
by flow cytometry as described in Materiols and methods. Events shown 
represent viable lymphocytes stained with FE labeled anti-IFNy mAb. The 
following cell samples were used: (a) Fab-GS-CD4jy transduced T lympho-
cytes, (b) mock transduced T lymphocytes (negative control!, and (c) CTL 
MZ2-82/30 (positive control). 
phocytes were used as effector cells. As a positive control 
for specific cytolysis and cytokine production the CTL 
MZ2-82/30 was used. 
Native MAGE-A 1Pos and HLA-A 1Pos melanoma cells 
specifically induce cytolysis and cytokine production by 
Fab-G8-CD4f(05 T lymphocytes 
Finally, we tested whether Fab-G8-CD4/y05 T lympho-
cytes were able to respond to native MAGE-AlPos and 
HLA-AlPos melanoma cells. For this purpose, we incu-
bated Fab-G8-CD4/y05 T lymphocytes with the MAGE-
Al/HLA-AlPos MZ2-MEL 3.0 cell line and with MAGE-
AI NEG or HLA-Al NEG cell lines of distinct histological ori-
gin (ie MEL 2A, MEL 78 and SKRC17 cell lines). Only 
MAGE-AlPOs and HLA-AlPos melanoma cells, but not 
control MAGE-AlNEG or HLA-AlNEG cells were specifi-
cally lysed by the Fab-G8-CD4/y05 T lymphocytes 
(Figure 6a), and triggered specific production of TNF-a. 
and IFN-y (Figure 7). MHC restriction of the observed 
lysis was further illustrated by the significant inhibition 
of Fab-G8-CD4/y05 T lymphocyte-mediated target cell 
lysis following addition of anti-class I mAbs (Figure 6b). 
Negative controls comprised addition of irrelevant 
mAbs, or incubation of MAGE-A1PD5, HLA-AIP05 mela-
noma cells with mock transduced T lymphocytes. More-
over, the cytolytic responses of the Fab-G8-CD4/ y 05 T 
lymphocytes are clearly inhibited by the addition of anti-
CDS mAb demonstrating that indeed the effector popu-
lation almost exclusively consists of CDSPOS cells (data 
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Figure 4 Peptide pulsed target cells are lysed by Fab-GS-CD4/y trans-
duced human T lymphocytes. MAGE-AI peptide-pulsed target cells were 
incubated with Fab-GS-CD4/y05 human T lymphocytes, and tested in 6 
h 51Cr release assays at four different effector to target cell ratios (E:T). 
SICr labeled MAGE-AI NEG and HLA- AIPos EBV transformed B cell 
blasts (ie APD) were used as target cells and pulsed with MAGE-AI or 
influenza virus peptides (at 10 JLgfml final!. As controls for specific lysis, 
mock transduced T lymphocytes and CTL MZ2-82/30 (positive control) 
were used. Experiments were performed in triplicate, and the s.d. did not 
exceed 10% of the mean value. One representative experiment out of three 
is shown. 
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Figure 5 Fab-G8-CD4/y05 human T lymphocytes produce TNFa and 
IFN-y upon stimulation with MAGE-AI peptide pulsed target cells. Fab-
G8-CD4/y05 human T lymphocytes ( 6 x 10'') were incubated for 24 h 
with HLA-AIPOs EBV transformed B cell blasts (2 x 1[]4) in the presence 
of MAGE-AI or influenza peptide (at 10 JLgfml final!. Production ofTNF-
a (a) and IFN-y (b) was quantified by EUSA as described in Materials 
and methods. 
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not shown). As a positive control again CTL MZ2-82/30 
was used. 
Discussion 
In this study we show efficient retargeting of human T 
lymphocytes to tumor cells presenting the MAGE-Al 
antigen in the context of the MHC class I molecule HLA-
Al by retroviral introduction of a human Ig-based chim-
eric receptor. The chimeric receptor was made by ligation 
of the anti-MAGE-Al/HLA-Al Fab-G8 to the CD4 trans-
membrane domain and intracellular Fc(E)Riy chain, and 
was successfully transduced into primary human T lym-
phocytes. Human T lymphocytes expressing this MHC 
restricted Fab-G8-CD4/ y receptor specifically bound 
MAGE-Al/HLA-Al complexes. Moreover, Fab-G-8-
CD4/y"05 T lymphocytes specifically responded to both 
MAGE-Al peptide pulsed HLA-AF05 B cell blasts and 
native MAGE-Al Pos /HLA-Al Pos melanoma cells by spe-
cific tumor cell lysis, as well as cytokine production. The 
MHC restriction of the observed immune reactivities was 
demonstrated by a significant reduction of target cell 
lysis by anti-MHC class I mAbs. 
Antibody-based retargeting ofT cells has already been 
achieved to tumor-associated antigens (TAA).21- 24 How-
ever, this is the first report on an Ig-based chimeric recep-
tor conferring MHC -restricted tumor specificity to pri-
mary human T cells. Since most known TRAs are in fact 
MHC restricted peptides, this may have major impli-
cations for immunotherapy. Adoptive immunotherapy 
by clinical transfer of autologous tumor or virus-specific 
T cells and interleukin-2 has met success in the treatment 
of both hematological malignancies and melanoma/"7 
and viral diseases caused by CMV and EBV.5 The overall 
difficulty in obtaining tumor-reactive TIL from individ-
ual patients, and TIL specific for cancers other than mela-
noma, however, has hampered the development of clini-
cally effective adoptive immunotherapeutic strategies. 
Research focussed on the engineering of chimeric recep-
tors to transfer specificities toT lymphocytes. Our labora-
tory developed strategies to genetically program human 
T lymphocytes with non-MHC restricted (Ab-based) and 
MHC-restricted (TCR-0:~-based) chimeric receptors.19•20 
Chimeric single chain or double chain Ig or TCR recep-
torPOs T lymphocytes specifically respond to tumor cells 
expressing the relevant antigen by tumor cell kill and 
cytokine production.22.26 However, in the case of TRA 
epitopes, this approach is still limited by the isolation of 
tumor-specific CTLs required for the cloning of TCR 
genes. A complete in vitro approach would allow for the 
selection of TRA-specific molecules, without being lim-
ited by the availability of CTL clones. The ability to pro-
duce numerous HLA complexes in vitro/8 as well as the 
availability of large non-immune human phage-antibody 
libraries has made such an in vitro approach within 
reach.36 In principle, any peptide with the right anchoring 
residues may be refolded in vitro with MHC class I heavy 
chain and ~2 rnicroglobulin, resulting in peptide/MHC 
complexes available for phage selection. Indeed, we have 
recently used our non-immunized library to select human 
antibodies against 12 HLA-A2 complexes presenting dif-
ferent peptides and we were able to isolate between three 
and nine different antibodies for each complex, some of 
them of high affinity, in less than 4 weeks (manuscript 
in preparation). This shows that it is possible to rapidly 
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Figure 6 Native MAGE-A1POs and HIA-A1Pos melanoma cells are susceptible to lysis by Fab-GS-CD4/y transduced T lymplwcytes. Cytotolytic 
activity of human T lymphocytes versus MAGE-AI expressing melanoma cells was determined as described in legend to Figure 4. MAGE-AF05 and 
HIA-AF05 melanoma cells (ie MZ2-MEL 3.0) and MAGE-A1NE0 and/or HIA-AlNEG cell lines of different histologies (ie MEL 2A MEL 78 and 
SKRC17 cl4) were used as target cells. Target cells were incubated with (1) Fab-GS-CD4/y transduced T lymphocytes (a and b); (2) mock transduced 
T lymphocytes (negative control, c and d); and (3) CTL MZ2-82/30 (positive control, e and f!. Anti-HIA-ABC or mouse Ig (both at 10 11-g/ml final! 
was added to the melanoma target cells (ie MZ2-MEL 3.0) 15-30 min before incubation with the effector T lymphocytes (b, d and fJ. Mean percentages 
of specific 51Cr release of triplicate measurements are shown, with s.d. not exeeding 10% of mean values. Data of one representative experiment out 
of three are shown. 
select anti-peptide/MHC antibodies against any complex 
and that this technology may become a reliable source of 
viral or TRA-specific receptors in the near future. In con-
trast to TCRs, Fab fragments can be easily produced in 
E. coli, making it possible to determine and modulate the 
fine specificity of Fab fragments by antibody-engineering 
techniques before their use in retargeting experiments. 
Hence, we believe that the use of phage display will 
prove to be a flexible tool to select and modulate TRA-
specific Fab molecules. 
Fab-GS has an affinity with a K0 of 250 run, which is 
already high compared to TCR/peptide MHC interac-
tions (average K0 around 10-s to 10-6 M). We have recently 
improved the affinity of Fab-GS by a factor of 18. During 
this process, low affinity variants have also been gener-
ated. Different mutants of Fab-GS with the same peptide 
fine-specificity, but covering a large range of affinities, 
with K0 s varying from 1300 to 14 run are thus available 
(manuscript in preparation). The effect of receptor affin-
ity on T cell retargeting and killing is currently being 
investigated. Moreover, we suggest that this Fab-CD4y 
fusion may be used for comparative functional analyses 
between antibody-based and TCR-based T cell retar-
geting. Preliminary results show that it is possible to 
retarget T cells using a double chain TCR directed against 
MAGE-A1/HLA-A1 fused to Fc(E)Rly. The TCR-based 
and Fab-GS-based constructs have identical specificities 
and signaling moieties, providing powerful tools for 
investigating the requirements of additional interactions 
upon peptide/MHC binding, such as TCR accessory 
molecules. 
Human T lymphocytes positive for a single chain Fv 
receptor with the same CD4/y domain show CD3 inde-
pendence for their cytotoxic response,25 implying that 
receptors with this type of configuration do not associate 
with endogenous CD3. The exact membrane topology of 
the Fab-based receptors is currently under investigation. 
In conclusion, the efficiency and reproducibility of T 
cell retargeting with chimeric receptor genes combined 
with the flexibility of antibody phage display to select 
TRA specific molecules hold great promise for clinical 
immunogene therapy. 
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Figure 7 Native MAGE-A1P05 and HLA-AlPos melanoma cells stimu-
late production of TNF-y and IFN-y by Fab-GS-CD4/y transduced T lym-
phocytes. Fab-GS-CD4/y0 s T lymphocytes were stimulated with MAGE-
AlPOs and HLA-AF05 melanoma cells (ie MZ2-MEL 3.0) and MAGE-
AI NEG and for HLA-AlNEG cell lines of different histologies (ie BLM, MEL 
78 and SKRC17 cl4), and analy=ed for production of TNF-a (a) and IFN-
y (b) as described in the legend to Figure 5. 
Materials and methods 
Cefls and antibodies 
Human T lymphocytes were derived from healthy 
donors, and were isolated and expanded as described.22 
Target cell lines used in this study were: (1) the MAGE-
A1Pos and HLA-A1Pos melanoma cell line MZ2-MEL3.0 
(kindly provided by T Boon and P Coulie, Ludwig Can-
cer Research Institute, Brussels, Belgium"); (2) the MAGE-
A1NEG and HLA-A1Pos melanoma cell line MEL2A; (3) 
the HLA-A1NEG melanoma cell line BLM (kindly pro-
vided by G Adema, Academic Hospital Nijmegen, 
Nijmegen, The Netherlands); (4) the HLA-A1NEG mela-
noma cell line MEL78; (5) the HLA-A1NEG renal carci-
noma cell line SKRC17-cl4 (kindly provided byE Ooster-
wijk, Academic Hospital Nijmegen); and (6) the HLA-
A1P05 EBV-transformed B cell blast APD. The human 
embryonic kidney cell line 293T39 (kindly provided by Y 
Soneoka, University of Oxford, Oxford, UK) was used as 
a packaging cell line for the pBullet Fab-G8-CD4/y retro-
viral vectors essentially as described.23 The HLA-A1-
restricted, MAGE-A1 specific CTL clone MZ2-82/30 
(kindly provided by T Boon and P Coulie) was used as 
a positive control in these studies. The following mAbs 
were used this study: anti-CD4 mAb (Becton Dickinson 
Biosciences, San Jose, CA, USA), anti-class I mAb W6/32 
(Seran Laboratories, Crawley Down, UK) and purified 
mouse Ig (Nordic, Tilburg, The Netherlands). 
Construction of the chimeric Fab-G8-CD4!y genes 
The chimeric heavy chain VhChCD4/y and lambda light 
chain VlClCD4/y were generated by amplification of the 
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Fab fragments from phage G8 DNA)6 using the primer 
pairs Vh-Sft1/Ch-Notl and Vl-Sft1/Cl-Notl, respectively. 
The resulting fragments were inserted via Sft1/Notl 
digests into the pBullet retroviral vector, which contains 
an expression cassette. The expression cassette contains: 
(1) the G250 variable heavy chain signal sequence, and 
(2) a constant kappa chain linker (Ck), the CD4 trans-
membrane domain and the intracellular y chain (CD4/y). 
All domains were derived from the G250 specific chim-
eric scFv-HKCD4/y receptor DNA.23 
Primer sequences were as follows: 
Vh-Sft1: 5' -CTC-TGG-CCC-AGC-CGG-CCA-TGG-CCG-
AGG-TGC -AGC-TGG-TGG-AGT -CTG-GG-3'; 
Ch-Notl: 5' -CTC-TGC-GGC -CGC-GCT-TGA-GAC-GGT-
GAC-CGT-GGT-CCC-3'; 
Vl-Sft1: 5' -CTC-TGG-CCC -AGC -CGG-CCA-TGG-CCC-
AGT-CTG-TGC-TGA-CTC-AGC-CAC-CCT-CG -3', and 
Cl-Notl: 5' -CTC-TGC-GGC -CGC-GAG-GAG-GGT -CAG-
CTT-GGT-CCC-TCC-3'. 
Retroviral transduction of Fab-G8-CD4!ygenes into 
primary human T lymphocytes and in vitro expansion of 
transduced T lymphocytes 
CD4P05 T lymphocytes were depleted from human per-
ipheral blood lymphocytes (PBL) with anti-CD4 mAb 
coated magnetic beads according to the manufacturer's 
instructions (Dynal, Oslo, Norway). The CD4-depleted 
human PBL (5 x 106) were activated by addition of anti-
CD3 mAb and then transduced using the pBullet retrovi-
ral vectors with the Fab-G8-CD4/y genes as described 
earlier.23 Briefly, anti-CD3 mAb activated lymphocytes 
were incubated for 72 h with an irradiated (25 Gy) mono-
layer of recombinant retrovirus producing 293T cells 
using culture medium supplemented with 4 fLg/ml 
polybrene (Sigma, StLouis, MO, USA) and 360 IU/ml 
human riL-2 (Proleukin; Chiron, Amsterdam, The 
Netherlands). Expansion of transduced primary human 
T lymphocytes was performed in the presence of feeder 
cells as described elsewhere. 40.41 
Flow-cytometric analysis of retrovirafly transduced 
primary human T lymphocytes 
Primary human T lymphocytes (5 x 105) were stained 
with soluble peptide/HLA-A1/streptavidffiPE complexes 
as described.26 Briefly, T lymphocytes (5 x 105) were incu-
bated for 30 min on ice, with a 1:10 dilution of freshly 
prepared complexes in a volume of 20 fLL The dot plots 
show viable T lymphoblasts gated on forward (FSC) and 
sideward (SSC) light scatter signals. Analysis was perfor-
med on a FACSCAN instrument (Becton Dickinson 
Biosciences, San Jose, CA, USA). Human T lympho-
cytes were stained with soluble peptide/HLA-A1/ 
streptavidinPE complexes and enriched via anti-PE mAb 
coated magnetic beads and mini-MACS columns accord-
ing to the manufacturer's instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). 
IFNy capture assay 
Transduced human T lymphocytes were incubated for 
18-20 h on inunobili2ed peptide/MHC complexes and 
were analyzed by flow cytometry for IFN-y production. 
To inunobili2e peptide/MHC complexes, non-tissue cul-
ture 24-well plates were incubated with PBS containing 
streptavidin (at 1 mg/ml final) for 12-15 hat room tern-
perature (RT). Non-bound streptavidin was removed by 
three washes with PBS. The 24-well plates were then 
blocked with PBS containing 2% FCS and 2 mm EDTA 
for 30 min at RT. After removal of the blocking mecl.ium, 
soluble biotinylated MAGE-A1/HLA-A1 complexes and 
influenza/HLA-A1 complexes (at 10 J.Lg/ml final) were 
added to the streptavidin-coated plates, and left to bind 
for an additional 30 min at RT. To remove non-bound 
peptide/MHC complexes, the plates were washed twice 
with PBS and once with culture mecl.ium. Finally, trans-
duced T lymphocytes (1 x 106 cells) were then stimulated 
in the peptide/MHC complex-coated plates for 18-20 h 
at 37°C/5% C02 in a volume of 1 ml. IFNy production 
was determined by IFNy capture assay (Miltenyi Biotec) 
according to the manufacturer's protocol. 
Cytotoxicity assays 
Cytolytic activities of Fab-G8-CkCD4/ y transduced 
human T lymphocytes were measured in 6 h 51Cr-release 
assays as described elsewhere. 22 The percentage-specific 
51Cr release was calculated as follows: ((test counts -
spontaneous counts)/(maximum counts - spontaneous 
counts)) x 100%. Spontaneous 51Cr release was always 
less than 10% of maximum release. Peptide loading of 
target cells was performed by adcl.ition of a MAGE-A1 
nonapeptide (EADPTGHSY, Leiden University Medical 
Center, Leiden, The Netherlands) or an irrelevant influ-
enza peptide derived from influenza virus A nucleopro-
tein (CTELKLSDY, Leiden University Medical Center) to 
the target cells 5-15 min before incubation with effector T 
lymphocytes. In blocking experiments, anti-class I mAbs 
were added to the target cells 15-30 min before adcl.ition 
of the T lymphocytes 0/116/32 or irrelevant mlg, both at 
10 J.Lg/ml final). 
TNFa and IFN.ry ELISA 
To quantify secreted amounts of TNFa and IFN-y, trans-
duced human T lymphocytes (6 x 104) were cultured for 
24 h either in the presence or absence of 2 x 104 adherent 
tumor cells in culture medium supplemented with 360 
IU/ml riL-2. Supernatants were harvested and levels of 
TNFa and IFN-y, were measured by standard ELISA 
according to the manufacturer's instructions (CLB, 
Amsterdam, The Netherlands). 
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TCR-Like Human Antibodies Expressed on Human CTLs 
Mediate Antibody Affinity-Dependent Cytolytic Activity1 
Patrick Chames,2 * Ralph A. Willemsen,t Gertrudis Rojas,* DetlefDieckmann,§ Louise Rem,* 
Gerold Schuler,§ Reinder L. Bolhuis,t and Bennie R. Hoogenboom3*"~~ 
The pennanent genetic programming via gene transfer of autologons T cells with cell surface receptors directed toward tumor· 
related Ags holds great promise for the development of more-specific tumor therapies. In this study we have explored the nse of 
Abs directed to MHC-peptide complexes (or TCR-Iike Abs) to engraft CTLs with exquisite specificity for cancer cells. First, we 
affinity matured in vitro a previously selected TCR-Iike Ab, Fab-G8, which is higbly specific for the peptide melanoma-associated 
Ag-Al presented by the HLA-Al molecule. A combination of L chain shuffiing, H chain-targeted mutagenesis, and in vitro 
selection of phage display libraries yielded a Fab-G8 Ab derivative, Fab-Hyb3, with an 18-fold improved affinity yet identical 
peptide fine specificity. Fab-G8 and Fab-Hyb3 were expressed on primary human T lymphocytes as cell surface-anchored Fab, 
demonstrating that T cells expressing the high-affinity Fab-Hyb3 molecule eradicate tumor cells much more effectively. Further-
more, the gain in ligand-binding affinity resulted in a 2-log improvement in the detection ofpeptide!MHC complexes on melanoma-
associated Ag-Al peptide-loaded cells. In summary, an affinity-matured Ab specifically recognizing a cancer-related peptidelMHC 
complex was generated and nsed to improve the tumor cell killing capacity of human T cells. This strategy, based on engraftment 
ofT cells with in vitro engineered Abs, is an attractive alternative to the laborions, and in many cases unsuccessful, generation of 
highly potent tumor-specific T lymphocytes. The Journal of Immunology, 2002, 169: 1110-1118. 
T he recent increase in understanding of the immune re-sponses associated with cancer and autoimmune disorders can further be advanced by recognizing the importance of 
the role played by peptide/MHC complexes in these diseases. and 
such knowledge provides various strategies for immunotherapy (1. 
2). Molecules that bind specifically to these peptide MHC 
(pMHC)4 complexes. which are involved in the molecular and 
cellular processes of Ag presentation. have a wide variety of ap-
plications. including direct visualization of the pMHC complexes 
(both intracellular and at the cell surface). specific masking of 
complexes involved in autoimmune disease. targeted delivery of 
toxins and drugs. and adoptive transfer of CTLs expressing 
pMHC-specific molecules involved in the immune response 
against cancer or viral infections (3). Two potent classes of re-
agents have been developed to bind to such complexes. Specific 
TCR. engineered from cloned T cells of known pMHC specificity. 
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have been used to visualize cell surface pMHC complexes (4. 5). 
and MHC-restricted. peptide-specific mAb. identified by various 
immunization and screening schemes, have been isolated and used 
similarly (5-12). However. it has recently been suggested that in 
vitro selection of phage libraries displaying Ab fragments could be 
one of the most efficient ways to select specific pMHC binders (3). 
We have recently taken advantage of this technique to select a 
human Fab capable of binding an Ag of strong clinical value (1 ). 
the tumor-related pMHC complex HLA-Allmelanoma-associated 
Ag (MAGE)-Al (13). Despite a moderate affinity of 250 nM. the 
selected Ab fragment Fab-G8 is highly specific for the HLA-Al/ 
MAGE-A1 complex and does not bind to HLA-Al/MAGE-A3. a 
complex with a peptide that differs in only three residues from 
MAGE-Al. Nevertheless. most therapeutic applications. including 
targeting of toxins or cytokines and adoptive immunotherapy, are 
likely to demand a higher affinity. Interestingly. TCRs. the mole-
cules that have been selected by evolution to bind pMHC com-
plexes. always display very low affinities for their targets (I 0 to 0.1 
!LM) (14). The activity ofT cells seems to be dependent on the 
affinity of the TCR/MHC interaction and/or the dissociation rate of 
the TCR from the peptide/MHC complex (15, 16). It was sug-
gested by Valitutti et al. (17) that a single peptide/MHC complex 
on target cells engages multiple TCR on T cells to activate the 
effector T cells. This process of serial triggering of multiple TCR. 
essential for optimal T cell triggering, favors the interaction of 
low-affinity TCR with peptide/MHC complexes. because the 
longer dissociation times of high-affinity TCR might prevent serial 
triggering and thus optimal T cell activities. In this work we in-
vestigated to what extent such affinity constraints apply when T 
cells are artificially equipped with an Ag receptor. Indeed. there is 
recent evidence suggesting that in vitro affinity-matured TCRs also 
mediate increased peptide activation (18). While lower affinities 
may be acceptable in natural TCR-MHC-mediated cellular interac-
tions. many therapeutic applications may benefit from higher-affinity 
TCRs or surrogate TCRs such as appropriately membrane-anchored 
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Abs or other receptors. We decided to see whether it would be pos-
sible to increase the affinity of Fab-G8 without losing the peptide fine 
specificity. and to subsequently examine the effect of such an affinity 
increase on chimeric Fab receptor-mediated T cell functions. 
In vitro affinity maturation of Abs can be conducted using phage 
display methods. Genetic diversity is introduced into the genes 
encoding the parental Ab and. from the resulting phage library: 
variants showing improved affinity for the specific target are se-
lected (for review see Ref. 19). We did not know a priori the 
specific amino acid residues in the Ab that confer the peptide fine 
specificity to Fab-G8. Therefore. we used two broadly comple-
mentary affinity maturation methods for diversifying the Ab genes. 
including 1) chain shuffiing of the intact L chain. and 2) site-di-
rected mutagenesis of the complementarity-determining region 
(CDR)3 of the H chain. which for most Abs forms the heart of the 
Ag binding site. Variants were selected under a variety of condi-
tions, and those with highest affinity were tested for pMHC bind-
ing specificity and for binding to the pMHC complex on the sur-
face of APCs. Finally, we expressed Fab-GS and higher-affinity 
variants as chimeric Fabs fused to the FcER.l y-chain signaling 
molecule on the surface of primary human T lymphocytes, and we 
examined the tumor cell killing capacity of these T cells express-
ing these low- or high-affinity pMHC binding molecules. The in-
creased affinity of the chimeric receptor is clearly associated with 
faster cytotoxic responses, increased sensitivity, and an enhanced 
tumor cell killing capacity. We anticipate that this higher-affinity 
molecule will be more effective than Fab-G8 in the eradication of 
cancer cells in vivo. 
Materials and Methods 
Library construction 
Chain-shuffling library construction. To build the L chain-shuffling (LS) 
library. the GS V H gene was cloned into a vector containing a library of 
human Ab K and A L chains. The latter libraries were generated during the 
construction of the large nonimmune Fab library (20). Briefly. the pCESl 
vector containing Fab-G8 was digested with Sfil and BstEII. and the frag-
ment corresponding to GS V H was gel purified and extracted using the 
QiaEX method (Qiagen. Valencia. CA). The K and A libraries were simi-
larly digested and gel purified. Large-scale ligations (using 20 J.Lg of insert 
and 20 f.Lg of vector) were performed overnight at 16oC: the mixture was 
ethanol precipitated and introduced into Escherichia coli TG 1 cells by 
electroporation. Cells were plated on 2X TY agar plates containing 100 
J.Lglml ampicillin and 2% glucose. After overnight incubation at 30°C. cells 
were scraped from the plates and stored at -80°C in 2X TY containing 
15% glycerol. 
H chain CDR3 mutagenesis for H chain-CDR3 spiking (HS) library con-
struction. To create the HS library in a one-step PCR amplification of the 
V H gene, we introduced diversity in the 13 amino acid residues of the H 
chain CDR3 by using a primer hybridizing on the CDR3 plus FR4 region. 
The primer used was 5'-GCTTGAGACGGTGACCGTGGTCCCTTG 
GCCCCAGACGTCCATACCGTAATAGTAGTAGTGGAAACCACCACC 
CCTCGCACAGTAATACACAGCC-3', with the underlined residues us-
ing 90% of the wild-type nucleotide and 10% of an equirnolar mix of A, T. 
C. and G (purchased from Eurogentec. Liege. Belgium). The V H fragment 
was amplified by PCR using the pCES!-Fab-G8 as template. This fragment 
was digested by Sfii and BstEII and cloned into the pCES 1 vector contain-
ing the G8 L chain. A library was made as before. Fingerprinting analysis 
was performed as already described (21) using the primers pUC reverse 
(5'-AGCGGATAACAATITCACACAGG-3) and fd-tet-seq24 (5'-TIT-
GTCGTCTITCCAGACGTTAGT-3'); DNA sequencing was performed 
by Eurogentec using pUC reverse for VL and CHl-fw (5'-GAAG 
TAGTCCTTGACCAGGC-3') for VH. 
Selection and screening procedures 
Except when mentioned in Results. all selections were conducted as de-
scribed (13). The Ag-binding specificity of individual Fabs was assessed by 
phage or Fab ELISA using indirectly coated complexes. as described (22). 
Fab were purified by immobilized metal affinity chromatography as de-
scribed (13). 
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Suiface plasmon resonance measurements 
Kinetic measurements were performed by surface plasmon resonance on a 
BIAcore 2000 (Pharmacia Biotech, Uppsala, Sweden). PBS (pH 8) plus 
0.1% Tween 20 was chosen as running buffer. A nitrilotriacetic acid chip 
(Pharmacia Biotech) was activated with 500 f1M NiCI2 for 1 min at 10 
f.Ll/min. Approximately 800 resonance units of hexahistidine-tagged Fab 
(20 f.Lg/rnl) was immobilized and different concentrations of pMHC com-
plexes were subsequently injected at a flow rate of 20 J.Lllmin to minimize 
rebinding effects. A blank (injection of the Ab only) was subtracted from 
each curve to take into account the dissociation of the Ab from the chip. 
The channels were regenerated by injection of 250 mM EDTA over a 
period of 2 min. Kinetic analysis was performed using BIAevaluation 2.0 
software (Biacore. Uppsala. Sweden). 
Flow cytometry 
Dendritic cells (DC) were generated as described (23). In brief, PBMCs 
were isolated from leukaphcresis by Ficoll (Amersham Biosciences, Pis-
cataway. NJ) density gradient centrifugation. Monocytes were isolated by 
plastic adherence and cultured in RPMI 1640 (BioWhittaker. Walkersville. 
MD) supplemented with 1% plasma, 20 f.Lg/ml gentamicin (Merck, West 
Point, PA), 2 mM glutamine (BioWhittaker). 800 U/rnl IL-4 (Novartis 
Pharmaceuticals, East Hanover. NJ), and 1000 U/rnl GM-CSF (Leukomax; 
Novartis Pharmaceuticals). At days 5-6. 2 ng/rnl IL-1{3 (Sigma-Aldrich. 
St. Louis, MO). 1000 U/rnl IL-6 (Novartis Pharmaceuticals). 1 f.Lg/rnl 
PGE, (Sigma-Aldrich), and 10 ng/ml TNF-a (Bender MedSystems, Vi-
enna. Austria) were added. After an additional day of culture nonadherent 
cells were harvested. To demonstrate maturation of DC. FACS analysis 
was performed on CD80, CD83, and CD86 (all from BD PharMingen. San 
Diego. CA). Mature DC were >90% double positive for costimulatory 
molecules and CD83. 
DC were then pulsed with 20 f.LM MAGE-AI (EADPTGHSY) or 
MAGE-A3 (EVDPIGHL Y). tyrosinase (KSDICTDEY). and influenza 
(INF) nucleoprotein (CTELKLSDY) as negative controls for 3 h. DC were 
washed two times in PBS (BioWhittaker) and resuspended at 106 cells/rnl. 
All staining procedures were performed at 4 °C. DC were incubated for 30 
min with fd-Fab-Hyb3, G8. or H2. washed again. and incubated with anti-
M13 mAb (Zytomed. Berlin, Germany) for additional 30 min. After two 
rounds of washing in PBS. DC were incubated with goat anti-mouse PE 
Fab (Caltag Laboratories, Burlingame. CA) for 15 min. Cells were washed 
again and analyzed by flow cytometry (FACScan and CellQuest software: 
BD Biosciences. San Jose. CA). Cultured EBV-transformed B celllym-
phoblasts (B-LCL) were pulsed with MAGE-A! peptide or irrelevant INF 
virus peptide (10 f.Lg/ml final concentration) for I h at 37°C. Unbound 
peptides were removed from the B-LCL by two washes with PBS. The 
peptide pulsed B-LCL were then incubated with fd-Fab-Hyb3. G8, or H2 
essentially as described for the DC staining. 
Primary human T lymphocytes (5 X 105 ) were stained with soluble 
peptide/HLA-Al/streptavidinPE complexes as described (24). Briefly. T 
lymphocytes (5 X 105 ) were incubated for 30 min on ice, with a 1/10 
dilution of freshly prepared complexes in a volume of 20 pl. The dot plots 
show viable T lymphoblasts gated on forward and side light scatter signals. 
Analysis was performed on a FACScan instrument (BD Biosciences). Hu-
man T lymphocytes were stained with soluble peptide/HLA-Al/strepta-
vidinPE complexes and enriched via anti-PE mAb-coated magnetic beads 
and mini-MACS columns according to the manufacturer's instructions 
(Miltenyi Biotec. Bergisch Gladbach. Germany). 
Construction of the chimeric Fab-CD4!y receptors and 
retroviral gene transfer to human T lymphocytes 
The chimeric Fab-G8/-y and Fab-Hyb3/-y receptors were made as recently 
described (24). The chimeric Fab-GS/y and Fab-Hyb3/y receptors were 
independently cloned into the pBullet retroviral vector (24) and introduced 
into OKT-3 mAb-activated primary human T lymphocytes using retronec-
tin-enhanced supernatant transduction (25). The retroviral supernatants 
were obtained from a mixture of Phoenix packaging cells (Phoenix Phar-
maceuticals. Belmont. CA) (26) and 293T cells that had been transfected 2 
days before harvest of the supernatants. with the following constructs: the 
GAG-POL construct pHit-60 (27). the pColt-GaL V vector, the pBullet vec-
tor with the V f1CD4/y chain. and the pBullet vector with the V L -CD4/y 
chain. After retroviral transduction the human T lymphocytes were ex-
panded as described elsewhere (28). 
Cytotoxicity assays 
Cytolytic activity of transduced human T lymphocytes was measured in 
51Cr release assays as described previously (29). Peptide loading of target 
cells was performed by adding MAGE-AI nonapeptide (EADPTGHSY; 
Leiden University Medical Center. Leiden. The Netherlands) or irrelevant 
HLA-Al-binding INF peptide derived from INF virus A nucleoprotein 
(CTELKLSDY: Leiden University Medical Center) at indicated concen-
trations to the target cells 5-15 min before incubation with effector T lym-
phocytes at indicated E:T cell ratios. The incubation period of effector and 
target cells is indicated in the figures. The percentage of specific 51 Cr 
release was calculated as follows: ((test counts - spontaneous counts)/ 
(maximum counts - spontaneous counts)) X 100%. 
TNF-a ELISA 
To quantify the secreted amount of TNF-a. transduced human T lympho-
cytes ( 6 X 104 ) were cultured for 24 h in either the presence or absence of 
2 X 104 adherent tumor cells in culture medium supplemented with 360 
IU/ml riL-2. Supernatants were harvested and levels of TNF-a were mea-
sured by standard ELISA according to the manufacturer's instructions 
(CLB. Amsterdam, The Netherlands). 
Results 
Construction of LS and HS libraries 
In the absence of any information regarding the specific amino 
acid residue interactions between Fab-G8 and the HLA-Al/ 
MAGE-AI complex. we decided to use two complementary li-
brary generation methods in parallel. The Fab-G8 V L gene has 18 
mutations compared with the nearest germline sequence (subgroup 
A ill. annotated lv318 by the V base index at www.mrc-cpe.cam. 
ac.uk/imt-doc/public/INTRO.html). whereas the V H gene has only 
one mutation. We decided to use V L chain shuflling to identify 
germline mutations that are important for binding and to possibly 
generate variants with a higher affinity for the HLA-A1/MAGE-A1 
complex. However. the H chain often dominates the interaction 
with Ag. and its CDR3 region is usually responsible for crucial 
interactions with the Ag. We surmised that the H chain CDR3 
might provide direct contact in the G8-Ag interaction; therefore. 
we created a library of G8-V H-CDR3 variants. The long length of 
the Fab-G8 V H-CDR3 (13 residues) prevents a representative sam-
pling of a library when made by complete randomization of each 
residue. Therefore. we decided to introduce a low percentage of 
mutation into each residue position using a "spiked" oligonucleo-
tide (see Materials and Methods). This should result in the intro-
duction of one to three mutations per clone. spread all along 
the CDR3. 
Both libraries were built using standard cloning procedures (20) 
(see Materials and Methods). We obtained a library of 2 X 108 
clones for the VL chain shuffling (l.S) library and 2 X 107 for the 
HS library. The quality of these unselected libraries was checked 
by fingerprint analysis using the restriction enzyme BstNI. by 
DNA sequencing. and by ELISA. Both libraries showed a high 
diversity (>88%): >95% of the LS clones and 65% of the HS 
clones displayed a correct open reading frame (Table I). 
Selection against HIA-Al/MAGE-Al 
Both repertoires were independently selected against the biotinyl-
ated HLA-Al/MAGE-1 complex as previously described (13). We 
Table I. Quality of the unselected repenoires 
Library Size Insert" 
initially chose to carry out several rounds of selection using de-
creasing Ag concentration to favor selection of high-affinity bind-
ers. For both repertoires, after the first round of selection, 92 of 92 
clones bound the Ag in phage ELISA. However. after three rounds 
of selection, most of the clones (82%) showed a high cross-reac-
tivity with HLA-Al/MAGE-A3 complexes by phage ELISA (data 
not shown). Because we wanted to use the frequency of Ag pos-
itives as a readout of the stringency of the selection procedure. and 
we also wanted to avoid the selection of these cross-reactive 
clones, we decided to optimize the selection procedure by using 
only one round of selection. Different conditions for selection were 
tested. and clones were screened to find affinity variants with 
higher affinity while maintaining peptide fine specificity. 
We compared three selection strategies based on different prin-
ciples, including 1) limited Ag concentrations (LAC). 2) stringent 
washes (SW). favoring low dissociation rate (kotrl· or 3) competi-
tion for binding to the Ag (COM). After selection. 40 clones de-
rived from each selection method and each library were tested for 
binding to HLA/MAGE-Al in ELISA. Clones showing the best 
signals were produced as Fab and screened for affinity by B!Acore. 
As indicated in Tables II-IV. the first two methods did not yield 
any significant increase of affinity and. surprisingly, the average Kd 
of the selected clones was above that of the parental clone value of 
250 nM (see Fig. 1). The third selection process (COM) was based 
on competition for binding and involved adding soluble Fab-G8 
directed against the same epitope. To choose a relevant concen-
tration range for the competitor molecule. we first performed a 
phage-Ab ELISA mimicking the selection conditions and chose 
different concentrations of competitor yielding from 90% (for 40 
nM) to 10% (for 5 I-'M) of the control experiment without com-
petition. During the selections. increasing the competitor concen-
tration resulted in a decrease of the output titer as well as in the 
number of positive clones in ELISA (see Table IV). and at 5 I-'M 
competitor none of the output phages was positive for binding to 
HLA-Al/MAGE-Al. Contrasting with results obtained from the 
other selection procedures, the affinities of all the ELISA-positive 
clones were better than the affinity of the parental clone. with the 
best affinities being 4.5-fold stronger. The best results were ob-
tained with the HS library. with clones Com6 and Com7 showing 
an affinity of 55 and 60 nM. respectively (Fig. 1). In all cases. the 
affinity improvement was essentially due to a decrease of the korr· 
Consrruction of V H!VL hybrids 
We next investigated whether the effects of the mutations selected 
in the L chain could be additive with those in the H chain. The best 
L chain available (from clone Lac3, 83 nM, 3-fold improvement) 
was combined with the H chain of clone Lac? (85 nM. 3-fold 
improvement), Com7 (60 nM, 4-fold improvement). and Com6 (55 
nM. <5-fold improvement) to give three new clones called Hybl. 
Open Reading 
Diversityb Framcc ELlS Ad 
LS 2 X 108 40/40 35 different clones/ 15/15 0/92 
40 (fingerprint) 
HS 3 X 107 37/41J 20 different clones/ 13/20 3/92 
20 (sequencing) 
a Number of clones presenting a full-length insert (checked by PCR). 
b Number of clifferent clones identified/total number of clones sequenced. 
c Number of clones without any stop codons. deletions. insertions. or frame shifts/total number of clones examined. 
d Number of clones positive against HLA-Al!MAGE-Al in incfuect ELISAJtotnl number of clones examined. 
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Table ll. Selection results: L4CZ 
LS HS 
Ag (pMt Output (10° CFU) Positive(%) Output (I 06 CFU) Positive(%) 
10.000 II 
1.000 1.3 
100 0.83 
10 3 
I 5.6 
0.1 1.4 
0.01 1.3 
55 
7 
0 
0 
5 
0 
0 
79 
5.8 
0.34 
0.58 
0.86 
1.6 
1.1 
85 
67 
7 
0 
0 
0 
2 
a Input for LS. 1.1 X 1012 CFU: input for HS. 1.6 X 1012 CFU. 
b Time of incubation with the Ag. 6 h. 
Hyb2. and Hyb3. respectively (see Fig. 2). The Fab encoded by 
these genes were produced and purified for BIAcore measure-
ments. All three clones have Kds well below the Kd of the parental 
clone (Fig. 2). At 14 nM. the Kd of the best clone. Hyb3. was 
18-fold lower than that of the parental clone. thereby demonstrat-
ing a synergistic effect among the selected mutations. 
Analyzing the Ag recognition fine specificity 
The binding specificity of G8 and its derivatives for the HLA-Al/ 
MAGE-A1 complex was confirmed by BIAcore analysis and by 
comparing binding to the HLA-Al/MAGE-A3 complex. No bind-
ing to the latter Ag could be detected for the selected clones (Lac3. 
Lac7. Com6. Com7. Hybl. Hyb2. and Hyb3; data not shown). We 
further compared the specificity of G8 (250 nM). Lac7 (85 nM). 
and Hyb3 (14 nM) by sandwich ELISA using indirect coating of 
nine different biotinylated HLA-Allpeptide complexes via strepta-
vidin. To choose the peptides for this study. we investigated the 
homology between the two MAGE peptides: MAGE-AI differs at 
three positions from MAGE-A3 ('12A. 15T. and L8S). To inves-
tigate which residue is critical for G8 and Hyb3 binding. we syn-
thesized hybrid peptides corresponding to MAGE-A3 or lNF with 
residues from MAGE-A1 at positions 2. 5. and 8 and used them to 
make HLA-Al complexes. Surprisingly. HLA-Al/INFA could not 
be refolded properly. as shown by the absence of binding of the 
conformation-specific mAb TU155 (13). although INFA possesses 
the required anchor residues for HLA-Al binding (E3 and Y9: see 
Fig. 3). All the other complexes were properly refolded. As shown 
in Fig. 3. Fab-G8 gave a strong signal against MAGE-A1 and no 
signal for MAGE-A3 or INF. Interestingly. M3T was strongly rec-
ognized by G8. implying that the threonine at position 5 is crucial 
for binding; however. lNFT with this central threonine was not 
recognized. The presence of a threonine in position 5 is thus nec-
essary but not sufficient to allow G8 binding. None of the other 
complexes was recognized by the Abs if the threshold for binding 
was set at a signal lower than three times the background: when set 
at twice the background. some binding was seen for the peptide 
Table ill. Selection results: SW favoring low ko./ 
LS LS Depletionb 
M3S. Clones Lac7 and Hyb3 gave an identical binding pattern. 
but. as expected for MAGE-AI. with higher intensities (Fig. 3). 
This result confirms that the peptide fine specificity of Fab-G8 was 
maintained during the affinity maturation process. 
Cell binding of G8 wild-type and affinity variants 
Clone Fab-G8 was used in our previous work to detect the com-
plex HLA-Al/MAGE-Al in flow cytometry. after recloning the 
Ab genes for display on fd particles (to increase the number ofFab 
per particle) (13). Fab-G8 expression on fd particles yielded a dif-
ference between control cells and MAGE-Al-pulsed cells of less 
than one log shift in the mean fluorescence index. To evaluate the 
effect of the 18-fold affinity increase on diagnostic assays. e.g .. 
flow cytometry. Hyb3 was also recloned for multivalent display 
and compared with fd-Fab-G8 in staining of peptide-loaded HLA-
Al + human DC or EBV-transformed B cell blasts (APD). After 
loading mature DC or APD with the MAGE-A1 peptide, a strong 
positive staining was obtained with fd-Fab-Hyb3 (Fig. 4). In ac-
cordance with our previous results. staining with fd-Fab-G8 was 
also positive on DC but almost two logs lower than fd-Fab-Hyb3 
(Fig. 4A) and not detectable on APD (Fig. 4B). As expected. bind-
ing with control fd-Fab-H2 as well as binding of fd-Fab-Hyb3 to 
DC and APD loaded with a control peptide (derived from the can-
cer-related protein tyrosinase or derived from the 1NF virus. re-
spectively) (Fig. 4). to DC loaded with MAGE-A3 (data not 
shown). or to cells with an irrelevant haplotype (data not shown) 
were all negative. Thus. fd-Fab-Hyb3 reliably visualizes HLA-All 
MAGE-AI complexes on cells, showing its exquisite specificity 
and improved sensitivity over the lower-affinity variant G8. 
Genetic retargeting of human T lymphocytes with affinity-
matured Fab-CD4/y receptors 
To determine whether an increased affinity for the HLA-Al/ 
MAGE-AI complex results in enhanced chimeric Fab-based re-
ceptor-mediated T cell functions. we constructed chimeric recep-
tors comprising either Fab-G8 or Hyb3. Retroviral transduction of 
HS HS Depletionb 
Washes Output (CFU) Positive(%) Output (CFU) Positive(%) Output (CFU) Positive(%) Output (CFU) Positive(%) 
3 he 
Overnight"' 
510 
2 
80 
oc 
140 
2 
a Input for LS library. 1.3 X 1010 CFU: input for HS library, 15 X 1010. 
b Depletion on immunotubes coated with HLA-Al/MAGE-A3 prior to selection. 
c Ten times for 15 min. 
d Three-hour washes plus a last wash overnight. 
e Only two clones tested. 
72 
2 
100< 
12,000 
6.500 
97 
87 
260 
87 
50 
45 
Table IV. Selection results: COMa 
LS Library HS Library 
Fab (nM) Output (103 CFU) Positive(%) Output (103 CFU) Positive(%) 
5000 2 
1000 
200 62 
40 120 
32 
40 
70 
16 
150 
690 
1600 
66 
62 
80 
82 
a Concentration of the Ag: 10 n1Vl (6-h incubation with Ag and competitor). Input: 1 X 10 1 ~ CPU. 
the G8-CD4/-y receptor gene and the Hyb3-CD4/-y receptor gene 
into primary human T lymphocytes resulted in stable expression of 
the receptors on the T cell surface after enrichment using HLA-
Al/MAGE-Al tetramers and anti-PE-coated magnetic beads (Fig. 
5). Enriched G8-CD4/-y+ T lymphocytes and Hyb3-CD4/-y+ T 
lymphocytes were expanded and analyzed for receptor-mediated 
tumor cell killing by incubation with 51Cr-labeled target cells. Fig. 
6A shows that human T lymphocytes. derived from the same donor 
and transduced with the G8-CD4/-y or Hyb3-CD4/-y receptor. were 
capable of lysing native HLA-Al/MAGE-Al + melanoma cells. 
However, at identical E:T cell ratios the Hyb3-CD4/-y+ T lympho-
cytes demonstrated considerably higher cytolytic activity than the 
G8-CD4/-y+ T lymphocytes. The kinetics of Fab receptor-medi-
ated tumor cell lysis were analyzed in cytotox.icity experiments 
with a duration of 1, 2. and 4 h. As shown in Fig. 6B. the Hyb3-
CD4/-y + T lymphocytes demonstrated faster kinetics with respect 
to their capacity to kill both peptide-loaded and MAGE-Al + tu-
A 
1400 + 
+ 
1200 
1000 
5? + + 5 800 
..t + 600 
400 + 
~ 
200 ~ ~ ~ 
LAC sw COM 
B 
350 
300 X 
~ 250 
_,'B 
200 + 
150 + 
100 + + 
50 ..:1:. !! 
+ + ~ 
LAC sw COM 
FIGURE 1. Affinity distribution of the selected clones: LAC. nine 
clones; SW. 15 clones: COM. eight clones. A. Kd ranking. B. k0 rr ranking. 
Measurements were done by surface plasmon resonance using a nitrilotri-
acetic acid chip (BIAcore) coated with 800 resonance units of each Fab via 
nickel. Different concentrations of pMHC complexes were injected at 20 
pJ/min. In both cases. the line shows the value corresponding to parental 
clone G8. The given values are the mean from three experiments. 
mor cells. Furthermore. we investigated the sensiilVIty of G8-
CD4/-y+ and Hyb3-CD4/-y+ T lymphocytes by incubating them 
with target cells that had been pulsed with increasing amounts of 
MAGE-Al peptide. As demonstrated in Fig. 6C. Hyb3-CD4/-y+ T 
lymphocytes required much less peptide to be activated and kill 
target cells than G8-CD4/-y+ lymphocytes. In addition, Hyb3-
CD4/-y+ T lymphocytes produced more TNF-a than G8-CD4/-y+ 
T lymphocytes when incubated with HLA-Al/MAGE-Al + mela-
noma cells (Fig. 7). 
Discussion 
In this study. we investigated whether the Ab fragment GS directed 
against the pMHC complex HLA-Al!MAGE-Al could be affinity 
matured without loss of peptide fine specificity. and whether such 
genetically grafted chimeric receptors with increased affinity for 
HLA-Al/MAGE-Al would accordingly result in enhanced chi-
meric receptor-mediated and immune-specific T cell functions 
such as cytotoxicity and cytokine production. In addition. we in-
vestigated whether such affinity-matured Fab could be used to ef-
ficiently detect pMHC complexes on APCs. 
In the absence of any structural information about this Ab-Ag 
interaction. several libraries were built to generate G8 variants. and 
different selection techniques were compared. The first two ap-
proaches devised to select higher-affinity binders used either low 
A 
RU 
400 
350 
300 
250 
~ 200 
~ 150 
~ 100 
50 
·50 
640 
B 
660 680 
Tlmo 
Clone k0 n (x105M·1s-'~) 
G8 
Lac3 
Lac7 
Com? 
Com6 
1.8 
1.7 
1.7 
2.5 
3.6 
Hyb1 (Lac3/Lac7) 3.2 
Hyb2 (Lac3/Com7) 3.1 
Hyb3 (Lac3/Com6) 3.8 
I 
700 
koff (x10"'1s·1) 
45 
16 
14 
15 
20 
6 
6 
5 
720 740 
K0 (nM) 
250 
83 
85 
60 
55 
19 
20 
14 
FIGURE 2. BIAcore sensorgram (A) and kinetic values (B) of selected 
and hybrid clones. BIAcore measurements were performed as described in 
Fig. 1. The given values are the mean from three experiments. 
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E 1.8 
~ 1.6 
ci 1.4 
0 1.2 
1 
0.8 
0.6 
0.4 
0.2 
0 
T0155 GS Lac7 Hyb3 H2 
IIIMAGE-A1 E A D p T G E s y 
riMAGE·Al E v D p ~ G E L y 
ESIM3A E A D p ~ G E L y 
DM3T E v D p T G E L y 
DM3S E v D p ~ G E s y 
!:liNF C T E L K L s D y 
I!IIINFA CAE L K L s D y 
CJINFT c T E L T L s D y 
!:liNFS c T E L K L s s y 
FIGURE 3. Fine specificity of the affinity-matured clones by phage-
ELISA. p:MHC complexes were refolded using each peptide and coated via 
streptavidin on an ELISA plate. Equal concentrations of phage-Abs were 
incubated for 1 h at room temperature. After extensive washing. bound 
phages were detected with an anti-Ml3 mAb coupled to HRP. mAb TLJI55 
binds only to HLA complexes presenting a peptide and was used to dem-
onstrate a proper conformation of the refolded complexes. H2 is an irrel-
evant phage-Ab (anti-Ras: Ref. 41). 
Ag concentration or long washes. Unfortunately. both of these 
methods yielded poor binders. with some clones even showing 
affinities weaker than that of the parent clone G8. 
A B 
{[Ed-Fot>-GS 
8 Ml 
0 
10° 101 102 10° 104 
G8 
/{E. fd-FDb-H2 
8 Ml 
0 
10° 101 102 103 104 
H2 
FIGURE 4. Staining of externally loaded human DC and EBV-trans-
formed B cell blasts using fd-Fab-G8 and fd-Fab-Hyb3. A. DC were pulsed 
with 20 pM peptides, washed. incubated with phage-Abs, washed again. and 
incubated with anti-M13 Fab followed by anti-Fab coupled to PE. fd-Fab-H2 
is an irrelevant phage-Ab. Thin line. Control peptide tyrosinase: thick line. 
MAGE-AI peptide. B. B-LCL APD was pulsed with 10 pM peptide, washed. 
incubated with phage-Abs. washed again. and incubated with anti-Ml3 Fab 
followed by anti-Fab coupled toPE. fd-Fab-H2 is an irrelevant phage-Ab. Thin 
line. Control peptide INF peptide: thick line, MAGE-AI peptide. 
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FL2-Height 
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FIGURE 5. Cell surface expression of the Fab-CD4/y receptors on 
transduced primary human T lymphocytes. Cell surface expression of the 
Fab-G8-CD4/-y and Fab-Hyb3-CD4/-y receptors on the transduced T lym-
phocytes was analyzed by incubation with MAGE-Al/HLA-Allstrepta-
vidinPE complexes. Results are shown as histograms. Data acquisition was 
restricted to viable cells. 
Why such clones could compete with higher-affinity binders in 
such stringent conditions is unclear, but the phenomenon might be 
explained by a dominant avidity effect of those phage that are most 
tightly bound to the beads. the phage particles that display multiple 
Fabs on their snrface (30). In a third approach. we competed off 
low-affinity binders during the selection with a high concentration 
of soluble Fab directed against the same epitope. Such competition 
would in principle also lower the frequency of avid interactions 
and may therefore also favor selection on the basis of affinity. 
Indeed. in contrast to the previous two methods used, this com-
petitive selection led to binders all having higher affinities than the 
original Fab-G8 clone (see Fig. 1). 
After sampling both libraries using this selection method. the 
best improvements in affinities found were only in the range of 3-
to 5-fold. Sampling of the full repertoire was made difficult by the 
presence in the library of variants with higher affinity but altered 
peptide fine specificity. For this reason the selection was limited to 
one round only and screening of a limited set of clones from this 
repertoire. Instead of further selecting the separate libraries. we 
decided to combine the best-selected H chains with the best-se-
lected L chain. In the best hybrid clone. Hyb3, we obtained an 
improvement in affinity up to 18-fold compared with Fab-G8. sug-
gesting that the effect of the mutations was synergistic. This syn-
ergistic effect is somewhat surprising because mutations selected 
in parallel are usually difficnlt to combine in a single protein (31). 
Strikingly. all selected L chains originated from the same germline 
gene. However. it is difficult to pinpoint the crucial residues in-
volved in binding. because most L chains have several mutations 
that differ from the germline. 
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FIGURE 6. Comparison of cytolytic capacity of G8-CD4/y+ T lym-
phocytes and Hyb3-CD4/-y+ T lymphocytes in 6-h 51Cr release assays. 
Shown are mean percentages of specific 51Cr release of triplicate measure-
ments, with SDs not exceeding 10% of mean values. Data from one rep-
resentative experiment are shown. A. Cytolytic capacity of G8-CD4/y+ and 
Hyb3-CD4/-y+ T lymphocytes toward the HLA-Al +MAGE-A!+ mela-
noma cell line MZ2-MEL3.0. the MAGE-AI Ag lost mutant MZ2-
MEL2.2. and MAGE-AI peptide-pulsed MZ2-MEL2.2 cells (10 pM final 
concentration). B. Kinetics ofFab-based chimeric receptor-mediated tumor 
cell kill. G8-CD4/-y+ and Hyb3-CD4/-y+ T lymphocytes were incubated 
with 51Cr-labeled MAGE-AI peptide-pulsed MZ2-MEL2.2 cells (10 pM 
final concentration) and nonpulsed MZ2-MEL2.2 cells and incubated for 1. 
2. and 4 h. C. Sensitivity of Fab-based chimeric receptor-mediated tumor 
cell kill. G8-CD4/-y+ and Hyb3-CD4/-y+ T lymphocytes were incubated 
with 51Cr-labeled MZ2-MEL2.2 cells pulsed with increasing concentra-
tions of MAGE-AI peptide (0.01-10 pM final concentration). Shown are 
the results at an E:T cell ratio of 30:1. 
Sequences of clones selected from the HS library showed a 
small number of changes compared with GS. whereas the uns-
elected clones showed an average of two to three mutations at the 
amino acid level. scattered all along the 13-residue CDR. These 
results suggest that most of the targeted residues either are in-
volved in Ag binding or are necessary for the CDR structural in-
tegrity. Clones with an improved affinity share the mutation G to 
R at the second residue of the CDR, except one clone presenting 
a V to I mutation at residue 13 of the CDR. Rather than providing 
new direct interactions with the peptide. which would probably 
affect the behavior of the cross-reactivity of the Ab. these muta-
tions likely allow a better fitting of the CDRs around the epitope. 
leading to higher affinity without a major change in cross-reactiv-
50 
45 
40 
35 
:§ 30 
Ol 25 
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tZ: 20 
z 
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15 
10 
FIGURE 7. TNF-a assays using Hyb3-CD4/y + and G8-CD4/-y+ T lym-
phocytes. Transduced human T lymphocytes were cultured for 24 h in the 
presence of tumor cells. After 24 h. levels of TNF-a present in the super-
natant were measured by standard ELISA. Results from one representative 
experiment of three are shown. 
ity. It was indeed postulated that these types of mutations are often 
selected during a natural in vivo affinity maturation process and 
may be responsible for major affinity increases (32). 
As expected. the 18-fold improvement measured by BIAcore 
resulted in a much stronger binding for Hyb3 compared with GS 
(almost two logs). as demonstrated by flow cytometry on exter-
nally loaded DC and EBV-transformed B cell blasts. These assays 
used fd particles. which allow multivalent display (up to five Fabs 
per phage particle) (33). thereby favoring avidity effects. This in-
creased avidity is probably responsible in part for the large in-
crease in cell binding by Hyb3 relative to GS. Staining was shown 
to be specific_ because HLA-Al-positive DC loaded with irrele-
vant peptides did not show positive staining. Staining was also 
negative with a control phage Ab and with DC displaying an ir-
relevant haplotype (data not shown). The affinity-matured Ab Fab-
Hyb3 allows for the first time the direct assessment of the level of 
class I pMHC Ag presentation at the single cell level in the human 
system. This work is similar to that of Krogsgaard eta!_ (34). who 
showed class II pMHC staining. However. the quantity of peptide 
available for binding is thought to be much lower for class I com-
plexes (for review see Ref. 35). making this Lask definitely a more 
challenging one. 
We compared primary human T lymphocytes expressing chi-
meric receptors comprising Fab-GS or Hyb3 fused to the FcERI 
-y-chain signaling molecule, with respect to their tumor cell killing 
capacity. T cells expressing the high-affinity chimeric receptor dis-
played higher lytic activity and faster kinetics of cell lysis. required 
a much lower density of epitope to be activated. and produced 
more TNF-a upon incubation with target cells. These results are in 
full agreement with the work of Derby et a!. (36). who recently 
demonstrated that high-avidity CTL provide better protection 
against viral infection for two reasons. First. they recognize lower 
Ag densities present earlier in the course of infection of each cell. 
Second. they initiate lysis more rapidly and thus more rapidly 
eliminate infected targets. Consequently. they prevent the accu-
mulation of new virus particles much more efficiently than low-
avidity CTL. In a cancer therapy perspective. high-affinity chi-
meric receptor T cells might be very advantageous. Indeed. tumor 
cells often express very low levels of HLA-Al. as is the case for 
the MZ2-MEL 2.2 cell line (data not shown). or low levels of 
MAGE-AI. In this case. only T cells harboring the high-affinity 
receptors will show a strong anti-cancer effect. Another clear ad-
vantage of chimeric receptor approach for cancer therapy is that 
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receptors chimerized to alternative signaling molecules other than 
TCRs bypass TCR-mediated proximal signaling events, which are 
often defective in cancer patients (37). Our results allow a direct com-
parison of the effect of the receptor affinity without any possible in-
terference due to different receptor expression levels or signal trans-
duction efficiency. Our results also show improved sensitivity and 
faster kinetics for cells displaying the high-affinity receptor. The re-
sults obtained by us and Holler et al. (18) are in conflict with the serial 
triggering model, which proposes that high-affinity TCR, with longer 
interaction times between TCR and peptide!MHC, results in de-
creased numbers of TCR interacting with the limiting numbers of 
specific peptide/MHC complexes on target cells. A decrease in the 
number of high-affinity TCR interacting with peptide/MHC com-
plexes, according to this modeL would result in decreased T cell func-
tions such as cytotoxicity and cytokine production. On the contrary, 
our results clearly demonstrate that an increase in affinity of the TCR-
like receptors results in enhanced T cell functions. 
A further demonstration of the utility of high-affinity receptors 
has recently been described by Stanislawski et al. (38). The authors 
were able to circumvent self-tolerance of autologous T lympho-
cytes to universal tumor Ags by transfecting them with genes en-
coding a high-affinity TCR, thereby producing efficient and broad-
spectrum tumor-directed CTLs. 
As shown by these last works and our results, high-affinity TCRs 
are highly desirable. Using phage display. we have recently isolated 
Abs against 5 different HLA-A2-based complexes, most of them dis-
playing affinity in the 10-50 nM range for their particular peptide 
complex (39, 40). This suggests that it is possible to select such mol-
ecules against any pMHC complexes in <3 wk. This efficient selec-
tion of high-affinity, specific pMHC binders, together with the versa-
tility of Abs in terms of protein engineering, should make anti-pMHC 
Fab very attractive tools in a variety of vims-related and cancer ap-
plications, including diagnosis with the Fab or its engineered variants 
directly, or in therapy, as chimeric Fab-based TCRs. 
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T cell retargeting with MHC class I restricted antibodies: 
the CD28 costimulatory domain enhances antigen specific 
cytotoxicity and cytokine production 
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T CElL RETARGETING WITH MHC ClASS I-RESTRICTED ANTIBODIES: THE CD28 
COSTIMULATORY DOMAIN ENHANCES ANTIGEN SPECIFIC CYTOTOXICITY AND CYTOKINE 
PRODUCTION. 
Ralph Willemsen, Cees Ronteltap, Reno Debets and Reinder Bolhuis 
Abstract 
T cells require both primary and co-stimulatory signals for optimal activation. The primary 
antigen-specific signal is delivered by engagement of the T cell receptor. The second antigen-
independent co-stimulatory signal is mediated by engagement of the T cell surface co-
stimulatory molecule CD28 with its target cell ligand 87. However, many tumor cells do not 
express these co-stimulatory molecules. We previously constructed phage display derived F AB• 
G8 and Hyb3, antibodies with identical specificity but distinct affinities for HlA-A1/MAGE-A1, 
i.e. 'TCR-Iike' specificity. These chimeric receptors comprised the Fc(s)RI-y signamng element. 
We analysed whether linking the CD28 costimulation structure to it (y+CD28) could affect the 
levels of MHC-restricted cytolysis and/or cytokine production. Human scFv G8Pos T 
lymphocytes comprising the y+CD28 versus the y signalling element alone produced 
substantially more IL-2, TNF-a. and IFN-y in response to HlA-A1/MAGE-A1Pos melanoma cells. 
Also a drastic increase in cytolytic capacity of scFv G8Pos T cells, equipped with CD28+y 
versus the y-chain alone was observed. 
Introduction 
Tumor associated antigens (TAA) [1] or MHC 
class I presented tumor rejection antigens 
(TRA) [2,3] can be targeted by cytotoxic T 
lymphocytes (CTL) expressing (chimeric) single 
chain (sc) or two chain (tc) mAbs [4-10] or TCR 
[11-16], respectively. Most immuno-therapeutic 
strategies targeting TRA aim to induce and 
enhance the number of tumor-specific T 
lymphocytes in patients by peptide vaccination, 
since such cells can have the capacity to lyse 
(native) tumor cells [17,18], and the transfer of 
such tumor specific T lymphocytes to patients 
can have clinical significance [19-22]. However, 
the isolation of tumor-specific CTL and their 
expansion to significant numbers for clinical 
application, on an individual basis is 
cumbersome and the outcome unpredictable. 
We and others developed strategies to 
permanently graft primary human T 
lymphocytes with MHC-restricted tumor 
specificity via retroviral introduction of e.g. 
chimeric or non-modified TCR a.f3 genes [11-
16] or mAb-based receptors [23,24]. 
Engineered primary human T lymphocytes 
expressing (chimeric) TCRs or two chain 'TCR-
Iike' mAbs, display the antigen specificity 
dictated by the introduced TCR or 'TCR-Iike' 
mAb, i.e., they specifically lyse relevant tumor 
cells and produce cytokines. To become 
independent of the availability of host-derived 
or in vitro stimulated tumor specific CTL 
(clones) as a source of TCR a.f3 genes but still 
target TRA, we generated phage display 
derived human mAbs with MHC-restricted, 
'TCR-Iike' antigen specificities to genetically 
retarget human T cells to their tumors [23,24]. 
TCR as well as 'TCR-Iike' Abs clearly differ 
from classical Abs not only with respect to their 
MHC restriction of antigen recognition, but also 
with regard to ligand binding affinity, which is 
generally at least a log phase higher for 
classical mAb versus 'TCR-Iike' Abs. We took 
advantage of the relative ease to adopt phage 
display libraries to allow for in vitro affinity 
maturation of these peptide/MHC specific 
mAbs. Indeed, affinity maturation of the HLA-
A1/MAGE-A1 specific Fab G8 resulted in a 
hyb3 variant, which displayed an 18 fold higher 
ligand binding affinity [24]. Primary human T 
lymphocytes expressing this affinity matured 
chimeric two chain Fab receptor showed 
enhanced in vitro immune functions, i.e. 
showed significant higher levels of antigen 
triggered production of TNFa., IFN-y and IL-2, 
but also tumor cell lysis [24]. Here we explored 
whether specific immune responses of T cells 
expressing chimeric single chain 'TCR-Iike' 
(scFv) receptors could be further enhanced by 
linking the CD28 costimulatory domain to the y-
chain signalling element in both low and high 
affinity 'TCR-Iike' scFvPos T lymphocytes. To 
this end we used scFv- rather than two chain 
'TCR-Iike' receptor genes because this 
approach allows the introduction of scFv-
versus two chain-TCR-Iike genes with higher 
efficiency. Primary human T lymphocytes with 
CD28+y signalling elements versus y alone 
showed a significantly enhanced specific anti-
tumor response, also at low TRA densities on 
tumor cells, and produce higher levels of the 
cytokines TN F-a., IFN-y and IL-2. 
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Results 
ScFvG8 (!ow affinity) and scFvHyb3 (high 
affinity) comprising either y+CD28 or y 
signalling elements can be functionally 
expressed on primary human T 
lymphocytes. 
Genes encoding the chimeric receptors 
scFvG8-y+CD28, scFvG8-y, scFvHyb3-
y+CD28 and scFvHyb3-y, specific for HLA-
A 1 /MAGE-A 1, were retrovirally introduced into 
OKT3 activated P8L (Figure 1 ). Cell surface 
expression of the chimeric low affinity scFvG8-
y+CD28 and scFvG8-y on the one hand and 
high affinity scFvHyb3-y+CD28 and scFvHyb3-
Y 'TCR-Iike' receptors on the other was 
demonstrated by phycoerythrin-labeled HLA-
A1/MAGE-A1 tetramer staining. Over 45 % of 
enriched T cell transductants specifically 
bound the MAGE-A1/HLA-A1 tetramers 
(Figure 2A). Expression of the endogenous 
CD28 co-receptor on anti-CD3 activated gene-
transduced T lymphocytes was lacking (Figure 
28), as reported for specific antigen activated 
T lyphocytes (25). 
scFvG8-CD4/y 
scFvHyb3-CD4/y 
scFvG8-CD28/y 
scFvHyb3-CD28/y 
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Figure 1: Schematic presentation of the low 
and high affinity scFvG8-y or scFvHyb3-y and 
scFvG8-y+CD28 or Hyb3-y+CD28 constructs. 
VH: Variable heavy domain; 1: linker; VL: 
variable light chain domain; CD4 Tm: CD4 
transmembrane domain amino acids 395 to 
419; CD28: CD28 amino acids 135 to 215; y: 
Fe(~:) Rl-y amino acids 45 to 88. 
ScFvG8-y+CD28Pos T lymphocytes produce 
higher amounts of TNFa, IFN-y and ll-2 in 
response to melanoma target cells than 
scFvG8-yPos T lymphocytes. 
TNFa, IFN-y and IL-2 production by scFvG8-
y+CD28Pos and scFvG8-yPos T lymphocytes 
was measured following 24 hr incubation with 
stimulator cells: a) native HLA-A1P08/MAGE-
A1Pos melanoma cell line MZ2-MEL3.0; b) 
MAGE-A1 peptide loaded melanoma cell line 
MZ2-MEL2.2; and c) HLA-A1P08/MAGE-A1NEG 
MZ2-MEL2.2 melanoma cells. The low affinity-
CD28+yPos T cell transductants showed 
increased and specific cytokine production in 
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response to MAGE-A1Pos melanoma cells in 
comparison with -yP08T lymphocytes. High 
affinity-CD28+l08 T cell transductants also 
showed higher cytokine groduction levels in 
response to MAGE-A 1 P s melanoma cells. 
However, this enhanced cytokine response 
was in part non-specific because MAGE-A 1 NEG 
antigen lost mutant melanoma cells triggered 
IFN-y and TNF-a production, but again this 
cytokine production in response to MAGE-
A 1 Pos melanoma cells was still higher (Figure 
38). Control MAGE-A 1 NEG target cells that 
were loaded with an irrelevant peptide did not 
induce cytokine production by scFvG8-
y+CD28P08, scFvG8-yPos and scFvHyb3-yPos T 
lymphocytes T lymphocytes (data not shown). 
scFvG8-'Y scFvG8-y+CD28 
A 
scFvHyb3--y scFvHyb3-CD28/y 
B 
CD28 + GAMPE 
Figure 2: (A) Low affinity scFvG8-y, scFvG8-
y+CD28 and high affinity scFvHyb3-y, 
scFvHyb3-y+CD28 transduced primary human 
T lymphocytes specifically bind HLA-
A1/MAGE-A1 tetramers. Cells surface 
expression of the scFv-y and scFv-y+CD28 
receptors on transduced T lymphocytes was 
analyzed via HLA-A1/MAGE-A1 tetramers 
(A1/M1; filled histogram). As a control for 
specific binding HLA-A1/Fiu tetramers were 
used, which contain a peptide derived from 
Influenza nucleoprotein A (A1/Fiu; open 
histogram). (B) absence of CD28 expression 
on OKT-3 mAb-activated T lymphocytes. 
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Figure 3: Tumor specific TNFa, IFN-y and IL-2 
production by: (A) low affinity scFvG8-
y+CD28Pos and scFvG8-l05 T lymphocytes, 
and (B) hi§h affinity scFvHyb3-y+CD28Pos and 
scFvG8-l 5 T lymphocytes. Transduced T 
lymphocytes were cultured for 24 h in the 
presence of the following tumor cells (i) A 1 + /M 1-
MZ2-MEL2.2, (ii) A1+/M1+ MZ2-MEL3.0; (iii) 
MZ2-MEL 2.2 + MAGE-A1 peptide (10 1-1g/ml 
final). After 24 h, levels of TN Fa, IFN-y and IL-
2, present in the supernatant were measured 
by standard ELISA. Results from one 
representative experiment out of three are 
shown. 
ScFv"'f+CD28Pos CTL mediate higher levels 
of MAGE-A1Pos melanoma cell lysis than 
scFv"'YPos CTL 
The cytotoxic responses of scFvG8-
y+CD28P05; scFvG8"'YPos; scFvHyb3-
y+CD28P05, and scFvHyb3-l05 T lymphocytes 
were measured following a 4 hour incubation 
with 51 Cr-labeled target cells: a) HLA-
A 1 Pos/MAGE-A 1 Pos MZ2-MEL3.0 melanoma 
cells; b) MAGE-A 1 peptide loaded MZ2-
MEL2.2 melanoma cells; c) HLA-A1P05/MAGE-
A1NEG MZ2-MEL2.2 cells; d) control HLA-A1Pos 
B-LCL APD, and e) control K562 myeloid 
leukemia cells. Significant higher levels of 
specific cytolysis were obtained when HLA-
A1P05/MAGE-A1Pos melanoma cells and 
MAGE-A 1-peptidePos melanoma target cells 
were incubated with low affinity scFvG8-
y+CD28Pos T lymphocytes when compared to 
scFvG8-l05 T lymphocytes (Figure 4A). 
Remarkably, significant higher levels of specific 
target cell lysis by high affinity scFvHyb3-
y+CD28Pos T lymphocytes were observed, not 
only of relevant HLA-A1P05/MAGE-A1Pos 
melanoma cells, but also of irrelevant K562 and 
APD target cells, as well as MAGE-A 1 NEG 
antigen lost mutant melanoma cells (Figure 
48). 
When MAGE-A 1 NEG antigen lost mutant MZ2-
MEL 2.2 melanoma target cells were loaded 
with increasing concentrations of MAGE-A1 
peptide (ranging from 1 nM to 10 1-1M) and used 
as specific target cells, the low affinity scFvG8-
CD28+l05 versus scFvG8-l05 T lymphocytes 
showed a significant increased specific lyic 
capacity. ScFvG8-CD28+l05 versus scFvG8-
l05 T lymphocytes required 1 0 fold less 
MAGE-A1 antigen at the target cell than 
scFvG8"'YPos T lymphocytes for triggering of 
equal levels of Ag-specific cytolytic activity 
(Figure 4C). 
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Figure 4: scfv receptors comprising y+CD28 
mediate a more potent cytolytic T cell 
response. 
(A) Low affinity ScFvG8-y+CD28Pos and 
scFvGS-/08 primary human T lymphocytes 
and (B) high affinity ScFvHyb3-y+CD28Pos and 
scFvHyb3-/08 primary human T lymphocytes 
were incubated for 4 hours, at indicated 
effector to target cell ratio's, with the following 
51 Cr-labeled melanoma target cells: (i) A1+/M1-
MZ2-MEL 2.2; (ii) MZ2-MEL 2.2 + MAGE-A1 
peptide (10 f.LM final); (iii) A1+/M1+ MZ2-
MEL3.0. 
(C) ScFvG8-y+CD28Pos T lymphocytes mediate 
cytol~sis with a higher ~~rsitivity to anti~~~ 
dens1ty. ScFvG8-y+CD28 and scFvG8-y 
primary human T lymphocytes were incubated 
for 4 hours, at indicated effector to target cell 
ratio's, with 51 Cr-labeled MZ2-MEL 2.2 cells 
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loaded with increasing concentrations of 
MAGE-A 1 peptide (M1, ranging from 0,01 to 10 
f.LM final concentration). 
51 Shown are mean percentages of specific Cr 
release of triplicate measurements, with SD,s 
not exceeding 1 0% of mean values. Data from 
one representative experiment (out of three) 
are shown. 
Discussion. 
We have in vitro generated HLA-A1/MAGE-A1 
specific human CTL's by genetically 
programming primary human T lymphocytes 
with low affinity G8 and high affinity Hyb3 
receptors comprising the y chain signalling 
element (23,24) These phage display-derived 
G8 and Hyb3 receptors display a 'TCR-Iike' 
specificity i.e., they recognize MAGE-A1 in the 
context of Class I-HLA-A1 Here we describe 
the immune response enhancing effects of 
genetically linking the CD28 co-stimulation 
structure to the y chain in low and high affinity 
receptors (G8 and Hyb3 mAbs, respectively). 
This was done because first, human tumor 
cells reportedly lack the 87 ligand for CD28 
(26); second, we discovered that virtually all 
human T lymphocytes lack functional 
expression of the critical co-stimulatory CD28 
molecule following T lymphocyte activation in 
vitro by anti-CD3 mAb (OKT3), which is 
required for subsequent gene transduction; 
third, classic scFv mAb-based receptorPos T 
lymphocytes, i.e. with MHC non-restricted 
antigen recognition, comprising y or s + CD28 
signalling structures show significant enhanced 
cytokine production but no enhanced cytolytic 
capacity (27-39). . 
The immune responses of phage display-
derived Ab-receptor08 CTL's with 'TCR-Iike' 
specificity comprising the combined y+CD28 
signalling elements were significantly 
enhanced, not only at the level of cytokine 
production triggered by TRAPos stimulator 
cells, but surprisingly also at the level of TRA 
specific target cell lysis. In contrast, human T 
lymphocyte transductants expressing classic 
scfv mAb-based receptors comprising CD28+s 
or s only showed increased cytokine production 
capacity but no increased lytic capacity 
(32,37,39). The immune responses of these 
low and high affinity receptorPos T cell 
transductants with the y+CD28 signalling 
element, that lack functional expression of 
CD28 themselves, are efficiently reconstituted 
by incorporation of the CD28 co-stimulatory 
element into the y-scfv receptor. Because the 
CD28 co-stimulatory element is now build into 
the y-scfv receptor the frequent lack of the 87 
ligand expression on tumor cells is bypassed. 
T lymphocytes expressing low affinity scFvG8 
comprising the combined y+CD28 signalling 
element display significant enhanced 
production of TN Fa, IFN-:r and IL-2 in response 
to relevant MAGE-A 1 Pos stimulator cells. The 
enhanced cytokine production levels may also 
have relevant consequences in adoptive 
immuno-genetherapy because it has been 
reported that classic MHC non-restricted scFv 
Ab-based receptorPos T cell transductants 
compnsmg y+CD28 or ~+CD28 provided 
animals with increased reduction of tumor 
mass that appeared IFN--y dependent 
(30,31 ,33). The tumor-specific induction of e.g. 
IL-2 production by scFvG8-y+C028Pos T 
lymphocytes may therefore bypass the need for 
exogenous 11-2 in clinical trials to obtain 
enhanced anti-tumor activity as well as 
prolonged life span (21 ,22,40). Reportedly, the 
life span of human CMV reactive CTL and 
adoptively transferred MART1/MelanA or 
gp100 specific T cell clones was indeed 
prolonged by the administration of exogenous 
IL-2 (21 ,40). 
The level of immune responses of low affinity 
scFvG8--y+CD28Pos T lymphocytes was 
~omp~,rable to thP~\ of high affinity scFv Hyb3-y 
alone receptor T lymphocytes and were 
HLA-A1/MAGE-A1 specific. However, when the 
high affinity receptor was engineered to 
comprise the combined y+CD28, we discovered 
that they also were triggered by i.e., non-
specific MAGE-A1NEG cells, to produce 
cytokines and lyse the target cells. For 
examplePos these high affinity scFvHyb3-
y+CD28 T lymphocyte also lysed MAGE-
A 1 NEG melanoma cells, APD B-LCL, and K562 
myeloid leukemia cells, albeit at lower levels 
(Figure 4B). Like TCR's, 'TCR-Iike antibodies 
may display affinities for Class I molecules 
presenting irrelevant peptides (41 ,42). 
However, the rate of dissociation of non-
specific TCRIMHC complexes is sufficiently 
high that dissociation always occurs before the 
non-specific interaction can activate the TCR 
expressing lymphocytes. The difference in 
dissociation constant between Hyb3 and non-
specific HLA-A1 complexes versus Hyb3 and 
HLA-A1 molecules presenting MAGE-A1 may 
be reduced when compared to the dissociation 
constants of the G8 Ab/HLA-A1 complexes. 
The consequently prolonged interaction of the 
Hyb3 receptor with the non-specific HLA-A1 in 
combination with the higher triggerable y+CD28 
signalling structure results in the "non-specific" 
cytolysis and cytokine production. 
The affinity maturation of the 'TCR-Iike' Ab 
scFvG8 allows the generation of a library of 
CTL clones with a range of affinities from low to 
high, based on the use of differential VHVL 
genes and hence mimics the natural 
polymorphic T lymphocyte response. The 
enhancement of the overall immune responses 
by either affinity maturation of the receptor, or 
linkage of distinct signalling elements together, 
or combinations thereof will produce T 
lymphocytes transductants that display distinct 
TRA triggerabilities: e.g. cytokine production 
levels and profiles; target cell lytic capacities; 
tumor mass penetration abilities. However, as 
shown here maximum trigger ability may result 
in loss specificity of the immune response and 
hence unwanted kill of innocent bystander 
cells, thereby triggering autoimmune reactions. 
Therefore, it is mandatory to test these T cell 
transductants for exquisite antigen specificity 
before use in clinical therapy protocols. 
Materials and methods 
Cells and antibodies. 
T lymphocytes derived from healthy donors 
were isolated and expanded as described (42). 
Target cell lines used in this study are: (i) the 
native MAGE-A1P08, HLA-A1Pos melanoma cell 
line MZ2-MEL.3.0; (il' the MAGE-A1NEG HLA-Pos 1 ' A 1 melanoma cell line MZ2-MEL 2.2 (kindly 
provided by T. Boon and P. Coulie, Brussels, 
Belgium (44); (iii) the HLA-A1Pos B-LCL APD, 
and (iv) the erytroid leukemia cell line K562. 
The human embryonic kidney cell line 293T 
(45) (kindly provided by Y. Soneoka, Oxford, 
UK,) and phoenix-amph. (46) (Kindly provided 
by G. Nolan, Boston, USA), were used as 
packaging cell lines for the pBullet scFv-CD4/y 
and scFv-y+CD28 retroviral vectors. Antibodies 
that were used in this study were: anti-CD3 
mAb OKT3 (ortho-diagnostics) and anti-CD28 
(CLB, Amsterdam, The Netherlands). 
Construct synthesis and retroviral gene 
transfer. 
Constructs containing chimeric receptors 
(figure 1) were generated in two steps. First, 
the genes encoding the Fab G8 or Hyb3 heavy 
and light chain fragments [23,24) were 
subjected to PCR to introduce restriction sites 
that allow gene insertion into the pBiue-212 
vector (12). Second, the scFv G8 and scFv 
Hyb3 were introduced into the pBullet retroviral 
vector (12), either 5' to a y+CD28 fragment 
which was derived from the scFv-SP6CD28/y 
construct (29), or 5' to a fragment comprising 
the CD4 transmembrane domain and the 
intracellular domain of Fe (c:) Rl y (23) resulting 
in the low affinity receptor vectors pBullet 
scFvG8-y+CD28 and high affinity receptor 
vectors pBullet scFvG8--y, and pBullet 
scFvHyb3-y+CD28, pBullet scFvHyb3-y, 
respectively. 
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These low and high affinity scFv receptor 
genes were introduced into OKT3 activated 
primary human T lymphocytes by retronectin 
enhanced supernatant transduction, essentially 
as described (23). Chimeric receptor 
expressing T cells were then expanded in 
medium supplemented with recombinant IL-2 
(43). 
Flow cytometry and enrichment of receptor 
expressing T cells 
To assess the expression of low and high 
affinity scFv-y+CD28 and scFv-y receptors on 
gene-transduced primary human T 
lymphocytes, 0,5x1 06 cells were stained for 30 
min at 4°C, with saturating concentrations (11 
nM final) of phycoerythrin (PE) labeled HLA-
A1/MAGE-A1 tetramers, as described (12). The 
dot plots show viable T lymphoblast gated on 
forward (FSC) and sideward (SSC) light scatter 
signals. Analysis was performed on a 
FACSCAN instrument (Becton Dickinson 
Biosciences, San Jose, USA) To enrich for 
chimeric receptor expressing cells, transduced 
lymphocytes were first incubated with PE 
labeled HLA-A1/MAGE-A1 tetramers, followed 
by anti-PE coated magnetic beads. Tetramer-
binding T cells were subsequently obtained by 
magnetic separation using Miltenyi miniMacs 
collums (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufactures 
instructions. Recombinant IL-2 (1 0 IU/ml) was 
present during the entire enrichment 
procedure. 
Cytotoxicity assays. 
Cytolytic activities of low and high affinity scFv-
y+CD28 or scFv-y transduced human T 
lymphocytes were measured in 51 Cr-release 
assays at indicated times, as described 
elsewhere (12). Peptide loading of target cells 
was performed by addition of MAGE-A 1 
nonapeptide (EADPTGHSY, Leiden University 
Medical Center, Leiden, the Netherlands) or an 
irrelevant Influenza peptide derived from 
Influenza virus A nucleoprotein (CTELKLSDY, 
Leiden University Medical Center) to target 
cells 5-15 min prior to incubation with effector T 
lymphocytes. The percentage specific 51 Cr 
release was calculated as follows: ((test counts 
- spontaneous counts)/(maximum counts -
spontaneous counts)) x 100%. 
TN Fa, IFN-y and ll-2 ELISA. 
To quantify secreted TNFa., IFN-y, and IL-2 
transduced human T lymphocytes (6x1 04) were 
cultured for 24 h either in the presence or 
absence of 2x1 04 adherent tumor cells. When 
TNFa. and IFN-y production was assessed, 
culture medium was supplemented with 360 
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IU/ml riL-2, whereas IL-2 production was 
assessed in medium without exogenous IL-2. 
Levels of TNF-a., IFN-y and IL-2 production 
were measured by standard ELISA according 
to the manufacturer's instructions (CLB, 
Amsterdam, the Netherlands). 
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CHAPTER 8 
Summary and general discussion 

SUMMARY AND GENERAL DISCUSSION. 
IMMUNO-THERAPY 
The ultimate goal of cancer immuno-therapy is to 
eliminate malignant cells using the patient's 
immune system. Research has mainly focused on 
the generation of effective antigen specific T cell 
responses because of the general belief that T cell 
immunity is essential in controlling tumor growth 
and protection against viral infections. An 
important milestone in tumor immunology was 
the cloning of the MAGE-l gene [1] and the 
subsequent characterisation of the first T -cell-
defmed antigenic epitope, presented by a MHC 
class I molecule [2]. This discovery led to the 
initiation of vaccination studies with tumor 
antigenic peptides derived from differentiation 
antigens, such as gplOO and MART 1, and cancer 
testis antigens such as MAGE-3. However, 10 
years later, it appeared that results from clinical 
trials have been for the most part disappointing, 
since vaccine protocols designed to elicit potent 
anti-tumor T cell activity have failed to result in 
tumor eradication and enhanced patient survival 
[3-5]. The disappointing results from these 
peptide vaccination trials may in the frrst place be 
explained by an inability to brake "immunologic 
tolerance" against the 'self' -antigens that were 
tarcrets in these studies. Tumors have evolved 
multiple mechanisms for evading the immune 
response, including antigen loss, down regulation 
of MHC and production of immuno-suppressive 
factors. Furthermore, tumors often lack expression 
of co-stimulatory molecules critical for the initial 
activation of naive T cells. Additionally, peptide 
vaccines generally did not stimulate CD4Pos T 
helper cells. Without T helper cells, that recognize 
class II presented epitopes, an effective anti-tumor 
response may not be mounted [6]. Other factors 
that might have contributed to this limited success 
include: the use of adjuvant or not, the use of 
dendritic cells for effective antigen presentation or 
not and intravenous vs. intra-dermal injection of 
antigenic peptides. Last but not least, presentation 
of externally loaded peptides might have induced 
a peptide specific T cell response that does not 
show cross-reactivity with native antigen 
expressing tumor cells [7,8, and also discussed in 
chapter 3]. 
An alternative to vaccination to enhance the 
number of antigen specific T cells in patients is 
adoptive immunotherapy, i.e. the isolation, 
expansion andre-infusion of tumor specific T 
cells from individual patients. Results obtained 
with Tumor Infiltrating Lymphocytes (TIL) and 
cloned tumor specific T cells, isolated from 
individual melanoma patients demonstrated that 
the adoptive transfer of ex vivo activated and 
expanded TIL and cloned T cells may indeed be 
effective in the eradication of tumors [9,10]. 
Although promising, the widespread clinical 
practise of adoptive transfer of autologous tumor 
specific T cells is limited by several factors, such 
as: the difficulty to isolate T cells with the desired 
specificity from individual patients and the 
laborious and time-consuming expansion process. 
Therefore, the genetic progranrrning of T cell 
specificity tlrrough introduction of antibody-based 
or TCR-based receptors into patient's primary 
human T lymphocytes has a lot of appeaL Most 
studies performed so far targeted non-MHC-
restricted tumor associated antigens (TAA) (Table 
3, chapter 1) tlrrough introduction of antibody-
based chimeric receptors into T cells. These target 
antigens are not tumor-specific, but over- or 
aberrantly expressed on tumor cells. Therefore, it 
remains to be determined whether adoptive 
transfer of T AA specific T cells can be safely 
applied in the clinic, i.e. without severe side 
effects as a result of the destruction of TAA-
positive healthy tissue by receptor modified T 
cells. To evaluate the safety of TAA specific T 
cells we recently started a phase I study with 
therapeutic intent of the treatment of metastatic 
renal cell cancer with autologous gene-modified T 
lymphocytes [11]. Renal cell cancer patients will 
be treated with autologous gene-transduced T 
lymphocytes expressing the renal cancer G250 
antigen specific receptor scFvG250-CD4/y. In 
vitro, primary human T lymphocytes retrovirally 
transduced with this scFvG250-CD4/y receptor 
demonstrate high levels of G250 antigen specific 
tumor cell kill and cytokine production [12]. 
As opposed to TAA, tumor rejection antigens 
(TRA) such as the MAGE genes are considered to 
be truly tumor specific as these antigens are not 
expressed in normal cells, except in the testis were 
MHC molecules are lacking. In addition, TRA 
serve as target antigens for the immune system, 
demonstrated by the induction of tumor regression 
in melanoma patients after vaccination with an 
HLA-Al binding MAGE-3 peptide [13]. The 
adoptive transfer of T cells that acquired a 
predefmed TCR-specificity tlrrough transfer of 
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TCR or 'TCR-like' genes may therefore be a safe 
treatment modality for cancer patients. The 
requirements that limit the application of TCR 
gene transfer is that patients must express the 
MHC molecule that presents the antigenic tumor 
peptide. However, already 20-50% of individuals 
express HLA-A20l and with a panel of "off t~e 
shelf' TCR or 'TCR-like' reagents With 
specificities for different MHC restriction 
elements, it should be possible to treat most 
patients. In this thesis, strategies to introduce 
MHC class I restricted, tumor specificity into 
primary human T lymphocytes are described. The 
first part is devoted to the expression ofHLA-Al-
restricted, MAGE-AI specific TCR a~-based 
chimeric receptors in primary human T 
lymphocytes, whereas the second part deals with 
HLA-Al-restricted, MAGE-AI specific "TCR-
like" antibody-based chimeric receptors. 
Chimeric TCR 
In chapter 2 the construction and functional 
expression of chimeric single chain and two-chain 
TCR genes, scTCR/1; and tc-TCR/1;, respectively, 
in primary human T lymphocytes is described. 
These chimeric scTCR and tc-TCR genes provide 
an alternative to non-modified, full-length TCR 
a~ genes to transfer MHC-restricted specificity to 
T lymphocytes. We and others (Greenberg PD., 
Nishimura MI, Falkenburg JH) have described the 
introduction of full-length TCR genes, of human 
origin, into primary human T lymphocytes. 
However, only a limited number of examples of 
successful transfer of full-length TCRa~ genes 
exist [14-17]. In fact, TCR a~ gene transfer may 
not always give rise to T lymphocytes that are 
capable of recognizing and responding to tumor 
cells that present endogenously processed tumor 
antiaen or to virally infected cells [18,19]. This 
inability to respond to relevant target cells might 
result from: a) the formation of heterologous TCR 
dimers consisting of introduced and endogenous 
TCRa~ chains, resulting in a lowered TCR a~ 
expression of the desired specificity [20] or b) 
unstable and low TCRa expression, possibly as a 
result of difficulties in the post-translational 
assembly process of a second TCR or as a result 
of a tightly controlled TCR a expression process 
[21, 22]. The formation of heterologous TCR a~ 
dimers may theoretically result in unknown and 
possibly dangerous (e.g. autoimmune) re~ctivity. 
Although, in a mouse model no autoumnune 
reactivity was observed after the adoptive transfer 
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of mouse TCR a~ transduced T cells [23], 
additional in vivo studies with a variety of TCRa~ 
transduced T cells are required, especially in 
humans. These problems and concerns are 
generally acknowledged by researches in the field 
(Greenberg PD, ref 18, Clay TM, ref 24), and 
chimeric TCRa~ genes are considered to provide 
an alternative. 
To create the chimeric scTCR and tc-TCR genes, 
scTCR VaV~C~ and tc-TCR VaCaN~C~ gene 
fraaments were linked to CD3-i; because 
ex;erimental data had showed that antibody-
mediated cross-linking of proteins expressed at 
the cell surface and linked to CD3-i; induces T 
cell activation [25]. Flow-cytometry analysis 
using TCR a and ~ specific mAbs showed that the 
tc-TCR/1; and scTCR/1; molecules expressed in the 
T cell membrane did not associate with 
endogenous TCR a~ chains, thereby avoiding the 
problems associated with transfer of full-length 
TCRa~ genes [26]. In fact, pairing of introduced 
chimeric TCRa~ with endogenous TCRa~ chains 
was excluded by a strictly coordinated expression 
pattern of the chimeric genes. In addition, 
introduction of chimeric tcTCR VaCat;N~C~i; 
aenes did not result in surface expression of the ~himeric genes. Primary human T lymphocytes 
transduced with chimeric scTCR/1; and tcTCR/1; 
genes demonstrated the exquisite MHC-restricted, 
tumor peptide specificity of the introduced 
receptors. Transduced T lymphocytes specifically 
bound HLA-Al/MAGE-Al tetramers and 
responded to MAGE-AI peptide pulsed 
melanoma cells as well as native antigen positive 
melanoma cells by cytokine production and tumor 
cell kill. Importantly, the gene transduction 
protocol used, in combination with the retroviral 
vector that expresses the chimeric TCR genes, 
allowed direct functional analysis of bulk gene 
transduced T lymphocyte populations. This is in 
contrast to studies that used other retroviral 
vectors and protocols, and that required selection 
or cloning of the TCR expressing T lymphocytes 
[14,15]. Thus, chimeric TCRa~ gene transfer 
provides a basis to endow patients T _lYI?phocytes 
with MHC-restricted, tumor specificity on a 
clinical scale. 
Antigen specificity of chimeric TCR 
In chapter 3 we demonstrated that T lymphocytes 
expressing chimeric scTCR with identical TCR 
Va and V~ domains, but with distinct non-
variable transmembrane and intracellular 
signalling domains, i.e., CD3-s v.s. CD4 Tm and 
Fc(s) RI-y, differentially respond to MAGE-AI 
peptide loaded target cells. Although both 
scTCRPos T lymphocytes specifically recognised 
and responded to tumor target cells that present 
MAGE-AI peptides in the context of HLA-Al 
molecules that were loaded intracellular, only 
scTCR/sPos T lymphocytes specifically responded 
to HLA-Al Pos target cells that presented 
externally loaded MAGE-AI peptides (Figure 1, 
chapter 3). The non-responsiveness of scTCRiy0 s 
T lymphocytes could not be explained by low 
levels of antigenic peptide present on target cells, 
or by the use of a synthetic peptide that was 
unable to stimulate scTCR/y0 s T lymphocytes. 
Indeed, scTCR/y0 s T lymphocytes did not 
respond to peptide loaded target cells at any of the 
peptide concentrations tested (range 0,01 to 100 
1-lg/rnl). More importantly, the peptide that was 
used for extracellular loading of HLA-Al 
molecules on target cells was also introduced 
intracellular by transfection and resulted in a 
peptide specific immune response by scTCR/y0 s 
T lymphocytes. The same synthetic peptide was 
also used for the generation of HLA-Al/MAGE-
Al tetramers, which specifically bound both 
scTCR/sPos and scTCR/y0 s T lymphocytes. We 
concluded that: (1) the difference in reactivity of 
the two scTCR must be due to differences in 
signalling elements and therefore differences in 
intracellular signalling events. Therefore (sc)TCR 
specificity is not solely dictated by the TCR 
VaVf3 chains (2) complexes between HLA-Al 
and MAGE-AI peptide formed by intracellular 
processing are antigenically distinct from HLA-
Al/MAGE-Al complexes formed by extracellular 
peptide loading, and 3) tetramers and membrane 
bound MHC complexes formed by intracellular 
binding of MAGE-AI to HL~-Al are 
conformationally identical. In extensiOn, these 
fmdings allows us to conclude that in vitro as well 
as in vivo peptide loading, used for the induction 
of peptide/MHC specific T-cells, yields peptide 
specific CTLs that may not always recognize 
TRA positive tumor cells. Therefore, vaccination 
strategies that facilitate intracellular peptide 
loading of MHC class I molecules are more likely 
to result in the generation of antigen-specific T-
cells that are capable of recognising and 
eliminating antigen positive tumor cells. Identical 
results were obtained by our collaborator Dr. 
Pierre van der Bruggen, for a CTL clone obtained 
from a melanoma patients. These T cells only 
responded to MAGE-A3 positive tumor cells and 
not to MAGE-A3 peptide loaded target cells 
(personal communication) 
CD4+ T lymphocytes 
The in vitro anti-tumor efficacy of antigen 
specific T -cells and the in vivo efficacy of 
adoptively transferred tumor and virus specific T 
lymphocytes has been studied primarily for CDS+ 
T lymphocytes. CDS+ T lymphocytes were 
considered to be the prime mediators of T -cell 
anti-tumor activity, at least because CDS+ cells are 
able to kill tumor cells or virally infected cells 
directly. The role of CD4+ T lymphocytes in 
tumor eradication has been thought to be indirect, 
primarily through provision of T -cell help. CD4+ 
T lymphocytes are nowadays considered to play 
an important role in the initiation and persistence 
of an immune response against cancer and viral 
infections. 
The induction of anti-tumor responses against 
MHC class II negative tumors and the induction 
of anti-viral T-cell responses in CD4NEG mice 
were shown to be ineffective or at least severely 
hampered [27,2S]. Furthermore, the persistence of 
adoptively transferred CMV-reactive CDS+ T 
lymphocytes in patients that suffered from CMV 
reactivation, and the persistence of LCMV virus 
specific CDS+ T lymphocytes in mice, was shown 
to depend on the presence of CD4+ T lymphocytes 
or alternatively the addition of exogenous IL-2 
[29,30]. 
Of special interest is the central role for CD4+ T 
lymphocytes in the initiation of protective 
immunity against cancer. This was elegantly 
demonstrated in experiments using tumor reactive 
CD4+ T lymphocytes that recognised a MHC class 
II presented tumor epitope. The adoptive transfer 
of these tumor specific CD4+ T lymphocytes 
induced de novo generation of tumor reactive 
CDS+ T lymphocytes [31]. These studies provided 
us with the arguments to include TCR transduced 
CD4+ T lymphocytes in our studies. We anticipate 
that the introduction of MHC class I restricted 
specificity in CD4+ T lymphocytes circumvents 
the lack of expression of MHC class II molecules 
on tumor cells. Since optimal T -cell activation 
requires that CDS co-receptors and TCR on T 
cells bind to the same peptide/MHC molecule 
[32,33], we transduced CD4+ primary human T 
lymphocytes with both chimeric tc-TCR/s genes 
and the CD Sa gene (chapter 4). CD4+ primary 
human T lymphocytes expressing the HLA-
Al/MAGE-Al specific chimeric tc-TCR/s genes 
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only bond to HLA-Al/MAGE-Al tetramers and 
responded to HLA-Al/MAGE-Al + melanoma 
cells when these cells co-expressed the introduced 
CD8a gene. The simultaneous expression of 
tcTCR/L; genes and CD8a in primary human T 
lymphocytes resulted not only in antigen specific 
production of cyokines such as IFN-y, TNF-a and 
IL-2, but also converted these CD4+ T 
lymphocytes into cells that were able to lyse 
HLA-Al/MAGE-Al + melanoma cells. Thus, TCR 
gene transfer to CD4+ primary human T 
lymphocytes may provide not only critical helper 
cells, but also potent tumor specific effector cells 
for use in adoptive immunotherapy. 
Antibodies with MHC-restricted specificity 
MHC class !-restricted specificity may also be 
introduced into primary human T lymphocytes by 
the transfer of 'TCR-like' antibody-based 
receptors. These antibodies with 'TCR-like'-
specificity were generated by our collaborators 
Dr. Hermie Hoogenboom and Dr. Patrick Chames 
through selection of a large non-immune phage 
display Fab library on in vitro generated HLA-
Al/MAGE-Al molecules [34]. These phage 
display-derived antibody fragments with MHC-
restricted specificity may provide valuable tools 
not only to transfer T -cell specificity, but also as a 
diagnostic tool to identify tumor antigen 
presentation on tumor biopsies. A large number of 
Fab fragments have already been isolated, with 
distinct peptide/MHC specificities and with 
relative ease [34-37]. Importantly, the ease of 
isolation of Fab fragments with MHC restricted 
specificity allows us to become completely 
independent of available T-cell clones, required 
for the isolation of TCR a~ genes. These Fab 
molecules are thus likely to become a valuable 
source for 'off the shelf' reagents for transfer of 
T -cell specificity. 
Chapter 5 describes the construction and 
functional expression of a chimeric Fab receptor on 
primary human T lymphocytes. The Fab-based 
receptor was derived from the FabG8 fragment, 
having specificity for HLA-Al/MAGE-Al [38]. 
Heavy and light chain gene fragments from the Fab 
G8 were each linked to the transmembrane 
domain of CD4 and intracellular domain of the 
F c( E )RJ-y chain, inserted into the retroviral vector 
pBullet, and transduced into activated primary 
human T lymphocytes. TheFabG8-CD4/y receptor 
was functionally expressed on primary human T 
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lymphocytes as demonstrated by the specific 
binding to HLA-Al/MAGE-Al tetramers and 
responsiveness to HLA-Al/MAGE-Al+ tumor 
cells. Primary human T lymphocytes transduced 
with the chimeric F abG8-CD4/y receptor genes 
specifically responded to HLA-Al/MAGE-Al+ 
tumor cells by cytokine production and tumor cell 
kill. These results demonstrated that antibodies 
with MHC-restricted tumor-specificity can serve 
as an alternative to TCRa~ chains for the genetic 
programming ofT -cell specificity 
Affinity matured receptors. 
A combination of L chain shuffling, H chain-
targeted mutagenesis, and in vitro selection of 
phage display libraries yielded a F ab G8 
derivative, termed Hyb3, with an 18-fold 
improved ligand binding affmity yet identical 
peptide fmc-specificity (chapter 6) [39]. 
Chimeric receptors based on these low and high 
affmity Fabs were functionally expressed on 
primary human T lymphocytes and compared for 
their efficacies to mediate antigen-specific 
rmmune responses. Primary human T 
lymphocytes expressing the high-affmity 
F ABHyb3-CD4/y receptor displayed higher lytic 
activities and faster kinetics of cell lysis, required 
a much lower density of the antigenic epitope to 
become activated, and produced more TNF-a 
upon incubation with relevant target cells. These 
data are of interest because high-avidity CTL 
were shown to provide better protection against 
viral infection due to their ability to recognise 
lower antigen densities present earlier in the 
course of infection of each cell, and to initiate 
target cell lysis more rapidly, thereby elinrinating 
more infected cells [40]. Fore these reasons, 
chimeric high-affinity receptors might be 
advantageous in cancer therapy. Tumor cells 
expressing low levels of antigen and/or MHC 
molecules might be recognized and eliminated 
more efficiently by high-affinity receptor 
expressing T lymphocytes relative to low affinity 
receptor expressing T lymphocytes. 
Receptors providing co-stimulatory activity 
The absence of co-stimulatory molecules, such as 
CD80 and CD86, on many tumor cells creates an 
unfavourable condition for the survival and 
activation of tumor-reactive T lymphocytes [41]. 
The engagement of the TCR on naive T -cells with 
MHC-restricted antigens is necessary to activate 
T -cells, but is insufficient to achieve full 
activation. Co-stimulation through the T-cell 
surface receptor CD28, which interacts with 
CD80 and CD86 on tumor cells induces signals 
that result in expansion of activated T -cells, and 
prevents apoptosis of these activated T -cells. 
Primary human T lymphocytes are prone to cell 
death when depleted of IL-2 or in the presence of 
tumor cells that lack co-stimulatory molecules 
[42,43]. In an attempt to overcome chimeric 
receptor-induced cell-death upon encounter of 
CD80 and CD86 negative tumor cells, CD28 co-
signalling capacity was linked directly to the 
antigen binding moiety of classic T AA specific 
chimeric antibody receptors [ 44 and reviewed in 
45]. These chimeric antibody-based receptors that 
comprised a tumor antigen specific scFv, together 
with CD28 and CD3-s or Fc(c) Rl-y signalling 
domains (e.g. tripartite receptors) were 
functionally expressed on primary (human) T 
lymphocytes, i.e. the expression resulted in 
enhanced cytokine production and proliferation 
upon incubation with antigen positive tumor cells. 
Of special interest is the boost in IL-2 production 
by these receptor engrafted T -cells, because 
persistence of adoptively transferred tumor-
specific T lymphocytes in cancer patients required 
administration of exogenous Il-2. In fact, CD28 
co-stimulation was shown to be required for 
efficient IL-2 production [46]. Although 
production of other cytokines tested, such as TNF-
a and IFN-y was not depended on CD28 co-
stimulation, their production was dramatically 
increased when T -cells expressed receptors that 
included the CD28 co-signalling domain. The 
superior activity of T lymphocytes expressing 
chimeric tripartite receptors was obvious in 
animal tumor models [47]. Although T 
lymphocytes expressing chimeric 'tripartite' 
receptors or receptors that lack the CD28 co-
stimulatory domain displayed equal cytolytic 
activity in vitro, T lymphocytes that express the 
tripartite receptor had a greater capacity to inhibit 
growth of established tumors and metastases. 
Importantly, the enhanced anti-tumor activity ofT 
lymphocytes expressing receptors with co-
signalling capacity was dependent on the 
production ofiFN-y. 
These results illustrate the advantages of 
engineering chimeric antibody-based receptors 
that include CD28 co-signalling capacity. 
However, these tripartite receptors were all 
directed against non-MHC restricted tumor 
antigens, T AA. The effect of CD28 co-signalling 
on TCR grafted T cells was not known. Therefore 
we determined whether or not the inclusion of a 
CD28 co-signalling domain into chimeric TCR or 
'TCR-like' receptors might enhance the anti-
tumor activity of primary human T lymphocytes. 
In chapter 7 experiments are described using low 
affinity scFv G8-based chimeric receptors as well 
as high affinity Hyb3 based receptors that were 
coupled to the Fc(c)RI-y signalling element alone, 
or in combination with the CD28 signalling 
element, low affmity scFvG8-y and scFvG8-
y+CD28 and scFvHyb3-y and scFvHyb3-y+CD28, 
respectively. In parallel to classical antibody-
based receptors that recognize non-MHC 
restricted antigens, low affinity 'TCR-
like'recepto?0s T lymphocytes with CD28 co-
signalling capacity produce more cytokines, such 
as IL-2, TNF-a and IFN-y, than T lymphocytes 
that express the low affmity receptor with y alone. 
However, in contrast to expression of classical 
antibody-based receptors, expression of the 
scFvG8-CD28/y receptor resulted in a dramatic 
increase in cytolytic capacity of the transduced T 
lymphocytes. High affmity recepto?0s T 
lymphocytes that comprised CD28 co-signalling 
capacity demonstrated to our surprise "non-
specific" immune responses when incubated with 
irrelevant MAGE-AI NEG Target cells. Due to the 
enhanced dissociation constant of the high affmity 
Hyb 3 receptor and the combined CD28 and y 
signalling elements, interactions of the scFvHyb-
y+CD28Pos T lymphocytes with non-specific 
HLA-Al/peptide complexes may result in 
intracellular signalling events before dissociation 
occurs. 
Perspectives of genetic T -cell retargeting . 
With the technology and the scientific advances 
made today, combined with the cytokines and 
drugs available, it is now possible to treat cancer 
patients with active immune cells. Inunune cells 
from the T, NK, or any other myeloid-lymphoid 
lineage can be engineered with any immune 
specificity for which antibodies or TCR have been 
identified, MHC restricted or not. New 
technologies such as the production of soluble 
peptide/MHC complexes now allow selection of 
TCR and TCR-like antibodies that could not be 
obtained before. Chimeric receptors can be 
generated for both MHC restricted as well as non-
MHC restricted antigens, which does not restrict 
treatment to tumors for which MHC presented 
antigens have been identified or that have down 
modulated these complexes. 
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Grafting primary human T -cells with chimeric 
receptors is rather technology oriented than disease 
oriented, and therefore may be instrumental for the 
clinical control not only of cancer but also for the 
elimination of viral infections, autoimmune disease 
and Graft-versus-host disease. The chimeric 
antibody-based receptor approach has demonstrated 
its in vivo efficacy in mouse tumor models and no 
adverse events have been reported so far in the 
clinical trails. Adoptive transfer of human T -cells 
genetically engineered to express human 
immunodeficiency virus (HIV)-specific chimeric 
CD4-i;; receptors to patients was shown to be safe 
[4S]. 
In spite of these promising results, several questions 
remain to be addressed to increase both the efficacy 
and safety of genetically retargeted T -cells for 
adoptive immunotherapy: 
A: Will chimeric Ab-based receptors expressed on 
T-cells induce an immune response? Fundamental 
to this question is the origin of the immunoglobulin 
heavy and light chain domains that were used to 
clone the scFv fragment; mouse or human. 
Immunoglobulins of mouse origin may indeed 
induce a human anti-mouse antibody (HAMA) 
response as observed in clinical trials with hi-
specific antibodies [ 49]. However, it is unlikely that 
the low amount of mouse immunoglobulin that is 
exposed to the immune system on receptor 
engrafted T -cells will result in a HAMA response. 
In contrast to an antibody mediated response, the 
possibility that peptides derived from the chimeric 
construct, antibody-based as well as TCR-based, 
will be presented by MHC molecules on the 
transduced T -cells, thereby eliciting an effective 
anti-receptor T -cell response may not be excluded. 
B: Do ex vivo gene transduced T lymphocytes home 
to the tumor site? Published data obtained in 
clinical studies with receptor modified T 
lymphocytes are restricted to a single study [50]. In 
this study "prolonged survival and tissue trafficking 
following adoptive transfer of CD4zeta gene-
modified autologous CD4+ and CDS+ T -cells in 
human immunodeficiency virus-infected subjects" 
was obtained. Adoptive transfer of ex vivo selected 
and expanded tumor specific T -cell clones or TIL 
for the treatment of patients with metastatic 
melanoma has demonstrated in vivo persistence, 
migration and antitumor effects [9,10]. Applying 
the same culturing conditions for the expansion of 
genetically engineered T lymphocytes cultured may 
yield T lymphocytes with identical homing 
capacities. Finally, also data obtained with 
syngeneic mouse tumor models demonstrated that 
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the adoptive transfer of chimeric scFv receptor 
transduced mouse splenocytes can result in the 
rejection of established tumors and metastases, 
indicating efficient homing to the tumor sites [ 4 7]. 
C: Do chimeric receptor grafted T-cells persist in 
patient, and/or do they require administration of 
exogenous IL-2 or may receptor grafted CD4+ T-
cells provide this T-he/per JUnction? As indicated 
before CD4+ T lymphocytes play a central role in 
the initiation and persistence of an, immune 
response. It may therefore be expected that 
receptor engrafted CD4+ T lymphocytes support 
the persistence and function of CDS+ T 
lymphocytes that are equipped with chimeric 
receptors. CD4+ T lymphocytes genetically 
engineered to express TCR or 'TCR-like' 
receptors may even facilitate the de novo 
generation of tumor specific CDS+ T -cells as has 
been described for CD4+ T lymphocytes with 
specificity for MHC class II presented tumor 
epitopes [31]. In addition, CD4+ T lymphocytes 
may induce T-cell memory [51]. These 
speculations on the in vivo function of receptor 
transduced CD4+ T lymphocytes are supported by 
data obtained both in clinical trials, as well as in 
animal models, were CD4+ T lymphocytes turned 
out to be essential for the initiation and 
persistence of tumor and virus specific T -cell 
immunity [29-31]. 
Other factors that may contribute to the homing 
capacity and persistence of genetically retargeted 
T lymphocytes are: expansion of gene-transduced 
T -cells in IL-15 containing medium together with 
cells that express the relevant antigen and co-
stimulatory molecules [43], inclusion of co-
stimulatory domains in chimeric receptors to 
bypass the absence of co-stimulatory molecules 
on tumor cells, and the inclusion of an 
inflammatory stimulus (CD40 activation) during 
the treatment with adoptively transferred T -cells 
[52]. 
Expansion of receptor transduced T lymphocytes 
with OKT3 and high dose IL-2 was shown to 
yield highly cytolytic T -cells in vitro, but resulted 
in rapid cell elimination and poor anti-tumor 
activity in vivo In contrast, expansion of 
transduced T -cells in the presence of antigen, 
costimulation and IL-15 resulted in more than 
1000 fold expansion and these T -cells were 
capable to travel to tumor sites without 
prematurely succumbing to apoptosis [43]. 
Inclusion of the costimulatory CD2S domain in 
chimeric receptors results in an enhanced 
proliferative capacity upon incubation with tumor 
cells, whereas T -cells that express receptors 
lacking the CD28 domain were unable to 
proliferate after antigen encounter [46]. 
In the murine listeria model antigen specific T-
cells were only able to provide protection against 
infection by the bacterium for the first days after 
infusion of the T-cells. Although the transferred 
CD8+ T -cells were still present a week after 
infusion, they were deleted in response to 
infection. The administration of anti-CD40 
monoclonal antibodies, before CTL infusion, and 
at the time of infection, a week later, restored the 
ability of the infused CTLs to control infection 
[52]. However, it should be noted that CD40 
stimulation could actually lead to the deletion of 
tumor-specific CTL in certain circumstances [53]. 
D:Are TAA on tumor cells bona fide targets for 
adoptively transferred chimeric receptor 
transduced T lymphocytes? To answer this 
question one should realise that cytotoxic T 
lymphocytes are very potent killer cells that may 
in fact eliminate complete organs. TAA that are 
merely over-expressed on tumor cells, and that are 
also present on healthy tissue in essential organs 
may indeed be a target for genetically retargeted 
TAA specific T lymphocytes. Although clinical 
studies with hi-specific antibodies proved to be 
safe, the proliferative capacity of T -cells 
permanently engrafted with T AA specificity may 
result in uncontrolled expansion and damage of 
healthy tissue. Carefully controlled clinical trials 
with receptor engrafted T-cells that target TAA on 
tumor cells are therefore required to evaluate these 
risks. The ability to eliminated the receptor 
engrafted T lymphocytes at will through 
introduction of suicide genes may reduce or even 
eliminate these any risks. Alternatively, TRA such 
as the MAGE genes, which may be considered 
truly tumor specific are more suitable to retarget 
T -cells to cancer tissues. 
Introduction of non-modified "full-length" TCR 
genes into primary human T lymphocytes also 
raises questions that have to be addressed before 
this technology can be safely and successfully 
applied in the clinic: 
E: Can we avoid the association of introduced non-
modified TCR, chains with endogenous TCR chains, 
thereby avoiding the risk of introducing new 
specificities and possibly autoimmune responses. 
Several possibilities are at hand to modify the TCR 
a. and 13 chain in such a way that it induces specific 
heterodimerisation upon simultaneous expression in 
T -cells. One could imagine the introduction of 
additional cysteine residues in both TCR chains or 
even the inclusion of specific dimerisation domains. 
However, all modifications of the complete TCRa. 
and 13 chain will have an effect on the expression 
and stability of these TCR chains and possibly have 
a negative effect on the T -cell mediated immune 
functions. 
The problem might also be dealt with in another 
way: as described for antibody-based receptors that 
target TAA on tumor cells, the inclusion of a 
suicide gene into the receptor modified T -cells will 
allow us to eliminate the adoptively transferred T-
cells upon any sign of auto-reactivity. This 
approach allows us to use non-modified TCR a.l3 
genes for the transfer ofT -cell specificity, which in 
our hands displayed superior activity, when 
compared to chimeric scTCR or tcTCR transduced 
T lymphocytes. Therefore, non-modified full-length 
TCR a.l3 genes are the most obvious choice to be 
used in the clinic for the adoptive transfer of 
genetically retargeted T -cells, unless modifications 
of the chimeric receptors improve the T -cell 
mediated functions up to the level of full-length 
TCR 
A low efficiency of retroviral transduction was 
considered to be a limitation for the successful 
transfer of two transgenes, i.e. TCR a. and 13 genes, 
into primary human T lymphocytes at a clinical 
scale. However, simultaneous highly efficient 
transfer of both TCR a. and 13 genes can be achieved 
using an optimized retroviral production and 
transduction protocol [39,54]. In fact, this procedure 
resulted in the expression of functional TCRa.l3 in 
up 60% of the transduced primary human T 
lymphocytes. Therefore, the requirements to 
transduce TCR or TCR-like receptors on a clinical 
scale are met by this transduction procedure. 
Future prospects ofT -cell specificity transfer 
The chimeric TCR approach offers advantages over 
the transfer of full-length TCR to patients T 
lymphocytes. The possible introduction of new 
unwanted specificities into patients lymphocytes 
can be avoided by the chimeric TCR approach. 
Furthermore, data obtained with TCR-like 
antibodies demonstrate that immune functions of 
receptor grafted T -cells can be improved by 
optimization of the receptors ligand binding affinity. 
The demonstration that high-avidity CTL provide 
better protection against viral infections [40] makes 
us believe that high-affinity chimeric receptors 
might be advantageous for adoptive immune 
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therapy of cancer. Firstly, because tumor cells often 
express low levels of MHC class I molecules or 
tumor antigen. Secondly, because chimeric receptor 
mediated signalling bypasses TCR-mediated 
proximal signalling events, which might be 
defective in cancer patients [55]. In addition to the 
optimization of receptor binding affinity inclusion 
of co-receptor and/or co-stimulatory functions into 
one chimeric receptor also improves the function of 
genetically retargeted T -cells. This approach is 
currently being pursued for TCR-based receptors, 
which might eventually result in an 'optimal' TCR 
format. However, there may be limits to this 
approach as demonstrated for receptors that 
comprise both the high affinity 'TCR-like' antibody 
and the CD28 co-signalling domain (chapter 7). 
Finally, genes encoding 'TCR-like' antibodies 
provide an alternative to TCR a~ genes, which may 
not be available due to the poor growth 
characteristics of many CTL clones 
The effectivity of adoptively transferred T -cells 
may be improved in several ways: 1) by the 
protocol used to expand the transduced T 
lymphocytes [43], 2) by introduction of genes 
encoding secreted pro-apoptotic or anti-angiogenic 
molecules into the T-cells, 3) by co-administration 
of e.g. anti-CD40 monoclonal antibodies [52], 4), or 
by pre-conditioning of the cancer patients by 
myeloablative therapy [9] . In addition, primary 
human T lymphocytes may be retargeted to more 
than one tumor rejection antigen or more than one 
MHC molecule. Indeed the adoptive transfer of 
tumor-reactive T -cells with only one specificity was 
shown to be ineffective as a result of the down-
regulation of MART-I expression in melanoma 
cells [9]. The infusion of T -cells with a variety of 
MHC-restricted, tumor-specificities might therefore 
be more effective. Furthermore, next to targeting 
MHC-restricted tumor antigens, targeting of the 
tumor endothelium through e.g. expression of a 
chimeric receptor comprising vascular endothelial 
growth factor, might also contribute to the 
eradication of tumors [57]. Taken together, the 
improvements made in chimeric receptor design 
and retroviral transfer technology calls for the 
initiation of clinical trials for the treatment of 
patients suffering from cancer or life-threatening 
viral infections 
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Samenvatting 

SAMENVATTING 
Het doel van immuno-therapie bij kanker is het 
elimineren van kwaadaardige cellen door 
gebruik te maken van het immuun systeem van 
de patient. Studies richten zich daarom veelal 
op de mogelijkheid om een effectieve tumors 
specifieke T-cel respons te genereren 
aangezien algemeen word aangenomen dat T 
cellen verantwoordelijk zijn voor zowel de 
controle als eliminatie van tumor cellen en 
viraal geTnfecteerde cellen. Een belangrijke 
mijlpaal voor de tumorimmunologie was de 
ontdekking van het kanker testis antigen 
MAGE-1 en de karakterisering van een MAGE-
1 peptide dat door MHC klasse I moleculen op 
de tumor eel membraan aan T cellen word 
gepresenteerd. Deze ontdekking, alsmede de 
identificatie van een groot aantal MHC-
gepresenteerde tumor antigeen peptiden leidde 
tot de initiatie van klinische peptide vaccinatie 
studies. Nu 10 jaar later moeten we echter 
constateren dat deze klinische studies niet het 
gewenste resultaat hebben opgeleverd. 
Alhoewel in deze studies een verhoging van 
het aantal tumor peptiden specifieke T cellen 
werd gevonden, werd er geen vermindering 
van het aantal tumoren en dus geen verhoogde 
overleving van patienten bereikt. Deze 
teleurstellende resultaten zijn mogelijk het 
gevolg van een onvermogen om de 
zogenaamde 'immunologische tolerantie' voor 
lichaamseigen antigenen te breken. Tumoren 
hebben diverse mechanismen ontwikkeld om 
een immunologische aanval te weerstaan. Zo 
kan de antigeen- en/of MHC expressie zijn 
verlaagd, alsmede de expressie van diverse 
co-stimulatoire moleculen. Een andere reden 
voor dit teleurstellende resultaat is de 
afwezigheid van peptiden in deze vaccins die 
CD4P0 T helper cellen activeren. Zander deze 
CD4Pos T helper cellen kan er geen effectieve 
immuun response worden gegenereerd. 
Een alternatief voor de verhoging van het 
aantal tumor specifieke T cell en door 
peptide vaccinatie kan adoptieve 
immunotherapie zijn. Hierbij worden tumor 
antigeen specifieke T cellen uit de patient 
geTsoleerd of in vitro gegenereerd, vervolgens 
tot klinisch relevante hoeveelheden opgegroeid 
en tenslotte in de patient met kanker 
ingespoten. Deze vorm van therapie heeft in 
een aantal gevallen geleid tot vermindering van 
het aantal tumoren en verlengde overleving 
van de patienten. Echter, de isolatie en 
expansie van deze tumor specifieke T cellen is 
niet in aile gevallen succesvol gebleken en is 
daarom niet op grote schaal te gebruiken. Een 
alternatieve methode is door ons en andere 
laboratoria ontwikkelt die het mogelijk maakt 
om grote hoeveelheden tumor specifieke cellen 
in handen te krijgen. De T cellen van patienten 
kunnen van een nieuwe specificiteit worden 
voorzien n.l.: tumor specificiteit, door 
introductie van genen die coderen voor tumor 
specifieke receptoren. Deze receptoren kunnen 
worden onderverdeeld in twee groepen: zij die 
zogenaamde tumor geassocieerde antigenen 
(TAA) herkennen, de antilichamen, en zij die 
zogenaamde MHC gepresenteerde tumor 
rejectie antigenen (TRA) herkenen, T eel 
receptoren (TCR) en op TCR gelijkende 
antilichamen. Een overzicht van de 
ontwikkeling van deze receptoren wordt 
weergegeven in hoofdstuk 1. 
De T AA die door antilichamen worden herkend 
zijn niet tumor specifiek. De expressie van 
deze T AA is verhoogd op tumor cellen ten 
opzichte van gezond weefsel en kan daarom 
leiden tot destructie van gezond weefsel. De 
veiligheid van de behandeling van kanker 
patienten met T AA specifieke T cellen wordt 
momenteel in een fase 1 klinische trial door 
ons laboratorium getest. T lymfocyten uit 
patienten met nier kanker worden hiertoe 
voorzien van een nierkanker antigeen (G250) 
specifieke receptor, de enkelketen receptor 
scFvG250-CD4/y. Wanneer deze receptor in 
primaire humane lymfocyten wordt 
geTntroduceerd krijgen de cellen een nieuwe 
specificiteit n.l. G250 antigeen specifiek, en zijn 
vervolgens in staat om G250 antigeen positieve 
cellen te doden. 
In tegenstelling tot TAA worden TRA zoals het 
MAGE antigeen wei als tumor specifiek 
beschouwt omdat deze antigenen niet in 
normaal weefsel voorkomen, met uitzondering 
van de testis. Op het testis weefsel zijn echter 
geen MHC moleculen aanwezig zijn die MAGE 
peptiden aan T cellen presenteren. 
Vanwege deze specificiteit is het gebruik van 
TRA specifieke T cellen voor de behandeling 
van kanker patienten waarschijnlijk veiliger 
dan het gebruik van TAA specifieke T cellen. 
Doordat de reagentia voor het introduceren van 
TRA specificiteit voorhanden zijn kunnen bijna 
aile patienten met deze TRA specifieke T 
cellen behandeld worden. 
Het doel van het onderzoek zoals hier 
beschreven was het genereren van TRA 
specifieke T cellen door constructie en 
retrovirale introductie van chimere- T eel 
receptoren en op T eel receptor gelijkende 
antilichaam receptoren. 
In hoofdstuk 2 word de constructie en 
functionele expressie van chimere enkelketen 
en dubbelketen TCR genen beschreven: 
scTCR/1;: en tc-TCR/1;:. Deze chimere ketens 
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werden gegenereerd omdat het gebruik van 
niet gemodificeerde TCR af3 ketens niet zonder 
problemen is. Alhoewel wij en anderen met 
succes deze niet gemodificeerde ketens in 
primaire T lymfocyten hebben ge"introduceerd, 
blijkt n.l. uit een aantal studies dat dit niet altijd 
leidt tot de generatie van T cellen die ook 
daadwerkelijk tumor cellen kunnen herkennen 
en doden. 
De chimere scTCR en tcTCR genen werden 
gegenereerd door scTCR, bestaande uit de 
variabele alfa en beta ketens afkomstig uit een 
HLA-A1/MAGE-A1 specifieke T eel kloon, aan 
het CD3-1;; signalering element te koppelen. 
Deze benadering werd gekozen omdat eerder 
was aangetoond dat eiwitten die aan CD3-1;; 
waren gekoppeld preferentieel dimeriseren. 
Hierdoor kan dus vermeden worden dat de 
chimere TCR alfa en beta ketens met reeds in 
de eel aanwezige TCR alfa en beta ketens 
associeren en er een nieuwe onbekende 
specificiteit in de T cellen word ge"introduceerd. 
lntroductie van de chimere scTCR/1;; en 
tcTCR/1;; genen in primaire humane T 
lymfocyten leidde tot de functionele expressie 
van deze genen: de T lymfocyten verkregen de 
door de chimere receptor gedirigeerde HLA-
A1/MAGE-A1 specificiteit. Melanoom cellen die 
zowel het betreffende HLA-A1 molecuul als het 
MAGE-1 molecuul tot expressie brengen 
werden door deze gen-getransduceerde T 
lymfocyten gedood. Tevens initieerden deze 
tumor cellen de productie van cytokinen zoals 
TNFa, IFNy en GM-CSF. Het is van belang te 
vermelden dat de retrovirale gen transfer 
technologie zoals door ons ontwikkeld voor 
deze specifieke toepassing er toe leidde dat de 
immuun response van bulk gen-
getransduceerde T lymfocyt populaties direct 
geanalyseerd kon worden, zonder gebruik te 
maken van intensieve klonering strategieen. 
In Hoofdstuk 3 beschrijven wij een studie naar 
de antigeen specificiteit van twee scTCR 
receptoren. Primaire humane T lymfocyten die 
deze receptoren met identieke variabele TCR 
alfa en beta ketens, doch verschillende 
signalering elementen, CD3-1;; versus Fc(s)RI-y, 
tot expressie brengen responderen beiden op 
melanoom cellen die positief zijn voor HLA-A1 
en MAGE-1. Echter, tot onze verbazing 
reageerden de scTCR!l05 T lymfocyten niet 
op doelwit cell en die met synthetisch MAGE-A 1 
peptide waren beladen, en scTCRI(;Pos T 
lymfocyten wei. Het feit dat deze scTCR/yPos T 
lymfocyten niet op peptide beladen cellen 
reageerden kon niet worden verklaard door aan 
te nemen dat het synthetische peptide niet 
identiek is aan het endogeen geproduceerde 
peptide. lndien het synthetische peptide door 
middel van electroporatie in doelwit cellen werd 
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ge"introduceerd werd het op de eel membraan 
door HLA-A1 moleculen gepresenteerd. Deze 
complexen werden vervolgens wei door de 
scTCR!l05 T lymfocyten herkend en leidde tot 
de productie van IFND. Het synthetische 
peptide was ook gebruikt voor de generatie van 
oplosbare HLA-A1/MAGE-A1 complexen die of 
werden gebruikt als stimulator moleculen door 
ze te immobiliseren op plastic, of werden 
gebruikt voor flow-cytometrische bepaling van 
de antigeen binding capaciteit. In beide 
gevallen werden de HLA-A1/MAGE-A1 
complexen herkend door scTCRI(;Pos 
en scTCR!l05 T lymfocyten. Ge"immobiliseerd 
op plastic leidde dit tot IFNy productie en 
gekoppeld aan een fluorochroom leidde dit tot 
specifieke binding door beide T lymfocyt 
populaties. De hoeveelheid antigeen die op de 
eel membraan van peptide beladen cellen 
aanwezig is tijdens de stimulatie studies was 
ook niet van invloed op de response van 
scTCR!l05 T lymfocyten aangezien bij geen 
enkele geteste peptide concentratie een 
response gemeten kon worden. Studies waarbij 
gekeken werd of de specifieke interactie tussen 
melanoom cellen die zowel HLA-A1 als MAGE-
1 tot expressie brengen en scTCR!l05 T 
lymfocyten kon worden geblokkeerd door een 
overmaat aan peptide beladen cellen toe te 
voegen aan HLA-A1 en MAGE-A1 positieve 
cellen lieten zien dat scTCR!yPos T lymfocyten 
niet in staat zijn om aan peptide beladen cellen· 
te binden. Wij concluderen daarom ook dat 1) 
de TCR specificiteit niet aileen afhankelijk is 
van de TCR alfa en beta ketens, maar ook van 
de ge"introduceerde signalering elementen. 
Daarnaast concluderen wij ook dat er een 
verschil moet zijn tussen HLA-A1 moleculen 
die in de eel worden beladen met MAGE-A 1 
peptide en HLA-A 1 moleculen die op de eel 
membraan worden beladen met MAGE-A1 
peptide. Tenslotte kan geconcludeerd worden 
dat oplosbare HLA-A1/MAGE-A1 complexen 
identiek zijn aan intracellulair gevormde HLA-
A1/MAGE-A1 comglexen. 
Aangezien CD4P s T cellen een grote rol 
spelen bij de initiatie en persistentie van een 
immuun respons werd door ons onderzocht of 
deze cellen ook konden worden uitgerust met 
een TRA specificiteit. In hoofdstuk 4 wordt de 
functionele introductie van chimere tcTCR/1;; 
genen in primaire CD4Pos T lymfocyten 
beschreven. Echter, de CD4Pos T lymfocyten 
die de tcTCR/1;; receptor tot expressie brengen 
waren aileen in staat om a) HLA-A1/MAGE-A1 
complexen te bin den en om b) te responderen 
op HLA-A 1 en MAGE-A 1 positieve cellen als in 
deze cellen ook het CD8a gen was 
ge"introduceerd. Na introductie van het 
CD8a gen respondeerden de CD4Pos T 
lymfocyten specifiek op HLA-A1/MAGE-A1 
positieve melanoom cellen door ze te dod en en 
cytokinen te produceren. Wij concluderen dat 
de introductie van MHC klasse I specificiteit in 
MHC klasse II specifieke CD4Pos T lymfocyten 
van belang kan zijn voor de toepassing van 
adoptieve immuun therapie aangezien vele 
tumoren geen MHC klasse II moleculen tot 
expressie brengen en gezien de centrale rol die 
CD4Pos T lymfocyten spelen in de 
immunologische controle van tumoren en virale 
infecties. 
Het tweede deel van het proefschrift beschrijft 
studies met een uniek type receptoren, n.l. 
receptoren gebaseerd op antilichamen die TRA 
herkennen in de context van MHC klasse I 
moleculen. Deze antilichamen werden door Dr. 
Patrick Chames in het laboratorium van Dr. 
Hennie Hoogenboom ge"isoleerd m.b.v. de 
"phaag-display" technologie. Het belang van 
deze technologie wordt duidelijk als men 
begrijpt dat de isolatie, klonering en expansie 
van TRA specifieke T cellen niet altijd 
succesvol is en dus de TCR genen niet 
beschikbaar zijn voor gen transfer. Daarnaast 
laat de flexibiliteit van de phaag-display 
technologie het toe om de antilichamen te 
modificeren. 
In hoofdstuk 5 word de constructie van een 
chimere antilichaam FAB receptor beschreven. 
De genen coderend voor het HLA-A1/MAGE-
A 1 specifieke F ABG8 fragment werden 
gekoppeld aan het Fc(z)RI-y signalering 
element en d.m.v retrovirale transductie in 
primaire humane T lymfocyten ge"introduceerd 
De lymfocyten brengen de chi mere F ABG8-y 
receptor tot expressie zoals bleek uit flow-
cytometrische analyse met fluorochroom 
gelabelde HLA-A1/MAGE-A1 complexen. 
F ABG8-l05 T lymfocyten waren in staat om 
HLA-A1/MAGE-A1 positieve melanoom tumor 
cellen te doden. Tevens respondeerden de 
F ABG8-l05 T lymfocyten met cytokine 
productie na stimulatie met deze melanoom 
cellen. Deze resultaten Iaten zien dat deze 
antilichamen als alternatief kunnen dienen voor 
TCR genen voor de transfer van T eel 
specificiteit. 
Een combinatie van technieken zoals "Iichte 
keten shuffling", plaats gebonden mutagenese 
van de zware keten en in vitro selectie van faag 
display bibliotheken leverde een variant van 
F ABG8 op met een 18 maal hog ere affiniteit, n.l. 
Hyb3. In hoofdstuk 6 beschrijven wij de 
constructie en functionele expressie van 
chimere FABG8-y en FABHyb3-y receptoren. Uit 
een directe vergelijking van primaire humane T 
lymfocyten die de laag affiniteit receptor G8-y of 
de hoog affiniteit receptor Hyb3-y tot expressie 
brengen bleek dat hoog affiniteit receptor 
Hyb3-yPos T lymfoc~en 1) in staat zijn om meer 
HLA-A1/MAGE-A1 °5 tumoren te doden 
gedurende de assay tijd, in vergelijking met 
G8-yPos T lymfocyten; 2) een hogere productie 
van cytokinen Iaten zien in response op HLA-
A1/MAGE-A1Pos tumor cellen, in vergelijking 
met G8-yPos T lymfocyten, en 3) tumor cellen 
met minder antigeen op de celmembraa~g:ter 
herkennen en doden dan met G8-y T 
lymfocyten. T lymfocyten die met deze hoog 
affiniteit receptoren zijn uitgerust kunnen 
mogelijk ook in vivo meer tumor cellen doden. 
De affiniteit maturatie van deze antilichamen 
met MHC gerestricteerde specificiteit kan 
daarom een belangrijke bijdrage leveren aan 
de optimalisatie van de effectiviteit van T eel 
retargeting. 
De afwezigheid van co-stimulatoire moleculen 
zoals CD80 en CD86 (87.1 en 87.2) kunnen er 
voor zorgen dat primaire T lymfocyten niet of 
onvoldoende worden geactiveerd. De interactie 
tussen CD28 op T lymfocyten en Cd80 op 
tumor cellen is naast de interactie tussen TCR 
en MHC complexen noodzakelijk voor optimale 
activatie na antigeen binding. Uit studies met 
TAA specifieke antilichaam receptoren is 
gebleken dat de incorporatie van het CD28 
signalering domein in de enkelketen 
antilichaam receptoren leidt tot verhoogde 
productie van cytokinen, echter niet tot een 
verhoogde capaciteit om tumor cellen te doden. 
Tevens is uit deze studies gebleken dat 
tumoren in muizen beter werden bestreden 
door T lymfocyten die waren uitgerust met 
receptoren die CD28 co-signalering capaciteit 
bevatten. Gezien deze opmerkelijke 
verbetering ten opzichte van receptoren die 
geen CD28 signalering element bevatten werd 
ook door ons een CD28 signalering element in 
laag affiniteit scFvG8-y en hoog affiniteit 
scFvHyb3-y receptoren ingebouwd 
(hoofdstuk7). Om de bijdrage van het CD28 
signalering element te bestuderen werden de 
scFvG8 en scFv Hyb3 receptoren met aileen 
het y signalering element in T lymfocyten van 
dezelfde donor ge"introduceerd. In vergelijking 
met de scFvG8-l05 T lymfocyten werd voor 
scFvG8-y+CD28Pos T 'd;mfocyten na incubatie 
met HIA-A1/MAGE-A1P 5 melanoom cellen een 
verhoogde cytokine productie waargenomen. 
Opmerkelijk was ook de waarneming dat 
scFvG8-y+CD28Pos T lymfocyten ten opzichte 
van scFvG8-yPos T lymfocyten een verhoogde 
tumor dodende capaciteit lieten zien, dit in 
tegenstelling tot T lymfocyten die een TAA 
specifieke receptor met het CD28 signalering 
element tot expressie brengen. De expressie 
van de hoog affiniteit scFvHyb3 receptor met 
CD28 signalering element, scFvHyb3-y+CD28 
in humane T lymfocyten resulteerde tot onze 
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verbazing in een tumor eel dodende capaciteit 
die niet MAGE-A 1 specifiek was. Ook MAGE-
A1 en HLA-A1 negatieve cellen werden door 
de scFvHyb3-y+CD28Pos T lymfocyten gedood. 
Onder normale omstandigheden wordt door T 
lymfocyten het oppervlak van cellen afgetast op 
aanwezigheid van lichaamsvreemde antigenen 
die door MHC moleculen worden 
gepresenteerd. De aspecifieke reactie door 
scFvHyb3-y+CD28Pos lymfocyten wordt 
veroorzaakt door het feit dat de T lymfocyten 
al worden geactiveerd voordat de receptoren 
dissocieren van met lichaamseigen gevulde 
MHC complexen. Het is daarom van groat 
belang de specificiteit van T lymfocyten met 
deze receptoren uitgebreid te testen. 
De in dit proefschrift gepresenteerde 
technologieen maken het mogelijk om op grate 
schaal tumor specifieke T lymfocyten te 
genereren. De retrovirale transductie van 
primaire humane T lymfocyten is momenteel 
n.l. zo efficient dat selectie van receptor 
positieve cellen overbodig is. 
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Ook is het mogelijk om receptoren met 
verschillende antigeen specificiteit tegelijk in T 
lymfocyten te introduceren. Dit heeft als 
voordeel dat tumoren die de expressie van een 
antigen verloren hebben toch nog herkend en 
opgeruimd kunnen worden. De mogelijkheid 
om chimere receptoren te construeren met een 
divers scala van signalering elementen zal er in 
de toekomst zeker toe leiden dat een 
zogenaamde optimale receptor structuur 
gevonden wordt. Als antigeen bindende 
structuren zullen de antilichamen met MHC 
gerestricteerde specificiteit een grote bijdrage 
kunnen leveren, zeker in het geval wanneer 
tumor specifieke T eel klonen ontbreken. Door 
genetische manipulatie kunnen antilichamen 
met een verhoogde affiniteit verkregen worden 
die mogelijk voor verdere verbetering van de 
antitumor effectiviteit zorgen. Kortom, deze 
technologieen zijn de voorboden van nieuw te 
initieren klinische studies met TRA specifieke 
receptoren. 
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Nawoord 
Zo, dit was het dan, de laatste pagina van het proefschrift en de laatste woorden die op 
papier gezet worden. 
De totstandkoming van het proefschrift was natuurlijk niet mogelijk geweest zonder de 
bijdrage van een groot aantal mensen. Allereerst Reinder Bolhuis, de initiator van het 
onderzoek en (misschien de enige persoon) die net als ik bleef geloven in de mogelijkheid 
om chimere T eel receptoren functioneel in primaire humane T lymfocyten tot expressie te 
brengen. Reinder bedankt voor "ALLES". Dan Cees; zonder zijn inzet en overwinnen van 
een hoop "kweekfrustratie" zouden vele proeven niet tot een goed einde gekomen zijn. Cees 
ook jij hartelijk dank! Mirjam, en Reno jullie zijn wat later bij het onderzoek betrokken geraakt 
maar ook jullie bijdrage aan de totstandkoming van het proefschrift is essentieel geweest, 
bedankt. Vervolgens een reeks collega,s die ieder op hun manier hebben bijgedragen: 
Letitia, Mo, Anke, Emmy, Cor, Jan Willem, Jako, Rienier, Wim, en nog vele anderen. Allen 
hartelijk dank!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
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